{
  "responseHeader":{
    "status":0,
    "QTime":17,
    "params":{
      "q":"(Background: lung cancer OR lung carcinoma OR small-cell lung carcinoma OR SCLC OR non-small-cell lung carcinoma OR NSCLC OR Doc_title: lung cancer OR lung carcinoma OR small-cell lung carcinoma OR SCLC OR non-small-cell lung carcinoma OR NSCLC) AND (Background: ERBB2 OR \"NEU\" OR \"NGL\" OR \"HER2\" OR \"TKR1\" OR \"CD340\" OR \"HER-2\" OR \"MLN 19\" OR \"HER-2/neu\" OR Doc_title: ERBB2 OR \"NEU\" OR \"NGL\" OR \"HER2\" OR \"TKR1\" OR \"CD340\" OR \"HER-2\" OR \"MLN 19\" OR \"HER-2/neu\")"}},
  "response":{"numFound":4242,"start":0,"docs":[
      {
        "Meeting_name":" Molecular profiling of small cell lung cancers in Japanese patients.",
        "Background":"['Background', '  Molecular abnormalities discovered in the last decade have led to a paradigm shift in the diagnosis and treatment of lung adenocarcinoma. But there have been few reports about molecular profiling of small cell lung cancers (SCLC). We conducted the Shizuoka Lung Cancer Mutation Study to analyze driver mutations in patients with thoracic SCLC malignancies.  Methods', '  We collected molecular profiling data of SCLC from the biobanking system in conjunction with the clinic, including the pathology lab, where 23 mutations in 9 genes (EGFR, KRAS, BRAF, PIK3CA, NRAS, MEK1, AKT1, PTEN and HER2), EGFR, MET, PIK3CA, FGFR1 and FGFR2 amplifications, and EML4-ALK translocations were assessed using pyrosequensing plus capillary electrophoresis, qRT-PCR, and RT-PCR, respectively. To evaluate mutation status for SCLC patients, we collected patient characteristics data from medical records. Results', '  Between July 2011 and July 2012, fifty small cell lung cancer patients were assessed in our biobanking system. Patient characteristics were as follows', ' median age (range) 70 (43 - 82) years; male 82%; smoker 96%; limited disease/extended disease 56/44%; small cell carcinoma/combined small cell carcinoma with adenocarcinoma 94/6%; surgically resected snap-frozen samples 8, formalin-fixed paraffin-embedded samples 40 and pleural effusion 7. We detected driver mutations in 8 cases (16%). Mutations found', ' EGFR 1 (2%), KRAS 1 (2%), PIK3CA 2 (4%), AKT1 1 (2%), MET amplification 1 (2%), PIK3CA amplification 6 (12%). EGFR and KRAS mutation were found in combined small cell carcinoma with adenocarcinoma. No significant differences in age, sex, disease extent at diagnosis or smoking status were found between patients with mutations and those without mutations. But serum neuron-specific enolase (NSE) levels were significantly higher in patients without mutations (p=0.03).  Conclusions', '  In our analysis, driver mutations were found in 16% of SCLC patients and PIK3CA amplification seemed to be relatively frequent in SCLC. Our results suggest that PIK3CA might become a target of treatment for SCLC patients.']",
        "Doc_id":"ASCO_116449-132",
        "Doc_title":" Molecular profiling of small cell lung cancers in Japanese patients.",
        "_version_":1606188985148768256},
      {
        "Meeting_name":" Concomitant mutation and amplification of the ERBB2 (HER2) gene in human tumors.",
        "Background":"['Background', '  Amplification of the ERBB2 (HER2) gene is a well-known genetic aberration in many tumor entities. Up to 20% of breast and gastric cancer show ERBB2 gene amplification and anti-HER2 targeting therapies are well established for these tumors. In other tumor entities such as lung cancer, colorectal cancer and bladder cancer the fraction of ERBB2 amplified tumors is considerably lower. In contrast to breast cancer, these tumors show heterogeneity of ERBB2 amplification in a substantial proportion. Oncogenic EGFR mutation with subsequent EGFR amplification is a common phenomenon in lung cancer. In analogy, primary ERBB2 mutation could explain the observed heterogeneity of ERBB2 amplification in some tumors. Methods', '  100 tumors showing ERBB2 amplification by fluorescence in situ hybridization were examined for ERBB2 mutation', ' 50 breast cancer samples, including 10 cases with borderline gene amplification, 10 cases with heterogeneous gene amplification and 11 samples of metastatic lesions as well as 15 colorectal carcinomas, 12 gastric carcinomas, 12 non-small cell lung cancers and 10 urothelial carcinomas. Tumor DNA was extracted and examined for mutations in the tyrosine kinase domain (exons 18-23) of the ERBB2 gene by Sanger sequencing. Results', '  ERBB2 mutation was found in two metastatic lesions of breast cancer, two lung cancers and two colorectal cancers. In five of these cases short in-frame insertions in exon 20 were found. In one case of a breast cancer lung metastasis a missense mutation in exon 19 (p.L755S) was detected. The semi-quantitative chromatograms show an overrepresentation of the mutations indicating a selective amplification of the mutated allele. Conclusions', '  In certain tumor entities the heterogeneity of ERBB2 amplification indicates a late genetic event. The finding of a concomitant mutation in ERBB2 amplified tumors might explain the heterogeneity in some of these tumors. The effect of a primary oncogenic ERBB2 mutation might be increased by selective amplification of the mutated allele resulting in an additional growth advantage. If ERBB2 amplified tumors with a primary ERBB2 mutation also benefit from an HER2 targeted therapy needs to be elucidated.']",
        "Doc_id":"ASCO_133558-144",
        "Doc_title":" Concomitant mutation and amplification of the ERBB2 (HER2) gene in human tumors.",
        "_version_":1606188998316785664},
      {
        "Meeting_name":" Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung",
        "Background":"['Background', 'As the comprehensive genomic analysis of small cell lung cancer (SCLC) progresses, novel treatments for this disease need to be explored. With attention to the direct connection between the receptor tyrosine kinases (RTKs) of tumor cells and the pharmacological effects of specific inhibitors, we systematically assessed the RTK expressions of high-grade neuroendocrine carcinomas of the lung (HGNEC), including SCLC and large cell neuroendocrine carcinoma (LCNEC).Patients and Methods', 'Fifty-one LCNEC and 61 SCLC patients who underwent surgical resection were enrolled in this research. As a control group, 202 patients with adenocarcinomas (ADCs) and 122 patients with squamous cell carcinomas (SQCCs) were also analyzed. Using immunohistochemical staining (IHC), we stained all tumors with antibodies for 10 RTKs; c-Kit, EGFR, IGF1R, KDR, ERBB2, FGFR1, c-Met, ALK, RET and ROS1. We scored the expression of these RTKs for all enrolled tumors, and compared them according to the histological types.Results', 'The LCNEC and SCLC patients exhibited similar clinicopathological characteristics. The IHC scores for each RTK were almost equivalent between the LCNEC and SCLC groups, but they were significantly different from those of the ADC or SQCC groups. Especially, c-Kit was the only RTK that was remarkably expressed in both LCNECs and SCLCs. On the other hand, about 20% of the HGNEC tumors exhibited strongly positive RTK expression, and this rate was similar to those for the ADC and SQCC tumors. Intriguingly, strongly positive RTKs were almost mutually exclusive in individual tumors.Conclusions', 'Compared with ADC or SQCC, LCNEC and SCLC had similar expression profiles for the major RTKs. The exclusive c-Kit positivity observed among HGNECs suggested that c-Kit might be a distinctive RTK in HGNEC. These HGNECs which have strongly positive RTKs could be the targets of personalized therapies.']",
        "Doc_id":"AACR_2015-5004",
        "Doc_title":" Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung",
        "_version_":1606188999424081920},
      {
        "Meeting_name":" Endothelin causes transactivation of the EGFR and Her-2/Neu in non-small cell lung cancer cells",
        "Background":"['Endothelin-1 (ET-1) is a 23 amino acid peptide which is present in many lung cancer cell lines (Ahmed et al., Am. J. Respir. Cell Mol. Biol. 2000; 22', ' 422). Expression of ET-1 or the ETA receptor is associated with poor prognosis of non-small cell lung cancer (NSCLC) patients (Boldrini et al., Eur. J. Cancer 2005; 41', ' 2828). ET-1 stimulates whereas the ETA antagonist ZD4054 inhibits the proliferation of cancer cells (Bagnato et al., Br. J. Pharmacol. 2011', ' 163; 220). Here the effects of ET-1 on the transactivation of the EGFR and Her-2/Neu were investigated in NSCLC cells. Twelve of 13 NSCLC cell lines tested had both ETA and ETB mRNA. Addition of ET-1 to adenocarcinoma cell line NCI-H838, which had both ETA and ETB mRNA, elevated cytosolic Ca2+, increased tyrosine phosphorylation of the ERK, EGFR and Her-2/Neu and increased colony number. The ability of ET-1 to increase cytosolic Ca2+, tyrosine phosphorylation of ERK, EGFR and Her-2/Neu and colony number was inhibited by ZD4054 or BQ123 (ETA antagonists). The transactivation of EGFR and Her-2/Neu by ET-1 was inhibited by lapatinib (EGFR and Her-2/Neu TKI), GM6001 (matrix metalloprotease inhibitor), PP2 (Src inhibitor) or N-acetylcysteine (anti-oxidant). ET-1 stimulated whereas lapatinib and ZD4054 inhibited the clonal growth of NSCLC cells. The results indicate that ET-1 may regulate the proliferation of NSCLC cells in an EGFR and Her-2/Neu-dependent manner.']",
        "Doc_id":"AACR_2016-1809",
        "Doc_title":" Endothelin causes transactivation of the EGFR and Her-2/Neu in non-small cell lung cancer cells",
        "_version_":1606189034495803393},
      {
        "Meeting_name":" Clinico-pathologic features of lung cancer with EML4-ALK translocation.",
        "Background":"['Background', ' A small subset of human lung cancer harbors the fusion of the gene for echinoderm microtubule-associated protein-like 4 (EML4) and the gene for anaplastic lymphoma kinase (ALK), resulting from a small inversion within chromosome 2p. A phase I dose escalation trial for ALK tyrosine kinase inhibitor showed promising activity against these tumors. We examined our cohort of patients for EML4-ALK translocation and tried to concentrate this rare type of lung cancer according to the clinico-pathologic background of the patients. Methods', ' Methods We studied 345 patients with lung cancer who underwent pulmonary resection in our hospital (adenocarcinoma 314, large cell carcinoma 5, small cell carcinoma 1, squamous cell carcinoma 21, adenosquamous cell carcinoma 4) after obtaining appropriate informed consent from the patients. EML4-ALK translocation was detected by RT-PCR and direct sequencing. Results', ' We found 10 EML4-ALK translocations (3%). Seven were variant 1, two variant 2 and one variant 1. All were adenocarcinoma. Eight patients were female and 7 were never-smokers. None of the tumors harbored either of EGFR, KRAS, HER2 or TP53 mutation. The incidence of ALK fusion was 10 of 97 (10%) without any of four mutations. Median age of patients with ALK fusion was 56 that was significantly younger than that of entire cohort (63) or those with EGFR mutation (64) or KRAS mutation (65). Histopathologically, most of the tumors with ALK fusion were solid-acinar type with cribriform pattern. Conclusions', ' Lung caners with ALK fusion tended to occur in younger female patients with acinar type adencoarcinoma devoid of EGFR, KRAS, HER2 or TP53 mutations. Although this type of lung cancer is rare, we have to establish efficient screening method because genotype-based therapy would be possible in the near future.']",
        "Doc_id":"ASCO_48829-74",
        "Doc_title":" Clinico-pathologic features of lung cancer with EML4-ALK translocation.",
        "_version_":1606189006346780672},
      {
        "Meeting_name":" Characterization of methylation profiles reveals distinct epigenomic patterns in SCLC and NSCLC",
        "Background":"['Background', ' Small cell lung cancer (SCLC) is a highly lethal malignancy characterized by rapid growth, early metastasis and poor prognosis. SCLC shows distinct molecular and clinical features when compared to other lung cancer subtypes. Previous analyses by us and others have identified genomic and proteomic differences between SCLC and Non-Small Cell Lung Cancer (NSCLC). Epigenetic alterations are some of the earliest events that could also lead to oncogenic changes and thus play an essential role in tumor initiation and progression. However, epigenetic differences between SCLC and NSCLC contributing to the alterations in gene and protein expression patterns, distinct biological features and therapeutic response have not been well characterized. Here, we investigate the differences in the methylation patterns of SCLC and NSCLC to provide novel insights into epigenetic associated gene alterations to identify potential therapeutic targets in SCLC.Material and Methods', ' A genome-wide DNA methylation profiling of SCLC and NSCLC cell lines was used for this investigation. We correlated DNA methylation status with gene expression and protein expression levels in 31 SCLC and 73 NSCLC lines to identify the relationship of epigenetic with genomic and proteomic features distinguishing SCLC from NSCLC.Results', ' SCLC and NSCLC lines exhibited different methylation profiles and we identified 484 genes that had a significant inverse correlation between methylation status and mRNA expression levels (Rho  -0.5 and FDR = 0.01), (genes regulated by methylation, GRM) that distinguished SCLC from NSCLC. Ingenuity pathway analysis of the 484 genes identified significant associations with neuregulin signaling, immune trafficking, integrin signaling, glioma invasiveness canonical pathways. Proteomic profiling by Reverse Phase Protein Array (RPPA) validated the different expression of some of the 484 genes identifying nine that were hypermethylated and downregulated at protein levels in SCLC compared to NSCLC lines (PTEN, CyclinD1, Caveolin, Notch3, TAZ, HSP27, STAT6 and both total and phosphorylated levels of receptor tyrosine kinases such Her2 and, MET).Conclusions', ' Genome wide methylation, mRNA expression, and detailed proteomic analyses have identified specific epigenic differences between SCLC and NSCLC that impact on important signaling pathways including widespread loss of PTEN function and receptor tyrosine kinase (RTK) expression in SCLCs which need to be considered in developing new rationale therapies for SCLC.']",
        "Doc_id":"AACR_2015-2961",
        "Doc_title":" Characterization of methylation profiles reveals distinct epigenomic patterns in SCLC and NSCLC",
        "_version_":1606188974895792128},
      {
        "Meeting_name":" Chemotherapy regulated microRNA-125/HER2 pathway as a novel therapeutic target for trastuzumab-mediated cellular cytotoxicity in small-cell lung cancer",
        "Background":"['Small-cell lung cancer (SCLC) accounts for 15% of all lung cancer cases and is a highly lethal disease. For the last several decades, the standard treatment for SCLC has been deadlocked, and new therapeutic strategies are urgently needed. Human epidermal growth factor receptor 2 (HER2) is a member of the HER family and has been reported to be overexpressed in 30% of SCLC cases with poor prognosis. However, the clinical relevance of HER2-targeted therapy for SCLC remains unclear. Here, we firstly identify that cytotoxic drugs induce significant HER2 overexpression through microRNA-125a (miR-125a) and miR-125b downregulation, which in turn act as a novel therapeutic target for trastuzumab-mediated cellular cytotoxicity in SCLC. In this study, we showed that treatment of the HER2-positive SCLC cells, SBC-3 and SBC-5, with cytotoxic drugs induced a significant upregulation of HER2. Cisplatin (CDDP) treatment of SCLC cells resulted in a significant downregulation of miR-125a and miR-125b. We confirmed that miR-125a and miR-125b bound to the 3-untranslated regions of HER2 mRNA, and that downregulation of miR-125a and miR-125b resulted in upregulation of HER2 in SCLC cells, suggesting a relationship between cytotoxic drug exposure and miR-125/HER2 dysregulation. Furthermore, using a calcein assay we demonstrated a significant synergistic cytotoxic effect of CDDP and trastuzumab that was mediated via antibody-dependent cellular cytotoxicity. Finally, we clearly demonstrated the synergistic anti-tumor effect of these agents in an orthotopic lung cancer model in vivo. Our result offer a novel therapeutic strategy for HER2-positive SCLC by using trastuzumab combined with cytotoxic drugs.']",
        "Doc_id":"AACR_2015-1334",
        "Doc_title":" Chemotherapy regulated microRNA-125/HER2 pathway as a novel therapeutic target for trastuzumab-mediated cellular cytotoxicity in small-cell lung cancer",
        "_version_":1606189029313740800},
      {
        "Meeting_name":" Regional screening network for characterization of the molecular epidemiology of non-small cell lung cancer (NSCLC) and implementation of personalized treatment.",
        "Background":"['Background', '    Personalized treatment of genetically stratified subgroups has the potential to substantially improve outcome in NSCLC. A major challenge now is to implement high-quality molecular diagnostics and personalized treatment strategies in routine clinical practice also outside of highly specialized academic centers.   Methods', '    We have established a molecular screening network in the catchment area of our comprehensive cancer center encompassing about 2.5 million inhabitants in March 2010 after review of the local ethics committee (10-242). Lung adenocarcinoma (AD) was screened centrally for ALK translocations, mutations in KRAS, EGFR, BRAF and PIK3CA and for amplification of ERBB2. Squamous cell carcinoma (SQ) was analyzed for FGFR1 amplifications.   Results', '    2032 NSCLC samples were acquired of which 1782 in the Cologne-Bonn area indicating a capture rate of 60-70% of all NSCLC samples in the area. Material was suitable for molecular analysis in 77%. Distribution of histological subtypes was as expected (AD 63.4%, SQ 26.7, large cell carcinoma 1.4%, adenosquamous cell carcinoma 1.8%, carcinoid 0.1%, NSCLC NOS 6.7%. In AD the following frequencies of genetic lesions were detected', ' KRAS (32%), EGFR (13%), ALK (3%), BRAF (2%), PIK3CA (2%), ERBB2 (2%). EGFR mutations were highly enriched in the lepidic and micropapillary subtype of AD (30-32%), whereas the solid subtype only harboured a very small amount of the tested oncogenic lesions. In SQ FGFR1 amplification was detected in 78/500. Overall 40% of all NSCLC samples harboured potentially tractable oncogenic lesions. All patients with ALK translocations received crizotinib when clinically indicated. 75% of the stage IIIB/IV patients with activating EGFR mutations received EGFR-TKI treatment. In addition, clinical trials have been initiated to provide personalized treatment options to all patients with tractable genetic lesions.   Conclusions', '    High-quality molecular diagnostics and identification of patients for personalized treatment approaches is feasible in daily clinical routine for the majority of diagnostic samples also in a non-academic setting.']",
        "Doc_id":"ASCO_96219-114",
        "Doc_title":" Regional screening network for characterization of the molecular epidemiology of non-small cell lung cancer (NSCLC) and implementation of personalized treatment.",
        "_version_":1606189040627875840},
      {
        "Meeting_name":" Gene expression profiling of lung tumors and matched normal airways reveals common and disparate aberrant pathways in squamous cell carcinoma and adenocarcinoma development and potential markers for detection and targets for chemoprevention in early stage lung cancer",
        "Background":"['Detection and chemoprevention of non-small cell lung cancer (NSCLC) have been unsuccessful in part due to our limited knowledge of the pathogenesis of the disease. It has been suggested that normal airway epithelia share molecular abnormalities with tumors and may serve as progenitors for lung malignancies. We sought to analyze molecular profiles of lung adenocarcinomas and squamous cell carcinomas (SCCs), two major subtypes of NSCLC, and matched normal airways to elucidate aberrant expression patterns in early phases of lung tumorigenesis. All specimens were obtained from primary early stage NSCLC consented patients who did not receive neoadjuvant therapy (n=20). We profiled RNA isolated from tumors and normal lung as well as from brushings of multiple matched airways that were histologically confirmed to lack neoplastic or preneoplastic cells (n=194). Expression signatures signifying genes significantly and concurrently differentially expressed between both tumors and airways compared to normal lung tissue (tumor-airway-normal/TAN signatures) were then derived independently for SCC and smoker adenocarcinoma cases and were comprised of 1,803 and 1,938 genes, respectively. The TAN signatures effectively clustered tumor and airways from normal lung samples (p<0.001). Further analysis showed that a subset of the genes separated SCC- and adenocarcinoma-adjacent airways. Moreover, pathways and gene-network analysis using Ingenuity pathways software highlighted similarities and differences in pathway modulation between airway epithelial fields of SCCs and adenocarcinomas. Embryonic stem cell and eicosanoid signaling pathways were most significantly modulated among those common to both TAN signatures (p<0.001). Retinoic acid receptor and stem cell signaling pathways mediated by NANOG and lineage oncogene SOX2 were most significantly modulated in the SCC TAN signature, whereas NF-kB and PTEN signaling pathways were most prevalent in the adenocarcinoma TAN airway signature (all p<0.001). Gene networks mediated by lineage oncogene NKX2-1/TITF-1 down-regulation and TP63 up-regulation, and networks mediated by increased expression of the MET and ERBB2 oncogenes were predominantly functionally modulated in the SCC and adenocarcinoma TAN signatures, respectively. Quantitative PCR analysis confirmed up-regulation of MET in adenocarcinomas and normal airways compared to normal lung. These findings highlight expression patterns and pathways that are deregulated differentially in the pathogenesis of lung adenocarcinomas and SCCs and thus offer detection markers as well as therapeutic targets to guide personalized chemoprevention in early stage NSCLC patients. Supported by DoD grant W81XWH-10-1-1007.']",
        "Doc_id":"AACR_2012-1721",
        "Doc_title":" Gene expression profiling of lung tumors and matched normal airways reveals common and disparate aberrant pathways in squamous cell carcinoma and adenocarcinoma development and potential markers for detection and targets for chemoprevention in early stage lung cancer",
        "_version_":1606189015776624640},
      {
        "Meeting_name":" Effect of reflex testing by pathologists on molecular testing rates in lung cancer patients",
        "Background":"['Background', '  IASLC/CAP and NCCN guidelines recommend molecular testing for non-squamous non-small cell lung carcinoma (NSCLC) patients. Testing is usually performed upon request by medical oncologist. Reflex testing by pathologists for ER/PR/HER-2 is routinely done in breast cancer patients. We instituted reflex molecular testing at Montefiore Medical Center (MMC) on all non-squamous NSCLC patients in Jan 2012.  Methods', '  We retrospectively reviewed our cancer registry database from Jan 2009 to July 2013 and analyzed all non-squamous NSCLC patients with pathology in our system. We examined annual molecular testing rates as well as testing rates before and after institution of reflex testing. Integrated Oncology (Labcorp) performed EGFR and KRAS testing by PCR-based technology. For patients with wild type EGFR and KRAS, the MMC cytogenetics laboratory performed ALK testing by FISH (Vysis assay).   Results', '  From 2009 to July of 2013, 1,910 patients with lung cancer were identified in our cancer registry and 874 of these had non-squamous NSCLC with pathology diagnosed at MMC. At least 1 set of molecular tests was performed in 14, 25, 46, 64, and 69 % of patients in 2009, 2010, 2011, 2012 and 2013 respectively. The molecular testing rates pre (prior to 2012) and post (after 2012) reflex testing were 28% (166/598) vs 64% (177/276). The testing rates pre and post-reflex testing for EGFR, KRAS and ALK are 26 vs 62%, 6 vs 43% and 7 vs 23% respectively. Among the tested patients, the incidence of EGFR, KRAS and ALK positivity were 14% (46/326), 40% (61/152), and 1.9% (2/106) respectively. Of 276 patients post reflex testing, 52 (19%) had cytology-only NSCLC diagnoses; 75% (39/52) of these patients did not have any molecular testing.  Conclusions', '  Reflex testing by pathologists increased the rate of molecular testing in a community based academic center. Despite the institution of reflex testing, ~30% of patients still do not have guideline recommended molecular testing. The reason for this is unclear; it may be in part due to lack of tissue available for molecular testing, particularly for cytology-only cases.  We will further examine factors that influence the lack molecular testing in these patients.']",
        "Doc_id":"ASCO_127183-144",
        "Doc_title":" Effect of reflex testing by pathologists on molecular testing rates in lung cancer patients",
        "_version_":1606188985041813504},
      {
        "Meeting_name":" Evaluation of genomic alterations in primary small cell carcinoma of the ovary (SCCO).",
        "Background":"['Background', ' As we have previously reported, SCCOis a rare, aggressive form of ovarian cancer associated with poor outcomes (Jamy 2015). In an effort to identify new treatment options, we utilized comprehensive genomic profiling to assess the potential for novel therapies in SCCO. Methods', ' Under an IRB approved protocol, we identified patients (pts) with SCCO, SCCO-HT (hypercalcemic type), neuroendocrine tumors of the ovary (NET-O) and small cell carcinoma of the lung (SCLC) profiled by Caris (company info) between 2007-2015. Tumors were assessed with up to 21 IHC stains, in situ hybridization of cMET, EGFR, HER2 and PIK3CA, and next generation sequencing (NGS) as well as Sanger sequencing of selected genes. Results', ' 46 pts with SCCO (10 SCCO, 18 SCCO-HT, 18 NET-O) were identified as well as 58 pts with SCLC. While small numbers prohibited comparisons SCCO patients were numerically younger (median 42 [range 12-75], SCCO-HT pts 26 [8-40] and NET-O pts 62 [13-76]) than SCLC pts 66 [36-86]. SCCO pts were numerically more likely to be metastatic (70%) than SCCO-HT (50%) or NET-O (33%) pts but at a similar rate to SCLC pts (65%). PD1 expression varied across tumor type with SCCO (100%), SCCO-HT (50%), NET-O (33%) vs SCLC (42%). PDL1 expression also varied with SCCO (50%), SCCO-HT (20%), NET-O (33%) and SCLC (0%). No amplifications were identified in cMET, EGFR, or HER2 and only 1 was found in PIK3CA (NET-O). Actionable mutations were rare with 50% of SCCO pts having a BRCA2 mutation and 29% of pts with NET-O having PIK3CA mutations. No other actionable mutations were identified. Conclusions', ' SCCO/NET-O represent rare and difficult to treat malignancies. While randomized trials will be difficult these tumors may respond to biomarker guided checkpoint or PARP inhibitors.']",
        "Doc_id":"ASCO_161369-176",
        "Doc_title":" Evaluation of genomic alterations in primary small cell carcinoma of the ovary (SCCO).",
        "_version_":1606188993501724672},
      {
        "Meeting_name":" Differential expression of Notch1 in lung, ovarian and breast cancers",
        "Background":"['Targeting the Notch signaling pathway for cancer treatment is currently the subject of early clinical trials. However, treatment-related toxicities, particularly gastrointestinal adverse events, have limited clinical development of this class of agents. The development of efficacy biomarkers to gamma-secretase inhibitors and antibodies to Notch ligands and receptors could speed clinical testing. Mutations in Notch1, a dominant Notch receptor, are rare in human solid tumors, and clinical activity has not been observed in patients with tumors bearing Notch1 activating mutations, including T-cell acute lymphoblastic leukemia from available clinical data. Identification of tumors with abundant target expression and/or active Notch signaling status characteristic of Notch intracellular domain (NICD) expression by immunohistochemistry may have clinical utility. All levels of tumor Notch1 expression comprised of low, moderate and high detected by immunohistochemistry and quantitated by digital imaging technology were observed in 52% (34/66) of lung cancers, 51% (35/68) of ovarian cancers, and 11% (7/63) of breast cancers (lung or ovary vs. breast, P<0.0001 by 2-sided Fisher Exact Test). Notch1 was expressed at high levels in 20% of lung cancers including sarcoma, neuroendocrine, small cell and undifferentiated carcinomas, as well as adenocarcinoma and squamous cell carcinomas. High expression of Notch1 was observed in 9% of ovarian tumors including undifferentiated carcinoma, serous adenocarcinoma, and endometrioid adenocarcinoma. In breast cancer, it was noted in one case of infiltrating ductal carcinoma with triple-negative phenotype. Expression of high-level Notch1 varies in lung cancer vs. ovarian cancer vs. breast cancer (P=0.002 by Chi-square statistic), and was frequently associated with NICD expression. Notch1 was not significantly associated with estrogen receptor, progesterone receptor or HER2 status in breast cancer. These data suggest that the frequency of all levels of Notch1 expression is significantly higher in lung cancer and ovarian cancer than breast cancer; and high-level Notch1 is more frequent in lung cancer than in ovarian cancer, and, likewise, more frequent in ovarian cancer than in breast cancer. For the first time, expression of Notch1/NICD has been identified in undifferentiated carcinomas. The findings may provide useful information for the rational design of Notch inhibitor clinical trials.']",
        "Doc_id":"AACR_2014-3838",
        "Doc_title":" Differential expression of Notch1 in lung, ovarian and breast cancers",
        "_version_":1606188985937297408},
      {
        "Meeting_name":" PD-L1 expression correlation with TP53 gene mutation status in lung cancer but not in colorectal cancer.",
        "Background":"['Background', ' Expression of PD-L1 is, in general, associated with response to immunotherapy. However, it is believed that additional intrinsic factors play a role in determining the potential of response to immunotherapy. Toward this goal we investigated the relationship between mutation profile and PD-L1 expression in lung and colorectal cancers. Methods', ' Molecular profiling using a panel of gene 24 genes was performed by next generation sequencing (NGS) on 158 non-small cell lung cancer (NSCLC) and 42 colorectal cancers. The genes studied included ERBB2, FGFR1, FGFR2, FGFR3, SRC, JAK3, ERBB4, ERBB2, and SMAD4. In addition, these tumors were studied for the expression of PD-L1 using immunohistochemistry (IHC). PD-L1 expression was performed using standard IHC approach using SP142 clone (Spring Biosciences). Results', ' The level of PD-L1 expression was significantly (P = 0.0005) lower in colorectal cancer as compared with NSCLC. The NSCLC cohort had significantly (P = < 0.0001) more cases with 3 or more genes mutated as compared with colorectal cancer. However, there was no significant difference in TP53 mutation frequency between the two tumor types. There was no correlation between PD-L1 expression and the presence or absence of 3 or more gene mutations in either NSCLC or colorectal cancer. However, PD-L1 expression was significantly (P = 0.01) higher in tumors with TP53 mutation in the NSCLC cohort, but not in the colorectal carcinoma cohort (P = 0.5). This was true whether PD-L1 level was used as a continuous variable or if it was dichotomized at 20% (P = 0.02) or 40% (P = 0.03) cutoffs. Conclusions', ' There is significant difference between NSCLC and colorectal cancers in PD-L1 expression levels. More importantly, TP53 mutation in NSCLC correlates with the expression of PD-L1 protein, but not in colorectal cancer despite similar rate of mutation of the TP53 between the two tumor types. This suggests a possible difference in the mechanism of regulating PD-L1 expression between the two tumor types.']",
        "Doc_id":"ASCO_166917-176",
        "Doc_title":" PD-L1 expression correlation with TP53 gene mutation status in lung cancer but not in colorectal cancer.",
        "_version_":1606189038580006912},
      {
        "Meeting_name":" Anti-tumor effect of afatinib, an irreversible EGFR/HER2 dual inhibitor, in lung cancers harboring HER2 oncogene",
        "Background":"['HER2 is a member of the EGFR family of tyrosine kinase receptors and plays important roles in the pathogenesis of certain human cancers. In non-small cell lung cancer (NSCLC), HER2 amplification or mutations are reported. However, little is known about the benefit of HER2-targeted therapy for NSCLC harboring HER2 alteration. In this study, we investigated the anti-tumor effect of afatinib, an irreversible EGFR/HER2 dual inhibitor, in lung cancers harboring HER2 oncogene alteration, including the novel HER2 mutations in transmembrane domain which we recently identified. Ectopically overexpressing HER2 wild-type or mutant (G776V,Cins, A775insYVMA, G660D, and V659E) in normal bronchial epithelial cells, BEAS2B, showed constitutive autophosphorylation of HER2 and activation of downstream signaling. They were sensitive to afatinib, but insensitive to EGFR-TKI (gefitinib). Furthermore, we examined anti-tumor activity of afatinib and gefitinib in several NSCLC cell lines, and investigated the association between their genetic alteration and sensitivity to afatinib treatment. Afatinib down-regulated the phosphorylation of HER2, EGFR, and their downstream signalings, and induced anti-proliferative effect through a G1 arrest and apoptotic cell death in HER2 altered cells (H2170, Calu-3, and H1781). Whereas, HER2 non-dependent NSCLC cells (A549, H1299, and H1993) were insensitive to afatinib. Our results strongly suggest that afatinib is a therapeutic option for NSCLC patients with HER2 alteration.']",
        "Doc_id":"AACR_2015-2588",
        "Doc_title":" Anti-tumor effect of afatinib, an irreversible EGFR/HER2 dual inhibitor, in lung cancers harboring HER2 oncogene",
        "_version_":1606189030539526144},
      {
        "Meeting_name":" Concordance between formalin-fixed paraffin-embedded biopsy samples and surgically resected snap-frozen samples in multiplexed molecular profiling of lung cancers.",
        "Background":"['Background', '  The results of comprehensive genome-wide characterization of lung cancer have recently been reported. However, the concordance of driver mutations between formalin-fixed paraffin-embedded (FFPE) and surgically resected snap-frozen samples is unclear. We conducted the Shizuoka Lung Cancer Mutation Study to analyze driver mutations in patients with lung cancer.  Methods', '  Based on the biobanking system in conjunction with the clinic including the pathology lab, we developed a multiplexed mutational panel designed to assess 23 mutations in 9 genes (EGFR, KRAS, BRAF, PIK3CA, NRAS, MEK1, AKT1, PTEN and HER2), EGFR, MET, PIK3CA, FGFR1 and FGFR2 amplifications, and EML4-ALK translocations, using pyrosequencing plus capillary electrophoresis, qRT-PCR, and RT-PCR, respectively.DNA concentration in FFPE samples was analyzed by measuring absorbance at 260 nm (A260) in a spectrophotometer.  Results', '  Between July 2011 and July 2012, sixty-five lung cancer patients with both FFPE and snap-frozen samples were included in this study. Patient characteristics were as follows', ' median age (range) 70 (38-92) years; female 68%; never-smoker 34%; histology adenocarcinoma/squamous cell carcinoma/small cell carcinoma/other 52/29/6/13 %. FFPE samples included 64 transbronchial biopsies and one pleural biopsy. We detected driver mutations in 58% of all cases. Mutations found', ' EGFR 28%, KRAS 12%, PIK3CA 6%, NRAS 2%, HER2 5%, EGFR amplification 5%, PIK3CA amplification 12%, FGFR1amplification 2%. Complete concordance of driver mutations between FFPE and snap-frozen samples was shown in 65%. Median DNA concentration in FFPE samples was 72.7 ng/ul (range; 2.4 - 472.4 ng/ul). Exploratory analyses using an ROC curve, done to evaluate the useful cutoff of DNA concentration in FFPE samples, showed low AUC (AUC; 0.5326).  Conclusions', '  These results suggest that the rate of complete concordance of driver mutations between FFPE and snap-frozen samples might be acceptable, and DNA concentration in FFPE samples might not be correlated with concordance.']",
        "Doc_id":"ASCO_116307-132",
        "Doc_title":" Concordance between formalin-fixed paraffin-embedded biopsy samples and surgically resected snap-frozen samples in multiplexed molecular profiling of lung cancers.",
        "_version_":1606189018811203584},
      {
        "Meeting_name":" DNA-based genomic profiling for classification of tissue of origin for patients with carcinoma of unknown primary site.",
        "Background":"['Background', ' Carcinoma of unknown primary (CUP) has a poor prognosis and accounts for diagnoses in > 30,000 patients annually in the United States. Current tissue of origin (TOO) methods use protein or RNA-based expression signatures, are costly, and often provide little clinically relevant information. We previously showed that use of comprehensive genomic profiling (CGP) identifies a clinically relevant genomic alteration in 96% of CUPs. We hypothesized that CGP could also potentially identify a TOO for some CUP patients, further refining potential targeted therapeutic options. Methods', ' DNA alterations from 44,065 samples that underwent CGP as part of standard clinical care were classified using logistic regression based on mutational profiles and select clinical features. Results', ' We first trained a logistic regression classifier to identify non-small cell lung cancers (NSCLC) with alterations in EGFR, ERBB2, BRAF, MET, KRAS, ALK, RET, or ROS1 (lung gene set). In cross-validation, the classifier correctly identified 79% of NSCLCs (92% of EGFR mutant samples) and 93% of non-NSCLCs. When applied to a set of 1352 CUPs with an alteration in the lung gene set, 425 (31%) were predicted to be NSCLC. We next trained a classifier to distinguish BRAF V600-mutant colorectal cancers (CRCs) from other BRAF V600-mutant cancers. The classifier correctly identified 90% of CRCs and 93% of non-CRC. Use of this classifier with a BRAF-mutant CUP data set predicted 32/87 (37%) of BRAF-mutant CUP tumors to be CRC. Conclusions', ' In a large series of CUP patients with alterations in the lung gene set, one-third were likely NSCLC, and could potentially benefit from approved targeted therapies in this disease. When applied to BRAF V600-mutant CUPs, 37% were predicted to be CRC, and therefore single agent vemurafenib therapy is unlikely to be effective and combination therapy indicated. This approach is useful for identifying targeted therapeutics likely to be effective based on molecular match and TOO. We plan to extend this DNA-based tool to 4 additional tumor types. Application of this classifier to CUPs may help identify therapeutic strategies from CGP without the need for additional material or testing.']",
        "Doc_id":"ASCO_168528-176",
        "Doc_title":" DNA-based genomic profiling for classification of tissue of origin for patients with carcinoma of unknown primary site.",
        "_version_":1606188993074954240},
      {
        "Meeting_name":" Targeting HER3 and EGFR in NRG1 positive and HER3 mutated lung squamous cell carcinoma",
        "Background":"['HER3 is a member of the ErbB family of receptor tyrosine kinases. Aberrant activation of HER3 as a result of HER2 amplification or neuregulin 1 (NRG1) over-expression has been demonstrated to mediate constitutive activation of downstream oncogenic signals. LJM716 is a fully human IgG1 anti-HER3 monoclonal antibody. It locks HER3 in an inactive conformation and prevents HER3 dimerization with other ErbB family members. This unique mode of action enables LJM716 to block both ligand dependent and ligand independent HER3 activation. In search of new indications that may benefit from anti-HER3 therapies, we noted that squamous cell carcinomas (SCC) tend to have relatively higher NRG1 expression as compared to their adenocarcinoma counterparts. Highest NRG1 expression was observed in the lung SCC cell lines in cell line encyclopedia (CLE). A subset of the lung SCC cell lines with high NRG1 expression are moderately sensitive to LJM716, with HER3 activation detected in all of the sensitive lines. Additionally, EGFR activation is consistently observed in our panel of squamous lung carcinoma models. In some cases, activation of HER2 and/or HER3 is also noted. We hypothesize that squamous lung carcinomas may be dependent on signaling through EGFR, HER2 and HER3. To completely block EGFR, HER2-HER3 signaling, we set to test the treatment of LJM716 and Cetixumab in a number of NGR 1 positive squamous lung carcinomas tumor models. Enhanced anti tumor activity of LJM716 and Cetixumab is observed in four out nine tumor models. Analysis of broad activation status of receptor tyrosine kinases (RTK) reveals that a subset of responsive models have activated pEGFR, pHER2 and pHER3. These data suggest that activated HER3 signaling may be important in a subset of lung squamous cell carcinoma. Combination of anti-HER3 and anti EGFR treatment is effective at inhibiting growth in these tumors.Note', ' This abstract was not presented at the meeting.']",
        "Doc_id":"AACR_2015-5320",
        "Doc_title":" Targeting HER3 and EGFR in NRG1 positive and HER3 mutated lung squamous cell carcinoma",
        "_version_":1606189020383019009},
      {
        "Meeting_name":" A targeted exome sequencing platform for routine clinical molecular profiling of advanced thoracic malignancies relevant to targeted therapy.",
        "Background":"['Increasing number of oncogenic mutations important to the clinical management of advanced thoracic malignancies is being identified. To translate this into routine clinical testing environment, we developed and validated a targeted exome sequencing method using next generation sequencing (NGS) technology that is designed to detect both single nucleotide variants and short insertions or deletions (indels) by employing a custom designed target selection system. In each individual assay, 197 cancer related genes, including 12 clinically relevant genes (AKT1, AKT2, BRAF, EGFR, ERBB2, HRAS, KIT, KRAS, MEK1, NRAS, PIK3CA, and PTEN) are simultaneously sequenced from 100-500ng of total DNA extracted from formalin-fixed paraffin-embedded (FFPE) tissue. To date, we have performed this assay on over 250 FFPE tissues from Non-Small-Cell Lung Cancers (NSCLC), Small-Cell Lung Cancers (SCLC), and thymic malignancies. Mutations in all 12 clinically relevant genes including EGFR L858R, KRAS codon 12 missense mutations as well as EGFR exon 19 deletions, EGFR exon 20 insertions, and ERBB2 exon 20 insertions have been identified and validated with alternate technology in approximately 30% of all samples tested. Compared with conventional capillary sequencing, which typically requires in excess of 25% mutant DNA, this assay can detect mutations with 5% - 10% mutant allele frequency. This is a robust, reliable and cost effective assay that not only is suitable for prospective molecular profiling of clinically relevant targets, but also provides a powerful tool for retrospective analysis of existing FFPE tissues from clinical trials.']",
        "Doc_id":"AACR_2013-1999",
        "Doc_title":" A targeted exome sequencing platform for routine clinical molecular profiling of advanced thoracic malignancies relevant to targeted therapy.",
        "_version_":1606189024928595968},
      {
        "Meeting_name":" A case series of ERBB2 indel driver mutations in non-small cell lung cancer identified by cell-free circulating tumor DNA NGS",
        "Background":"['Background', ' In-frame insertions between codons 775 and 881 in exon 20 of the ERBB2 gene, of which a 12 base pair YVMA insertion is the most common, are activating mutations in 2%-4% of non-small cell lung cancers (NSCLC), and have also been reported in exon 19 and 20 in breast cancer. These driver mutations are not captured with IHC or FISH staining because in the majority of cases, the ERBB2 gene is not amplified and HER2 protein is not overexpressed. Next generation sequencing (NGS) of circulating cell-free DNA (cfDNA) provides a non-invasive means of identifying these potential driver mutations.Method', ' Guardant360TM is a targeted cfDNA NGS panel using hybrid capture and complete exon sequencing for single nucleotide variant detection in 70 genes, copy number amplifications (CNA) in 16 genes, and fusions in six genes and indels in EGFR, ERBB2 and MET exon 14 skipping. De-identified pathology and genotyping reports were reviewed for consecutive patients in which ERBB2 indels were identified in clinical practice.Results', ' Guardant360 identified ERBB2 indels in 27 of 2,093 (1.3%) of non-squamous NSCLC cases, with a single concomitant ERBB2 gene amplification. For this ERBB2 indel series, pathology reports revealed no patients with HER2 amplification via IHC or FISH, nor ERBB2 point mutation via NGS, but were only available in 25% of cases. Eight of the ERBB2 indels were confirmed by tissue NGS reports with zero false positives (100% PPV). 80% of ERBB2 indels were the common p.Tyr772_Ala775dup (YVMA insertion) in exon 20 followed by other insertions in codons 772 through 814. A single ERBB2 exon 20 p.Leu755_Glu757delinsProLys net deletion at 3.9% mutant allele fration (MAF) was noted in one patient, for whom outcome data was available. Initial tissue was IHC negative for HER2 overexpression at the referring hospital where the archival tissue biopsy was exhausted and so could not be sequenced. Based on the cfDNA finding of ERBB2 indel, the patient was switched from cytotoxic chemotherapy to trastuzumab with objective response on PET/CT and a repeat Guardant360 showed the ERBB2 indel MAF had dropped below the test limit of detection. After four months the patient progressed and it was decided to switch to ado-emtansine trastuzumab (T-DM1) in late November.Results', ' ERBB2 indels can be identified without tissue in NSCLC patients with 100% PPV in this modest cfDNA series. In a patient whose tissue was not available for sequencing, an objective response with trastuzumab was obtained.']",
        "Doc_id":"AACR_2016-2240",
        "Doc_title":" A case series of ERBB2 indel driver mutations in non-small cell lung cancer identified by cell-free circulating tumor DNA NGS",
        "_version_":1606189013979365376},
      {
        "Meeting_name":" Targeting stepwise HER2 and VEGF can overcome multidrug resistance in small cell lung cancer",
        "Background":"['Small-cell lung cancer (SCLC) accounts for approximately 15% of primary lung cancer and has the poorest outcome of all its histological types. One of the major reasons of extreme aggressiveness of SCLC is that it recurs shortly after initial therapy with multidrug resistance (MDR) phenotype. However, standard therapeutic strategy for relapsed-SCLC has not been established yet. As one of the targetable receptor tyrosine kinases, human epidermal growth factor receptor 2 (HER2) was reported to be a negative prognostic factor in extensive-disease SCLC (Micke et al. Int J Cancer. 2001;92', '474-9). We found that HER2 was more frequently overexpressed in SCLC cell lines of Japanese origin (6/10) compared to those of Caucasian origin (0/3). We also detected HER2 expression in SCLC tissues in 7 out of 25 patients tested by our highly sensitive immunohistochemistry system. Moreover, we found that HER2 was upregulated when HER2-positive SCLC cells acquired MDR. Trastuzumab, a humanized monoclonal antibody against HER2, exerted differential levels of killing effect on HER2-positive parental and chemoresistant SCLC cells only when Fc receptor-positive natural killer (NK) cells coexisted. This result suggests that trastuzumab-induced SCLC cell-killing effect was caused mainly via antibody-dependent cell-mediated cytotoxicity (ADCC) but not via direct inhibition of HER2 signal. Among these cell lines, etoposide-resistant SCLC cells were most susceptible to trastuzumab in vitro and in vivo, and the antitumor effects of trastuzumab were not only dependent on the amount of HER2 expression on SCLC cells. We focused on cell-cell contact between SCLC cells and NK cells to determine the molecule affecting trastuzumab-mediated ADCC other than HER2. We found that intercellular adhesion molecule (ICAM)-1 was abundantly expressed on etoposide-resistant SCLC cells, and trastuzumab-mediated ADCC was canceled in the presence of an ICAM-1 functional blocking antibody. These results indicate that ICAM-1 expression on SCLC cell surface is indispensable to augment trastuzumab-mediated ADCC. Thus, trastuzumab could overcome etoposide-resistance in SCLC. On the contrary, irinotecan-resistant SCLC cells were still refractory to trastuzumab. The reason for this was thought that they not only lacked ICAM-1 expression but also came to produce abundant vascular endothelial growth factor (VEGF). Bevacizumab, a humanized monoclonal antibody against VEGF, treatment could significantly inhibit the in vivo growth of irinotecan-resistant xenografts through decreasing microvesseles in mice. These results suggest that bevacizumab-mediated antiangiogenesis is a promising therapeutic strategy to salvage irinotecan-resistance.Collectively, targeting stepwise HER2 and VEGF could overcome MDR in SCLC and bring about a favorable outcome for patients with relapsed-SCLC.']",
        "Doc_id":"AACR_2014-4506",
        "Doc_title":" Targeting stepwise HER2 and VEGF can overcome multidrug resistance in small cell lung cancer",
        "_version_":1606188992451051520},
      {
        "Meeting_name":" The GALAXY Trial(NCT01348126)",
        "Background":"['Background', ' Hsp90 is a molecular chaperone required for proper folding and activation of many cancer-promoting proteins and is recognized as a key facilitator of cancer cell growth and survival. In pre-clinical models, Hsp90 inhibition causes degradation of multiple client proteins and leads to cancer cell death. Ganetespib is a resorcinolic Hsp90 inhibitor that has shown potent anti-tumor activity in patients with lung, breast, and other cancers that had progressed on standard treatment agents. Moreover, combination of ganetespib with docetaxel results in synergistic antiproliferative effects in several human non-small cell lung carcinoma (NSCLC) tumor xenografts. Ganetespib is well tolerated and is devoid of severe liver or common ocular toxicities that have been observed with some other Hsp90 inhibitors. Diarrhea is the most common adverse event and is manageable with appropriate supportive care. In a recent report, ganetespib administered at 200 mg/m2 weekly showed activity in pretreated patients with advanced NSCLC patients with ELM4-ALK translocation and KRAS mutations. Methods', ' Stage 1 (240 subjects)', ' randomized, international open-label Phase 2B study in subjects that progressed on or after  one prior systemic therapy for stage IIIB or IV NSCLC', ' patients are prospectively stratified for ECOG performance status, histology, total LDH, interval since diagnosis, and smoking status. Co-primary endpoints are PFS in the ITT population, and PFS in patients with KRAS mutations. Main secondary endpoints include ORR, disease control rate, OS and clinical activity in different molecular subtypes, including BRAF, HER2, EGFR, EML4-ALK. Patients on the control arm are treated with docetaxel 75 mg/m2 on day 1 of a three-week cycle. In the combination arm, ganetespib 150 mg/m2 is given on day 1 (with docetaxel) and day 15 of a three-week cycle. At the time of submission 90 subjects had been enrolled in Stage 1.']",
        "Doc_id":"ASCO_95192-114",
        "Doc_title":" The GALAXY Trial(NCT01348126)",
        "_version_":1606189036798476289},
      {
        "Meeting_name":" Monitoring of peripheral lymphocyte and neutrophil counts to predict efficacy of nivolumab (nivo).",
        "Background":"['Background', ' Programmed death-1 (PD-1) antibody is a key drug for treating non-small cell lung cancer (NSCLC), but the response rate is about 20% in non-selected populations and efficacy is difficult to predict. We examined correlations between peripheral blood tests, including counts of lymphocytes (Lym), neutrophils (Neu), and C-reactive protein (CRP), and the efficacy of nivolumab (nivo) monotherapy. Methods', ' Eighty NSCLC patients treated with nivo (3mg/kg every 2 weeks) in our hospital between December 2015 and September 2016 were evaluated. Peripheral blood tests on day (d) 0 (the day before 1st nivo), d15 (the day of 2nd nivo), d29 (the day of 3rdnivo) were evaluated. Absolute counts and the change ratio (%) of Lym, Neu and CRP from baseline (d0) were calculated. Response to nivo was evaluated according to RECIST v1.1. Results', ' Response to nivo was partial response in 23 cases, stable disease in 13 and progressive disease (PD) in 44 patients (overall response rate, 28%; disease control rate, 45%). Absolute counts of Lym, Neu and CRP at baseline did not differ significantly between non-PD and PD (Lym, 1323/l vs. 1376/l; Neu, 4830/l vs. 5189/l; CRP, 3.48 mg/dl vs. 3.38 mg/dl). Neu was significantly increased from baseline to d15 and d29 in the PD population compared with the non-PD population (Neu (d15)', ' 25.2% vs. -6.3%, P= 0.008; Neu (d29)', ' 16.7% vs. -8.6%, P= 0.006). CRP was also significantly increased from baseline to d29 in the PD population compared with the non-PD population (CRP', ' 60.1% vs. -21.2%, P= 0.010). In contrast, Lym was significantly increased from baseline to d29 in the non-PD population compared with the PD population (Lym', ' 9.6% vs. 6.7%, P= 0.010). Conclusions', ' Changes in peripheral blood test results after nivo differed between non-PD and PD populations. Monitoring of Neu and Lym and CRP may allow prediction of the efficacy of nivo.']",
        "Doc_id":"ASCO_184963-199",
        "Doc_title":" Monitoring of peripheral lymphocyte and neutrophil counts to predict efficacy of nivolumab (nivo).",
        "_version_":1606188971816124416},
      {
        "Meeting_name":" HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer",
        "Background":"['Small Cell Lung Cancer (SCLC) easily acquires multidrug resistance after successful initial therapy. Overexpression of ATP-binding cassette (ABC) transporters is important for the multidrug resistance. Among them, ABCB1 and ABCG2 are known to be upregulated in chemoresistant SCLC. We found that human epidermal growth factor receptor 2 (HER2) expression is also upregulated in chemoresistant SBC-3/ETP, SBC-3/SN-38 and SBC-3/CDDP cells, compared to chemosensitive SBC-3 cells. Lapatinib, a tyrosine kinase inhibitor of HER2, could not suppress proliferation of these HER2-positive SCLC cells, but successfully restored chemosensitivity to etoposide and SN-38 in SBC-3/ETP and SBC-3/SN-38 cells, respectively. The reversal effect of lapatinib was thought to be caused by inhibition of drug efflux-pump functions of ABC transporters, and was producible with a clinically applicable concentration. Moreover, knocking down of HER2 by a small interfering RNA weakened the effect of lapatinib on ABCB1, indicating the involvement of HER2 in the inhibitory mechanisms. Notably, we demonstrated that caveolin-1 and Src play key roles in modulating ABCB1 function via HER2 inactivation. In SBC-3/ETP cells, dephosphorylation of HER2 by lapatinib activates Src and successively leads to increase caveolin-1 phosphorylation. Through this process, caveolin-1 dissociates from HER2 and strengthens association with ABCB1, and finally impairs the pump functions. Furthermore, we demonstrated that treatment by lapatinib in combination with etoposide or irinotecan significantly suppresses the growth of subcutaneous SBC-3/ETP and SBC-3/SN-38 tumors in mice, respectively. Collectively, these results indicate that combination therapy with lapatinib and cytotoxic agents could conquer ABC transporter-mediated chemoresistance in SCLC, especially in HER2-positive cases.']",
        "Doc_id":"AACR_2012-778",
        "Doc_title":" HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer",
        "_version_":1606188973818904576},
      {
        "Meeting_name":" Analysis of MET-amplified solid tumors using chromogenic in situ hybridization (CISH)",
        "Background":"['MET amplification has been implicated in signaling pathways that promote cell proliferation, invasion, and survival. It has been identified as an oncogenic driver in various malignancies and is currently being investigated as a potential therapeutic target. To date, MET exon 14 skipping by sequencing and MET amplification by FISH have been found to have potential clinical utility in predicting those patients who may derive benefit from MET-targeted therapy. However, little research has been conducted on alternative technologies to FISH such as CISH, which does not require a dark room and can be interpreted by a board-certified pathologist. The purpose of this study is to report our experience with MET amplification across solid tumors using CISH.A retrospective analysis was done on 26,619 specimens analyzed for MET amplification by CISH at a CLIA-certified lab (Caris Life Sciences). The validated CISH assay, previously validated against a FISH assay, utilized a gene copy number > 5 to assess amplification. Concordance and correlative studies were done in MET-amplified, non-small cell lung cancer (NSCLC) specimens analyzed using a cMET IHC (SP44, 2+ or 3+ staining intensity in 50% or more tumor cell membrane) analyzing protein expression. Correlative studies involving co-existing aberrations, including PD-L1 (SP142, any intensity in at least 50% of tumor cells), in this MET-amplified, NSCLC cohort were also performed.MET amplification utilizing CISH was 0.7% (188/26,619) overall. MET-amplified solid tumors included carcinomas such as NSCLC (3.1%, 87/2767), gastric adenocarcinoma (3.8%, 11/293), esophageal and esophagogastric junction adenocarcinoma (3.3%, 11/338), and endometrial carcinoma (0.4%, 9/2020) along with non-carcinomas, including glioblastoma multiforme (1.0%, 5/510), uterine sarcoma (1.3%, 5/400), melanoma (0.4%, 2/538), and rare tumors such as placental-site trophoblastic tumor (100%, 1/1) and prostatic neuroendocrine tumor (100%, 1/1). A sub-analysis of MET-amplified, NSCLC specimens demonstrated co-occurring protein overexpression in 92.6% (75/81) of cases. These same MET-amplified, NSCLC specimens were found to have EGFR pathogenic/presumed pathogenic mutations (19.7%, 15/76), ALK rearrangements (2.5%, 2/80), and PD-L1 overexpression (27.5%, 14/51). ROS1 rearrangements were not detected in this NSCLC cohort (0%, 0/76).Our data suggest MET amplification detection utilizing CISH is a viable option for identifying MET-driven cancers. The presence of MET across various solid tumors contrasts with biomarkers like HER2, which are exclusive to carcinomas. A sub-analysis of our NSCLC population shows MET-amplified tumors contains a similar molecular distribution to the general NSCLC population. Future studies should incorporate MET CISH in clinical trials utilizing MET-targeted agents to determine its potential as a predictive test for evaluating who may derive the most benefit.']",
        "Doc_id":"AACR_2016-396",
        "Doc_title":" Analysis of MET-amplified solid tumors using chromogenic in situ hybridization (CISH)",
        "_version_":1606188983115579392},
      {
        "Meeting_name":" Inhibition of HER2 mutant non-small cell lung cancer using 3rd generation EGFR/HER2 inhibitors",
        "Background":"['HER2 is modified in approximately 20% of lung cancers and is mutated in approximately 2-3% of non-small cell lung cancer (NSCLC). Several HER2 mutations within the tyrosine kinase domain are activating mutations, and irreversible EGFR TKIs such as afatinib are known to be effective at inhibiting HER2 phosphorylation in tumor cells expressing HER2 activating mutations. However, the clinical use of these second generation irreversible EGFR inhibitors, such as afatinib, has been limited by adverse toxicities such as skin rash and diarrhea. Our recent study in lung cancer showed that ibrutinib, a well-tolerated TKI currently FDA approved for B-cell lymphoma, is capable of inhibiting EGFR. Study by others also demonstrated that ibrutinib can inhibit HER2 phosphorylation in HER2 overexpressing breast cancer cell lines. In addition, recent studies in other cancers show that the effects of ibrutinib can be amplified in combination of with other small molecule inhibitors targeting AKT and mTOR. Therefore, we hypothesized that HER2 overexpression or activating mutations render NSCLC tumor cells sensitive to ibrutinib. To investigate this, we generated a panel of Ba/F3 cell lines expressing twelve individual clinically observed HER2 mutations and evaluated the transforming capability of the mutations as indicated by sustained cell viability following IL-3 deprivation. Common HER2 mutations such as A775insYVMA, G776del/insVV, and G776C V777insC as well as others were observed to be activating mutations. Mutant HER2 expressing Ba/F3 cells and the human HER2 mutant NSCLC cell line, H1781, were then screened against first, second, and third generation EGFR/HER2 inhibitors including ibrutinib, and cell viability was determined by the Cell Titer Glo assay. Drugs effective in growth inhibition were verified by Western blot analysis. The results showed that EGFR TKI erlotinib and the EGFR/HER2 TKI lapatinib failed to inhibit cell proliferation. However, ibrutinib and third generation EGFR/HER2 TKIs, EGF816 and AZD9291, inhibited cell proliferation and induced apoptosis at sub-micromolar concentrations. Western blotting analysis showed dose dependent decreases in phosphorylation of HER2 as well as HER2 downstream signaling molecules such as p-AKT, and p-MAPK. In order to determine if targeting downstream effectors of HER2 in combination with inhibition of the receptor would increase inhibition of cell proliferation and induction of apoptosis, we screened ibrutinib, EGF816 and AZD9291 in combination with both mTOR and AKT inhibitors. There was a modest additive effect when ibrutinib was used in combination with everolimus, an mTOR inhibitor, but there was no additive effect of EGF816 or AZD9291 was used in combination with everolimus. These results indicate that EGF816, AZD9291, or ibrutinib alone or in combination with mTOR inhibition may be effective therapeutic strategies for the treatment of HER2-driven NSCLC.']",
        "Doc_id":"AACR_2016-4799",
        "Doc_title":" Inhibition of HER2 mutant non-small cell lung cancer using 3rd generation EGFR/HER2 inhibitors",
        "_version_":1606189009250287616},
      {
        "Meeting_name":" Incidence of inconsistent driver mutations between multiple lung ground-glass nodules in patients with non-small cell lung cancer.",
        "Background":"['Background', '  Intertumor heterogeneity had been observed in various kinds of malignant tumors including non-small cell lung cancer. Comparing with extra-pulmonary metastasis, patients with multiple pulmonary nodules have a significantly higher rate of heterogeneity. The aim of this study was to compare the known driver mutations distribution among non-small cell lung cancer(NSCLC) patients with multiple intrapulmonary ground-glass nodules(GGNs). Methods', '  35 consecutively resected lung cancer patients with multiple lung GGNs  at a single institution (Tongji University, Shanghai, China) were analyzed for mutations in EGFR, KRAS, HER2, BRAF and PIK3CA together with genes fusion in ALK, ROS1 and RET.  Results', '  The median age was 60 years old, male/female', '12/23, never smoker/smoker', ' 25/10, PS 0/1', ' 22/13. Totally, 72 lesions were included into this analysis, including 9 of adenocarcinoma in situ, 9 minimal invasive adenocarcinoma and 54 invasive adenocarcinoma. Among them, 33 (45.8 %) tumors harbored EGFR mutations, including 13 were deletions in exon 19, 18 were L858R missense changes, and two were 19 deletion together with L858R mutations. 5 (6.9 %) harbored EML4-ALK fusions, 4 (5.6%)had HER2 mutations, 3(4.2%)had KRAS mutations, 1 had ROS1 fusion and BRAF mutation respectively.  A majority of the mutations were mutually exclusive, except 1 both with EGFR mutation and ALK fusion. The discordant frequency rate of the driver mutation distribution was 68.6%(24/35) in the whole population, while it was 80%(24/30) in the patients harbored at least one of the detected driver mutations. In one of the 2 cases who had 3 resected lung lesions, exon21 L858R point mutation, exon 19 deletion, and L858R point mutation together with ALK fusion were found in the 3 tumor samples separately.  Conclusions', '  The high incidence of inconsistent driver mutations distribution between multiple intrapulmonary nodules in this study suggested that these GGNs might arise as independent events and contributed to the higher rate of heterogeneity in intrapulmonary nodules. Patients with multiple GGNs should be given a separate staging and treatment strategy.']",
        "Doc_id":"ASCO_133162-144",
        "Doc_title":" Incidence of inconsistent driver mutations between multiple lung ground-glass nodules in patients with non-small cell lung cancer.",
        "_version_":1606189008598073344},
      {
        "Meeting_name":" Synergistic effect of SNDX-275 with lapatinib or erlotinib in breast, lung, or head and neck cancer cell lines expressing HER- 2.",
        "Background":"['Background', ' We previously demonstrated the synergistic effect of the histone deacetylase inhibitor SNDX-275 and gefitinib in non-small cell lung cancer (NSCLC) cell lines lacking E-cadherin expression. We evaluated the combination effect of SNDX- 275 with erlotinib or lapatinib in lung, head and neck (H&N) and breast cancer cell lines resistant to erlotinib or lapatinib(IC50> 1uM) and expressing Her2. Methods', ' This study included 10 H&N and 17 NSCLC cell lines, 2 breast cancer cell lines with expressing Her2 (SK BR3, MCF7) and one lacking Her2 expression, MDA-MB231. Cell lines were incubated for 5 days with increasing concentrations (0.16, 1 and 6M) of SNDX-275, lapatinib and erlotinib alone or in combination. The growth inhibitory effect was analyzed with MTT assay. The combination drug effect was evaluated using CalcuSyn (Cambridge, UK). E-cadherin and Her2 expression was evaluated using microarray analysis and RT-PCR. Her2 was considered positive if the relative expression was >300 by RT-PCR. Protein expression was analyzed with western blots. Results', ' Among the 17 NSCLC and 10 H&N cell lines 16 (12 NSCLC and 4 H&N) had positive Her2 RNA expression. 2 NSCLC (A549, H1703) and 2 H&N (UMSCC10, UMSCC19) were resistant to erlotinib or lapatinib (IC50>1M). The 2 breast cancer cell lines 2, MCF7 and MDA-MB-321, were resistant to erlotinib and lapatinib. SNDX-275 increased the expression of E-cadherin in 5 of the 6 cell lines selected (A549, H1703, UMSCC19, MCF7 and MDA- MB-321). Synergistic effect of SNDX-275 1M and lapatinib 1M was detected in the MCF7, UMSCC10, UMSCC19 cell lines (Combination Index, CI', ' 0.09, 0.9, 0.67; respectively), while SNDX-275 1M and erlotinib 1M were synergistic in MCF7, MDA-MB-321, H1703 and A549 (CI', ' 0.2, 0.95, 0.58, 0.32; respectively). Conclusions', ' The combination of SNDX-275 and erlotinib or lapatinib is active in breast, NSCLC, H&N cell lines resistant to either drug alone.']",
        "Doc_id":"ASCO_34659-65",
        "Doc_title":" Synergistic effect of SNDX-275 with lapatinib or erlotinib in breast, lung, or head and neck cancer cell lines expressing HER- 2.",
        "_version_":1606189013737144320},
      {
        "Meeting_name":" Activating ERBB4 mutations in non-small cell lung cancer",
        "Background":"['Genes encoding the ErbB receptor tyrosine kinases (EGFR/ERBB1, ERBB2, ERBB3, and ERBB4) are key regulators of cellular proliferation, survival, and differentiation, and thus represent potent proto-oncogenes. In particular, mutations or copy number variations of EGFR or ERBB2 are present in human malignancies and serve as predictive markers for targeted therapies. Recent efforts to comprehensively characterize the mutational landscape of human cancers have identified frequent somatic mutations in ERBB4 in various cancer types, such as non-small cell lung cancer (NSCLC), melanoma, and colorectal cancer. However, the significance of mutated ERBB4 in cancer remains elusive.Here, we have functionally characterized nine ERBB4 mutations previously identified in lung adenocarcinoma. Four out of the nine mutations, Y285C, D595V, D931Y and K935I, were found to be activating, increasing both basal and ligand-induced ErbB4 phosphorylation. According to structural analysis, the four activating mutations were located at critical positions at the dimerization interfaces of the ErbB4 extracellular (Y285C, D595V) and kinase (D931Y and K935I) domains. Consistently, the mutations enhanced ErbB4 dimerization and increased the trans activation in ErbB4 homodimers and ErbB4/ErbB2 heterodimers. The expression of the activating ERBB4 mutants promoted survival of NIH 3T3 cells in the absence of serum. Interestingly, serum starvation of NIH 3T3 cells expressing the ERBB4 mutants only moderately increased the phosphorylation of canonical ErbB signaling pathway effectors Erk1/2 and Akt as compared to wild-type ERBB4. In contrast, the mutations clearly enhanced the proteolytic release of signaling-competent ErbB4 intracellular domain.These results suggest the presence of activating, oncogenic mutations of ERBB4 in non-small cell lung cancer.']",
        "Doc_id":"AACR_2015-139",
        "Doc_title":" Activating ERBB4 mutations in non-small cell lung cancer",
        "_version_":1606188985749602304},
      {
        "Meeting_name":" Systematic deconvolution of kinase inhibitor profiles identifies synthetic lethal targets in ERBB2-mutant and BRD4-NUT rearranged cancer",
        "Background":"['The development of targeted therapies that efficiently inhibit cancer signaling pathways is one of the main goals of modern precision cancer medicine. Consequently, genetic and biological phenotypic data of in vitro screens are increasingly utilized to develop compounds directed against distinct oncogenic alterations. However, current targeted therapies are often limited to small genetically defined patient cohorts due to the very finite number of proteins amenable to direct chemical inhibition. An alternative approach is the exploitation of synthetic lethality, i.e. inhibition of an unaltered protein required for cell viability in a certain genetic background. Systematic chemo-genomic analyses of cancer cell lines have been shown to be suitable tools for the identification of novel synthetic lethal dependencies in cancer (Chan et al. Sci Trans Med, 2011; Sos et al. PNAS, 2012; Kim et al. Cell 2013).To systematically extend this strategy to non-small cell lung cancer (NSCLC) we characterized the efficacy of 1505 chemical compounds based on a variety of kinase inhibitor motifs in a high-throughput screen against 80 NSCLC cell lines. We extracted patterns of biological activity based on chemical and genetic information and found that potency and selectivity of compounds are strongly related to their molecular scaffold, but independent of their overall chemical complexity. We thereby discovered a sunitinib derivative that exhibited exquisite activity against ERBB2-mutant cell lines but was devoid of ERBB2 kinase activity. Instead a kinome scan and an shRNA screen suggested a mechanism of synthetic lethality by activity against NTRK family members. Moreover a CDK9 inhibitor was identified as selective and potent against a midline carcinoma cell line - a tumor entity characterized by recurrent BRD4-NUT gene fusions. Using additional cell lines we validated the upregulation of c-Fos and selective induction of apoptosis in BRD4-NUT positive midline carcinoma compared to control cell lines following CDK9 inhibition. This can augment existing therapeutic approaches, which have primarily focused on directly targeting the fusion product with bromodomain inhibitors, and offers a novel target in this entity.In conclusion, by systematically screening a large number of compounds against a panel of genetically well characterized NSCLC cell lines and incorporating chemical information we were able to derive structure activity relationships and to identify potential synthetically lethal targets in two genetic entities in clinical need of advanced selective therapies.']",
        "Doc_id":"AACR_2016-1349",
        "Doc_title":" Systematic deconvolution of kinase inhibitor profiles identifies synthetic lethal targets in ERBB2-mutant and BRD4-NUT rearranged cancer",
        "_version_":1606189012725268480},
      {
        "Meeting_name":" Simultaneous detection of multiple key genes in Chinese non-small cell lung cancer was feasible in clinical practice.",
        "Background":"['Background', '    The identification of genetic mutational profiles is significant in personalized management of non-small cell lung cancer (NSCLC). Previous techniques are limited to analyzing only a single or a few mutations together. The study was to investigate the feasibility of simultaneously rapid detection of several key genes in a Chinese cohort. Methods', '    A multiplexed PCR-based assay (SnapShot) and GeneScan were integrated to genotype hotspots across over 9 key genes with pertinence to current or potential targeted therapy in NSCLC. Clinicalpathologic features, distribution frequency of individual gene and mutation overlap were reviewed.  Results', '    Totally 45 treatment-nave and 44 treated NSCLC patients with eligible tumor specimens were enrolled into the study. Eighty-four percent of the cohort was with adenocarcinoma, and 54% of patients were smokers. EGFR, KRAS, NRAS, PTEN, BRAF, PIK3CA, MEK1, HER2 and BIM were simultaneously analyzed in a platform. Forty-three percent of patients were classified as wild type in the analysis. Fifty-seven percent of the cohort harbored mutated genes. EGFR was the most prevalent mutated gene, and its rate reached 42% in the cohort; rare mutations were found in 9.0% of the enrolled patients. Four patients with BIM_DEL were male, adenocarcinoma, and no response to erlotinib treatment. None of patients were found to harbor BRAF, PTEN, or MEK1 mutation. Sixty-four percent of patients with adenocarcinoma were detected gene mutations. None mutated genes were detected in nine patients with squamous cell carcinoma. Three patients had overlap of mutations', ' EGFR_L858R/BIM_DEL, KRAS_G12R/EGFR_L858R, and NRAS_Q61R/EGFR_L858R.  Conclusions', '    Simultaneous detection of several targeted genes by multiplexed molecular testing was feasible in clinical practice. More studies are warranted to establish its utility as more targeted therapies are developed.']",
        "Doc_id":"ASCO_129709-144",
        "Doc_title":" Simultaneous detection of multiple key genes in Chinese non-small cell lung cancer was feasible in clinical practice.",
        "_version_":1606189038788673536},
      {
        "Meeting_name":" Pharmacokinetics and pharmacodynamics of AV-203, a humanized anti-ERBB3 antibody",
        "Background":"['ERBB3 is widely expressed in human carcinomas, and its over expression is associated with poor prognosis in patients with various carcinomas, (i.e., breast, ovarian, prostate, colorectal, pancreatic, gastric, and head and neck cancers). The presence of ERBB3 correlates with local to distal metastasis in lung, gastric, and colorectal cancers as well as bone invasion in prostate cancer. Activation of ERBB3 is also implicated in the development of resistance to current cancer treatments. Due to its lack of kinase activity, the activation of the ERBB3 receptor is dependent on heterodimerization with active receptor tyrosine kinases (RTKs). The recruitment of ERBB3 into active, heterodimer complexes is mediated by its ligand Neuregulin-1 (NRG-1) or by amplified, over expressed RTKs in a ligand independent manner. Therefore, ERBB3 can crosstalk with most major receptors involved in cancer development and maintenance such as epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and c-MET. AV-203 is a potent, humanized anti-ERBB3 antibody that inhibits both ligand-dependent and independent activation of ERBB3 both in vitro and in vivo. Pharmacokinetics and pharmacodynamics of AV-203 were characterized in mice using the A549 non-small cell lung cancer xenograft model. AV-203 administered IV in mice exhibits acceptable pharmacokinetics supporting preclinical efficacy studies. AV-203 administered IV in A549 NSCLC xenograft tumor bearing mice had lower serum AUC than nave mice, demonstrating that the presence of human ErbB3 may alter the PK parameters of AV-203. In evaluating pharmacodynamics in vivo, AV-203 was able to down regulate total ERBB3 and ERBB3 signaling in A549 tumors in a time-dependent manner. Inhibition of ERBB3 signaling correlated with significant dose-dependent tumor growth inhibition in the A549 xenograft model. Dose scheduling studies with the constant AV-203 dose of 2.5 mg/kg revealed that the most efficacious schedule is the more frequent dosing at Q3D. In comparing the total dose of 10 mg/kg per 14 day cycle, at varying dose per injection and frequency, AV-203 resulted in significant tumor growth inhibition at all dose schedules. These data conclude that the efficacy of AV-203 is driven by total drug exposure and that AV-203 is not dependent on Cmax for its antitumor activity.']",
        "Doc_id":"AACR_2012-3787",
        "Doc_title":" Pharmacokinetics and pharmacodynamics of AV-203, a humanized anti-ERBB3 antibody",
        "_version_":1606189012806008832},
      {
        "Meeting_name":" Establishment,characterization and utilization of models of central nervous system metastasis",
        "Background":"[\"Metastases to the central nervous system (CNS) are the most common intracranial malignancy and are typically associated with survival times of only a few months. Lung and breast are the most common type of CNS metastasis, representing over half of such tumors. The molecular characteristics of these tumors as well as the factors driving cancers to metastasize to the CNS are poorly understood. This is due in part to inaccessibility of clinical samples and a lack of established, well-characterized models. In order to shed light on the molecular biology of these highly heterogeneous tumors and establish resources for preclinical testing, we are working to create both in vivo and in vitro models of CNS metastases originating from lung or breast cancer. We have thus far received surgical specimens from 7 lung and two breast CNS metastases. Of these, one was a spine metastasis and 6 were brain metastases. Each surgical specimen was used for the generation of patient-derived xenografts (PDX) and cell lines. Of these specimens, we have successfully established continuous cell lines of CNS metastases originating from three lung adenocarcinomas, one squamous lung carcinoma and one ductal breast carcinoma. To verify the presence of metastatic carcinoma cells in culture, cell lines were characterized by immunofluorescence based on staining profiles obtained from each tumor's pathology report. Adenocarcinomas of the lung expressed cytokeratins typical of lung cancer (CK7, 8 and 18), as well as Napsin-A, a highly specific pulmonary marker. The squamous cell carcinoma of the lung expressed these as well as CK5/6 and p63-, pathological markers of squamous differentiation. A metastatic ductal carcinoma of the breast expressed ER, Her2, GATA-3, and Vimentin. For the development of PDX models, tumors were initially implanted into flank of NOG mice and then passaged orthotopically for preclinical testing. Of nine implants, tumor growth was evident for 3 animals harboring adenocarcinoma of the lung, 2 with squamous cell carcinoma of the lung, and 1 with breast carcinoma. Samples from metastatic tissue, xenograft tissue and primary tumors (when available) were flow sorted to identify different clonal subpopulations and sequenced for exome and RNA level changes. Genomic characterization of the different clones allowed reconstruction of the evolution of metastasis and identified therapeutically targetable genes. Studies are ongoing to develop personalized preclinical mouse studies based on the integration of multi-omics data derived from the models and patient tumors.\"]",
        "Doc_id":"AACR_2014-1183",
        "Doc_title":" Establishment,characterization and utilization of models of central nervous system metastasis",
        "_version_":1606189035177377792},
      {
        "Meeting_name":" Both amplification and protein expression are required to predict FGFR tyrosine kinase inhibitor sensitivity in lung cancer",
        "Background":"['FGFR1 amplification has been suggested to be a driver oncogene in squamous and small cell lung carcinoma. However, early clinical trials show that response rate of FGFR tyrosine kinase inhibitors (FGFR-TKIs) is 20-30% in patients with FGFR1 amplified lung cancer. To elucidate the reason for de novo resistance to FGFR-TKI, six FGFR1 amplified lung cancer cell lines (NCI-H1581, DMS-114, NCI-H520, NCI-H1703, HCC95, and Calu-3) were analyzed. These cells were confirmed to have FGFR1 amplification by FISH analysis. Cell viability assay showed only 2 of six cell lines, NCI-H1581 and DMS-114, are sensitive to a FGFR-TKI, BGJ-398. Among BGJ-398 insensitive cells, NCI-H1703, HCC95, and Calu-3 cells express low mRNA and protein level of FGFR1 even in the presence of FGFR1 amplification. In addition, while BGJ-398 downregulates ERK phosphorylation in FGFR1 protein expressing cells, the drug had no effect on ERK signaling in BGJ-398 resistant cells with low FGFR1 protein expression. Importantly, other driver oncogenes were found in these BGJ-398 insensitive cell lines. PDGFRa amplification in H1703 cells and HER2 amplification in Calu-3 cells were reported previously. In this study, we have also found ERBB3 ligand NRG1 was overexpressed in HCC95 cells. Knockdown of NRG1 suppressed cell growth and combination of lapatinib with BGJ-398 led to cell death. To further determine whether FGFR1 protein expression is enough for the sensitivity to FGFR-TKIs, lung cancer cell lines were screened to FGFR-TKIs, BGJ-398 and PD-173034. This screen identified that all FGFR-TKI sensitive cell lines harbor FGFR1 amplification with high protein expression. These results suggest FGFR-TKIs should be used to patients harboring both FGFR1 amplification and protein expression. In case tumors with FGFR1 amplification, but expressing low FGFR1 protein, another driver oncogene may coexist and targeting both FGFR1 and these coexisting driver oncogenes are required to treat these tumors.']",
        "Doc_id":"AACR_2015-749",
        "Doc_title":" Both amplification and protein expression are required to predict FGFR tyrosine kinase inhibitor sensitivity in lung cancer",
        "_version_":1606189031261995009},
      {
        "Meeting_name":" Mutation profile in non-small cell lung cancer",
        "Background":"['Background', '  Non-small cell lung cancer (NSCLC) is known to harbor molecular mutations or rearrangements predictive to a variety of targeted therapies, which have been increasing the overall survival (OS) in recent years. There is a lack of studies evaluating the prevalence of those molecular alterations in NSCLC patients in Brazil.  Methods', '  This was a retrospective analysis of patients diagnosed with lung adenocarcinoma who were treated at Antonio Ermirio de Moraes Oncology Center (Brazil) from January 2011 to December 2014. Status of EGFR (epidermal growth factor receptor) mutation, ALK (anaplastic lymphoma kinase) translocation, KRAS (kirsten rat sarcoma) mutation, HER2 (human epidermal receptor-2) ampification, and ROS1 (c-ros oncogene 1) rearrangement status was evaluated. Results', '  A total of 290 patients with lung adenocarcinoma were included in the analysis. Median age was 65 years (range 30-89), 51.7% were male and 67.9% were smokers or previously smokers. At diagnosis, 57.6% were metastatic and 4.8% were stage IIIB according to AJCC 2010. The analysis of EGFR status was performed in 162 patients (55.9%). The prevalence of EGFR mutation was 32.7%', ' 23 patients at exon 19, 21 at exon 21; 6 at exon 20; and 1 at exon 18. The prevalence of ALK translocation was 4.0% (3/75 patients). KRAS mutation was detected in 20% (3/15), BRAF mutation in 11.8% (2/17), HER2 amplification in 14.3% (2/14), and ROS1 mutation in 9% (1/11).   Conclusions', '  Despite being a retrospective analysis, a high prevalence of EGFR mutation (32.7%) and ALK translocation (4.0%) was detected in a brazilian population with NSCLC, which offers further clinical benefit.']",
        "Doc_id":"ASCO_152730-156",
        "Doc_title":" Mutation profile in non-small cell lung cancer",
        "_version_":1606189005181812737},
      {
        "Meeting_name":" Discovery of orally active 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes with dual EGFR and HER2 inhibitory activity.",
        "Background":"['Growth factor receptors of the ErbB family, especially ErbB1 (EGFR) and ErbB2 (HER2), have attracted considerable attention in recent years as therapeutic targets for the treatment of numerous malignancies including cancers of the lung, colon, and breast, either through blockade of the extracellular ligand binding site by monoclonal antibodies (e.g. anti-EGFR antibodies cetuximab and panitumumab, and anti-HER2 antibody trastuzumab) or inhibition of the intracellular tyrosine kinase domain by small molecule inhibitors (e.g. EGFR kinase inhibitors gefitinib and erlotinib, and dual EGFR/HER2 inhibitor lapatinib). The abundance of small molecule kinase inhibitors in clinical development or on the market attests to the acceptance of ErbB inhibition as a clinically relevant paradigm. Nevertheless, the emergence of resistance mechanisms in ErbB driven or dependent tumors indicates that continued research is required to discover more effective drugs. We previously reported the discovery of JNJ-28871063, a potent inhibitor of EGFR and HER2 kinases in vitro that also showed excellent antitumor efficacy in EGFR (A431 epidermoid carcinoma) and HER2 (N87 gastric carcinoma) overexpressing xenograft models and significant extension of survival in a mouse intracranial tumor model. This compound is a 4-amino-6-arylaminopyrimidine-5-carbaldehyde oxime, a monocyclic chemotype that mimics the traditional bicyclic quinazoline scaffold via an intramolecular hydrogen-bonded pseudocycle involving the adjacent 4-amino and 5-oximino groups. In this study, we present results of a structure-guided analog program designed to optimize in vitro kinase potency and in vivo antitumor efficacy of the pyrimidine-oximes. While substituents on the 6-arylamino group are critical for ErbB inhibitory potency and kinase selectivity, substitution on the oxime oxygen may be changed to modify physico-chemical properties and bioavailability. We will discuss structure-activity relationships for the 5-oximino and 6-arylamino groups as well as the important role played by O-aminoalkyl oxime substituents in improving in vivo activity.']",
        "Doc_id":"AACR_2013-2456",
        "Doc_title":" Discovery of orally active 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes with dual EGFR and HER2 inhibitory activity.",
        "_version_":1606188971905253376},
      {
        "Meeting_name":" Low dose Ganetespib (STA-9090) enhances radiotherapy effects on lung cancer cells by synergistically altering levels of cell cycle progression proteins",
        "Background":"['Radiotherapy is an important component for the curative management of locally advanced non-small cell lung cancer (LA-NSCLC); however radioresistance can hamper the efficacy of treatment. Biological innovations by combining molecular targeted therapy with radiation could potentially enhance radiotherapy efficacy. Hsp90 (heat shock protein 90) is a chaperone protein that assists other proteins in folding, stability and degradation. Since Hsp90 stabilizes a variety of client proteins required for survival of cancer cells, Hsp90 inhibitors are currently studied for their therapeutic benefit in the treatment of various types of malignancies. One drug in particular is Ganetespib, a potent second generation HSP90 inhibitor with minimal ocular and hepatic toxicities, has proven improved efficacy in Stage IV NSCLC in combination with docetaxel, and is now in phase III clinical testing (GALAXY-II). The purpose of our study is to determine if low dose (25 nM) Ganetespib in combination with irradiation can enhance the radiotherapeutic effects on human lung cancer cells. The experiments were conducted using Kras mutant H460 and A549 cells, and Kras wild type H1650 cells with p53 mutation. Cell survival was measured by clonogenic survival assay (CSA). Cell cycle distribution was analyzed by flow cytometry. Expression and activity of radiosensitivity related proteins was investigated by RPPA and western blotting. Our results demonstrated that Ganetespib reduced radiation clonogenic survival on lung cancer cells, and greatly attenuated DNA damage repair with irradiation as assessed by P53BP1 foci formation. Cell cycle analysis showed that Ganetespib dramatically increased G2/M arrest between 24-48 hours, which placed cells in the radiosensitive part of the cell cycle, thereby promoting subsequent apoptosis after 48 hours. On RPPA, while higher doses of Ganetespib (50-100 nM) completely attenuated the expression of important client growth factor and survival promoting proteins such as EGFR, Her-2, AKT, and mTOR, and enhanced expressed of apoptotic pathways proteins, radiation dose-dependently acted in concert with low dose Ganetespib to upregulate p21 and downregulate pRb levels that were not apparent with either drug or radiation alone. These results suggest that low dose Ganetespib can act as a potent radiosensitizer in the treatment of NSCLC by altering levels of cell cycle progression proteins. Ganetespib in combination with radiotherapy should be explored clinically in LA-NSCLC.']",
        "Doc_id":"AACR_2014-4902",
        "Doc_title":" Low dose Ganetespib (STA-9090) enhances radiotherapy effects on lung cancer cells by synergistically altering levels of cell cycle progression proteins",
        "_version_":1606189012837466112},
      {
        "Meeting_name":" Somatic driver mutations among never smoking female lung cancer cases in China identify unique mutation pattern that may be associated with household coal burning",
        "Background":"[\"Globally, about 53% of lung cancer cases in women and 15% of lung cancer cases in men are not attributable to active tobacco use, making lung cancer in never smokers the seventh leading cause of cancer death. Experimental and epidemiological evidence suggest that lung cancer in never smokers has unique risk factors, clinical features, and histological distributions as compared to those lung cancer cases attributed to tobacco smoking. In general, lung cancer in never smokers presents predominately as adenocarcinoma and in females. The lung cancer rate among females in Xuanwei, China is among the highest in the world for nonsmoking females, and has been attributed to indoor air pollution from domestic fuel combustion, particularly from bituminous coal. To further explore the clinical and histological aspects of lung cancer in Xuanwei, we collected formalin-fixed paraffin embedded (FFPE) tissue samples from a series of 76 female lung cancer cases. The mean age of the patients was 47.7 years old (9.2 years). Expert consensus review found 54 (71%) of the female lung cancer cases were adenocarcinomas (ADCs), 11 (14.5%) were squamous cell carcinomas (SCCs), 1 (1.3%) was an adenosquamous carcinoma (ADSC), 8 (10.5%) were large cell carcinomas, and 2 (2.7%) were other subtypes. We then used two multiplexed assays to detect in DNA from FFPE tissue more than 40 recurrent mutations in nine genes relevant to existing and emerging targeted lung cancer therapies among subjects who were confirmed never smoking female lung cancer cases (32 ADCs, 7 SCCs, 1 ADSC). These assays include amplification of DNA through Applied Biosystem's SNaPshot technology to detect 38 different recurrent somatic point mutations in 8 driver genes (EGFR, KRAS, BRAF, NRAS, PIK3CA, MEK1, AKT1, and PTEN) and a PCR-based sizing assay that assesses for EGFR exon 19 deletions, EGFR exon 20 insertions, and HER2 exon 20 insertions. We detected 15 EGFR mutations [E20-6bp-ins. (n=1); EGFR_19-15bpDel (n=4); EGFR_G719A_2156G>C (n=2); EGFR_G719C_2155G>T (n=3); EGFR_G719S _2155G>T (n=1); EGFR_G719S_2155G>A (n=1); EGFR_L858R_2573T>G (n=2); EGFR L861Q_2582T>A (n=1)] in 12 ADCs and 2 SCCs. Six KRAS mutations, all of which were KRAS G12C_34G>T, were detected in 5 ADCs and 1 SCC. EGFR and KRAS mutations were mutually exclusive and no mutations were observed for BRAF, NRAS, PIK3CA, MEK1, HER2, AKT1, or PTEN. The high percentage of samples with KRAS mutations (15.0% overall; 15.6% ADCs; 14.3% SCCs) in our series is of interest, primarily because KRAS mutations are reportedly more rare in other populations from Asia (5%) and populations of never smokers from Asia (2%). Given that all subjects with KRAS mutations burned coal indoors for heating and cooking, our findings may provide new insights into the pathogenesis of lung cancer among never smoking females exposed to indoor air pollution from coal.\"]",
        "Doc_id":"AACR_2012-5479",
        "Doc_title":" Somatic driver mutations among never smoking female lung cancer cases in China identify unique mutation pattern that may be associated with household coal burning",
        "_version_":1606188997303861248},
      {
        "Meeting_name":" Comparative surface proteomics of NCI-H2122 cells reveals distinct cell surface phenotype of a metastatic NSCLC cell line expressing oncogenic KRASG12C",
        "Background":"['Oncogenic KRAS mutations are found in 40% of non-small cell lung carcinomas (NSCLC). In order to expand the treatment options for NSCLC harboring oncogenic K-Ras, new therapeutic cell surface targets need to be identified and characterized. Towards this goal we carried out comparative cell surface analysis of the NSCLC cell line H2122-KRASG12C and the BL2122 cell line (i.e., control), which has been established from the peripheral blood lymphocytes of the same NSCLC patient. Here, we describe optimized hydrazide-based glycoproteomics for mapping of the cell surface proteome of the NSCLC H2122 cell line harboring oncogenic KRASG12C. Our comparative glycoproteomics revealed 632 proteins identified by LC-MS at the surface of both H2122-KRASG12C and BL2122 cell lines. Subtractive proteomics revealed 215 proteins detected solely at the H2122-KRASG12C cell surface while 214 proteins were found germane to the cell surface of BL2122 cells. A total of 203 proteins were commonly identified at the surface of both cell lines. Spectral counting based quantitation revealed 44 proteins showing  3-fold increase in their relative concentration at the cell surface of H2122-KRASG12C cells. Subsequent meta-analysis via Ingenuity Pathway Analysis (IPA) revealed significant activation of canonical pathways known to be involved in NSCLC biology (e.g., EGFR/neuregulin, and PI3K/AKT signaling). From a subset of proteins showing significant up-regulation at the surface of H2122-KRASG12C cells, we further cross-validated CD147 using immunofluorescence analysis (IFA) and Western blotting (WB). Interestingly, subsequent IFA confirmed the over-expression of CD147 at the cell surface of pancreatic KP-3, lung H2444, and colon SW620 cancer cell lines, each harboring constitutively activated KRAS. Importantly, amongst 215 proteins identified solely at the cell surface of H2122-KRASG12C cells, proteins upstream of K-Ras, epidermal growth factor receptor (EGFR), receptor tyrosine-protein kinase erbB-2 (ERBB2), receptor tyrosine-protein kinase erbB-3 (ERBB3), and disintegrin metalloproteinase domain-containing protein 17 (ADAM17) were unambiguously identified. Using WB analysis, we first confirmed the expression K-Ras in the membrane preparation of H2122-KRASG12C cells. Interestingly, insulin-like growth factor 1 receptor, (IGF1R), and mesothelin (MSLN) were also detected exclusively at the cell surface of the H2122-KRASG12C. We further cross-validated the expression of mesothelin using WB. Taken together, present approach greatly extends the known cell surface phenotype of the NSCLC H2122-KRASG12C cells and can be readily employed as a primary proteomic screen to provide the basis for discovery and characterization of novel cell surface therapeutic targets or diagnostic assays in cells/tissues harboring oncogenic K-Ras.']",
        "Doc_id":"AACR_2015-1829",
        "Doc_title":" Comparative surface proteomics of NCI-H2122 cells reveals distinct cell surface phenotype of a metastatic NSCLC cell line expressing oncogenic KRASG12C",
        "_version_":1606188971593826304},
      {
        "Meeting_name":" Uncovering signals of somatic selection through whole exome and whole genome sequencing of lung adenocarcinoma",
        "Background":"['We have sequenced the exomes of over 100 and the genomes of over 20 lung adenocarcinoma tumor-normal specimen pairs. We performed hybrid capture exome sequencing of nearly 18,000 genes to >100X median per-sample coverage with 76bp paired-end reads. We performed whole genome sequencing achieving 60X median tumor and 20X median normal coverage with 350bp median insert size and 101bp paired-end reads. Our exome analysis yielded over 50,000 substitution and small indel coding events, with a mean somatic mutation rate of 10-11 events / MB. This resulted in over 300 non-synonymous coding events per patient, most of which were presumed to be passenger mutations unrelated to tumorigenesis. This high mutational load required us to develop novel statistical approaches (MutSig, Lawrence et al, in preparation) to identify putative lung adenocarcinoma driver genes under positive somatic selection. We constructed a complex neutral mutation model that considered sequence context and several additional genomic covariates shown to mediate gene to gene inhomogeneities of passenger mutation rates. Identification of significant deviations from this background model allowed us to recover almost all known frequently mutated lung adenocarcinoma genes, including TP53, KRAS, STK11, PIK3CA, EGFR, ERBB2, RB1, SMARCA4, and KEAP1, as well as a host of novel putative driver genes. We applied similar principles to identify pathways and sub-networks of genes undergoing apparent positive selection in lung adenocarcinoma. Whole genome analysis yielded several high-confidence in-frame protein fusion and promoter-gene fusion events enriched in tumor vs normal specimens. We also found large numbers of somatic substitution and indel events in promoters, enhancers, and non-coding DNA elements and identified putative sites of somatic retrotransposition in our whole genome data. Overall, our study eclipses previous large-scale characterization of somatic sequence variation (Refs. 1-3) in lung adenocarcinoma by at least an order of magnitude. Using novel methods adapted to the analysis of high-mutation rate tumor types (lung squamous cell carcinoma, melanoma, colorectal cancer), we are able to recover signals of selection in both known and novel genes and pathways. Our results illuminate novel lung adenocarcinoma tumor biology and provide targets for therapeutic and diagnostic investigation. References 1. Ding et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) vol. 455 (7216) pp. 1069-75 2. Kan et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) vol. 466 (7308) pp. 869-73 3. Lee et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature (2010) vol. 465 (7297) pp. 473-7']",
        "Doc_id":"AACR_2012-1682",
        "Doc_title":" Uncovering signals of somatic selection through whole exome and whole genome sequencing of lung adenocarcinoma",
        "_version_":1606189036532137984},
      {
        "Meeting_name":" Do pan-negative never-smoker (NS) lung cancer patients (pts) represent a new distinct subgroup? Data from a single-institution experience.",
        "Background":"['Background', '  Identification of oncogenic drivers has dramatically changed current therapeutic strategies for lung cancer, initiating the era of personalized therapy. \"Pan-negative\" NS non-small cell lung cancers (NSCLC) represent an exciting challenge to discover rare gene fusions and to define the best treatment options.  Methods', '  From a 243 never-smoker NSCLC database, we identified 113 oncogene-addicted lung tumors, analyzed for a 5-genes panel', ' EGFR, K-RAS, ALK, ROS1, HER2. Out of  the 130 pan-negative pts, we were able to collect archived histological material of 29, to be analyzed for RETgene rearrangement, through the FISH test. Outcomes to first line chemotherapy and TKI treatment, were evaluated by Cox multivariate analysis.  Results', '  Patients characteristics', ' good clinical conditions (PS ECOG 0-1), predominance of female sex (21 pts, 64%), median age 55 (23-81), advanced moderately and poorly differentiated adenocarcinomas. In our cohort, 3 RET+ cases (10%) were identified, one compatible with KIF5B', 'RET and the other two with a non-KIF5Bfusion partner. There was no difference neither in progression free survival (PFS) (9 months, mo) for both groups nor in overall response rate (ORR) (66.7% vs 50%; p=0.24) for pts treated with a pemetrexed-based regimen (15 pts, 52%) as compared with the non-pemetrexed group (14 pts, 48%). Median overall survival (OS) of the pts who received pemetrexed was 17 mo compared to 25 mo of the non-pemetrexed subgroup (p=0.03). In our cohort 13 pts received an oral TKI. Median OS showed no significant differences between TKI and not-TKI treatment (22 vs 23 mo, p=0.94).  Conclusions', '  Our study in a highly selected population confirms the lack of benefit in any of the outcome measures in the absence of a genetic driver. Longer survival in pan-negative NS lung cancer pts compared to an unselected NSCLC population is probably a result of their distinct clinical features.']",
        "Doc_id":"ASCO_134872-144",
        "Doc_title":" Do pan-negative never-smoker (NS) lung cancer patients (pts) represent a new distinct subgroup? Data from a single-institution experience.",
        "_version_":1606188993377992704},
      {
        "Meeting_name":" HER-2 isoform interaction in mammary carcinoma onset and progression",
        "Background":"['Human breast cancer cells express full-length HER-2 along with proteins resulting from mutation, alternative splicing, alternative initiation of translation and post-translational modification. The Delta16 splice variant, lacking exon 16, has the properties of an activated oncogene, but it could also play beneficial roles in the response to targeted therapeutic agents. To study mammary carcinogenesis in a mouse model that mimics human coexpression of full-length HER-2 and Delta16 isoforms, we produced hybrid mice bearing heterozygous copies of both human transgenes (F1 mice), and we compared them to parental mice (Delta16 and HER-2 transgenic mice, respectively). Tumor onset in F1 and Delta16 mice was much faster than in HER-2 mice (30 vs >80 weeks), but the growth of established tumors and metastatic spread were not enhanced. Each mammary carcinoma of F1 mice expressed both isoforms at variable ratios. Most (80%) expressed high levels of Delta16 and low levels of full length HER-2, a few (5%) expressed full-length HER-2 and little, if any, Delta 16, and the remainder (15%) coexpressed at high level both isoforms. The study of tumor vascularization showed that full-length HER-2 tumors mainly contained few large vessels or vascular lacunae, whereas Delta16 tumors were perfused by numerous endothelium-lined small vessels. F1 tumors with high full-length HER-2 expression made few large vessels, whereas tumors with low full-length HER-2 and high Delta16 contained numerous small vessels and expressed high levels of both VEGF and VEGFR2. Administration of trastuzumab to young F1 mice effectively prevented mammary carcinoma onset in 85% of mice at 1 year of age. The preventive effect of trastuzumab was stronger in F1 mice than in both parental strain. To analyze the intrinsic sensitivity of F1 mammary carcinoma cells to targeted drugs in 3D, we established cell lines expressing different HER-2 isoform ratios. High Delta16 expression caused high sensitivity to HER-2 inhibitors (trastuzumab, neratinib, lapatinib), whereas high full-length HER-2 was associated with a lower sensitivity. Interestingly, high levels of both isoforms was associated with resistance to trastuzumab, but sensitivity to small molecule inhibitors. In conclusion, the coexpression of full-length HER-2 and Delta16 controls several determinants of mammary carcinoma development, progression and sensitivity to targeted agents, as revealed by the study of F1 mice.']",
        "Doc_id":"AACR_2016-1200",
        "Doc_title":" HER-2 isoform interaction in mammary carcinoma onset and progression",
        "_version_":1606189013059764224},
      {
        "Meeting_name":" EGF has stimulatory and survival effects in osteosarcoma in vitro and pan-ERBB kinase inhibition causes cell growth inhibition in vitro and reduces lung metastases in vivo",
        "Background":"['Osteosarcoma is the most common primary bone tumor in children and adolescents, with recurring disease or lung metastases being the primary cause of death in patients. Expression of EGFR, Her-2, and Her-4 (ERBB1, 2 and 4) have been reported in human primary osteosarcoma, suggesting that they may be contributing to osteosarcoma pathogenesis, but the correlation of expression levels with patient outcomes has been controversial. We have shown that a pan-ERBB small molecule kinase inhibitor causes growth inhibition and apoptosis of osteosarcoma cell in vitro, suggesting a potential therapeutic benefit of using this drug in vivo. In the present study, we show that protein expression levels of EGFR, Her-2 and Her-4 are higher in osteosarcoma lung metastases than in primary tumors by TMA, and that these levels are significantly higher for Her-2 and Her-4. We created eight new osteosarcoma cell lines from primary patient tissues and found that all eight, in addition to six commonly used osteosarcoma cell lines, express detectable levels of EGFR and Her-2, and several express detectable Her-4. EGF ligand stimulation in vitro produces robust phosphorylation of EGFR, Her-2 and Her-4 in most cell lines and moderate activation in others. EGF stimulation also produces phosphorylation of Akt, MAPK and p70S6K in most cell lines and of STAT5 in six cell lines, suggesting that EGF has growth and survival stimulation effects. When adding a pan-ERBB kinase inhibitor, Pf-299804, to cells pre-stimulated with EGF, phosphorylation of EGFR, Her-2, Her-4, Akt, etc. are inhibited in a dose-dependent manner. Reverse phase protein array also shows an increase in pro-apoptotic proteins Bim and cleaved PARP with Pf-299804 treatment, confirmed by Western blots. Mouse xenograft experiments, where cells injected in the tibia spontaneously form lung metastases, showed a significant decrease in three categories of Her-4-positive lung metastases in drug-treated mice based on size', ' 1-4 cell oligomets (p=0.0055); 5 cell-200 micron micromets (p=0.0276); and greater than 200 micron macromets (p=0.0055). These data suggest that EGF produces mitogenic and survival stimulation in osteosarcoma cells and that pan ERBB-family kinase inhibition causes growth inhibition and apoptosis in vitro and reduction of lung metastases in a mouse model in vivo. This provides evidence that pan-ERBB kinase inhibition has therapeutic potential for osteosarcoma lung metastases.']",
        "Doc_id":"AACR_2014-3970",
        "Doc_title":" EGF has stimulatory and survival effects in osteosarcoma in vitro and pan-ERBB kinase inhibition causes cell growth inhibition in vitro and reduces lung metastases in vivo",
        "_version_":1606188980885258240},
      {
        "Meeting_name":" An analysis of ERBB2 alterations (amplifications and mutations) found by next-generation sequencing (NGS) in 2000+ consecutive solid tumor (ST) patients.",
        "Background":"['Background', '  Testing for ERBB2 amplification by FISH and IHC is routine in breast and gastro-esophageal cancer. There are 3 approved and multiple targeted therapies in clinical trials that rely on the results of these tests. ERBB2 amplification and activation by mutation/fusion has also been described in a wide variety of other ST. As these alterations are not routinely tested for but may predict response to anti-ERBB2 agents we sought to determine their frequency in an unselected cohort of specimens from advanced ST patients.    Methods', '  We reviewed genomic profiles from the first 2,223 formalin-fixed, paraffin-embedded specimens received and analyzed by our CLIA-certified lab (Foundation Medicine) with our NGS platform. 3,230 exons in 182 cancer-related genes and 14 genes frequently rearranged were assayed for base pair substitutions, small insertions/deletions (indels), amplifications, and rearrangements.   Results', '  110/2,223 (4.9%) specimens had 116 ERBB2 alterations', ' 67 (58%) amplifications, 29 (25%) substitutions, 16 (14%) indels, 2 (2%) splice site variants and 2 (2%) translocations, including a potential fusion. Six samples (5%) had multiple alterations, and two had both ERBB2 substitution and amplification.  14 ST types had evidence of ERBB2 alterations including 29% of esophageal, 20% of uterine, 14% of breast, and 12% of stomach carcinomas. 6% of all lung cancer samples had ERBB2 alterations. Amplifications predominated, but lung specimens had predominantly indels. Durable responses exist to anti-ERBB2 agents in STs with activating ERBB2 mutations.  Conclusions', '  Use of a broad NGS panel identifies an unprecedented number of actionable genomic changes including a significant rate of ERBB2 alterations across 14 different solid tumor types. The discovery of unanticipated ERBB2 amplifications and activating mutations in a wide variety of ST highlights the need to study a broad range of genes at a high level of sensitivity and specificity when searching for novel targets of therapy. Widespread use of this approach could provide more treatment options and enable more rapid accrual to ongoing and planned trials of agents targeting pathways under study.']",
        "Doc_id":"ASCO_114501-132",
        "Doc_title":" An analysis of ERBB2 alterations (amplifications and mutations) found by next-generation sequencing (NGS) in 2000+ consecutive solid tumor (ST) patients.",
        "_version_":1606188981924397056},
      {
        "Meeting_name":" The molecular characters of acquired resistant non-small cell lung cancer cells to afatinib",
        "Background":"['[Background] The non-small cell lung carcinomas (NSCLCs) with activating epidermal growth factor receptor (EGFR) gene mutation show significant response to EGFR-tyrosine kinase inhibitors (TKIs). However, almost all of them acquire resistance to EGFR-TKIs due to various mechanisms, such as T790M mutation or MET amplification. Afatinib is an irreversible TKI for EGFR and HER2 and known to be effective to the EGFR T790M variant. However, a half of the patient responded afatinib acquire resistance by 12 months in clinical use. Thus, to unravel the mechanisms of the resistances and to overcome them are still important issues of EGFR-TKI treatment. In this study, we established various kinds of afatinib resistant cell lines with changing drug exposing condition as we previously reported (Shien K. et al Cancer Res. 2013). We also investigated these cell lines to understand mechanisms of afatinib resistances in NSCLC.[Materials and Methods] Afatinib resistant cell lines were established using four NSCLC cell lines with activating EGFR mutations by exposing afatinib with different procedures, escalation from 1 nM, escalation from 10 nM, intermittent 2 M and continuous 2 M procedures. These cell lines were investigated about previously reported resistant related features, T790M mutation, MET amplification, and epithelial to mesenchymal transition (EMT). ALDH1A1 and ABCB1 expression, which were putative stem cell markers, were also investigated. Proliferative inhibitions with various drugs were evaluated using MTS assay.[Results] There were no T790M mutations in all afatinib resistant cell lines. HCC827 sublines exposed afatinib with escalation from 1 nM and intermittent 2 M, and HCC4011 sublines showed MET amplification. HCC827 sublines exposed afatinib with escalation from 10 nM and continuous 2 M, and HCC4006 sublines showed EMT features. Furthermore, ALDH1A1 and ABCB1 expression were up-regulated in HCC827 afatinib resistant sublines with EMT features. Next, we examined the effect of afatinib or crizotinib for the afatinib resistant cell line with MET amplification. We found that combination therapy with afatinib and crizotinib was effective to the MET amplified cell. The combination exposure was continued to establish a resistant subline (HCC827-ACR) to combination therapy. The HCC827-ACR was also showed EMT features and up-regulation of stem cell markers.[Conclusions] As in the cases of reversible EGFR-TKI, MET amplification, EMT, and stem cell-like features were emerged in afatinib resistant cells. To develop strategies to resistant cells with stem cell-like property may be critical part to overcome EGFR-TKI resistance.']",
        "Doc_id":"AACR_2014-1834",
        "Doc_title":" The molecular characters of acquired resistant non-small cell lung cancer cells to afatinib",
        "_version_":1606189014498410497},
      {
        "Meeting_name":" Identification of putative molecular targets in Merkel cell carcinoma.",
        "Background":"['Background', '  Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous neuroendocrine tumor.  MCC is attributed to Merkel Cell Polyoma virus infection in up to 80% of patients, but is of unknown molecular pathogenesis in the remainder.  Advanced disease has been managed by analogy, using regimens for small-cell lung cancer (SCLC).  No targeted agents have been identified for treatment.  We profiled molecular changes in MCC to provide insight into new therapeutic strategies.   Methods', '  64 MCC cases referred to Caris Life Sciences between 2009 and 2013 were evaluated.  Diagnoses were collected from referring physicians and classified at intake based on pathology and clinical history.  Specific testing was performed per physician request and included a combination of sequencing (Sanger, NGS), protein expression (IHC), and gene amplification (CISH or FISH).   Results', '  Positive expression of biomarkers occurring in more than half of specimens included MRP1 and TOP2A (94%), TUBB3 (90%), RRM1 (79%), PTEN (66%), and TS (63%).  Low expression of biomarkers occurring in more than half of specimens included PGP and SPARC (84%), ERCC1 and TLE3 (80%), PDGFRA (75%), and BCRP, cKIT, and MGMT (~60%).  TOPO1 and PR were overexpressed in approximately 40% of patients.  Gene amplification was not observed in cMET, EGFR, HER2, or TOP2A.  Sanger sequencing did not reveal mutations in BRAF, cKIT, EGFR, KRAS, NRAS, or PIK3CA.  NGS detected variant genes in 6 of 11 (55%) patients', ' alterations occurred in APC (n=1), ERBB4 (n=1), HRAS (n=1), RB1 (n=1), and TP53 (n=5).  Two patients exhibited multiple mutations.   Conclusions', '  Our data support the utility of cytotoxic therapies for MCC by analogy to SCLC, including platinum agents, anthracyclines, and topotecan.  MRP1 was however expressed in 94%, suggesting etoposide resistance.  A novel finding was overexpression of PR in 37% (22/60) of patients; anti-hormonal therapies merit further investigation in light of the diseases male predominance.  Sporadic mutations of cancer-related genes were identified by NGS.  The only mutational pattern observed was the presence of TP53 mutations in 5/11 (45%), potentially targeted by Wee1 and ChK1 inhibitors. Further evaluation is necessary to identify key changes in MCC that might be exploited.']",
        "Doc_id":"ASCO_134802-144",
        "Doc_title":" Identification of putative molecular targets in Merkel cell carcinoma.",
        "_version_":1606188987250114560},
      {
        "Meeting_name":" Clinical and molecular profiling of surgically resected small-cell lung cancer",
        "Background":"['Background', '  NCCN and Japanese guidelines suggest surgery for patients with c-stage I small-cell lung cancer (SCLC). However, the clinical impact of surgery with other variables on patients with early-stage SCLC has yet to be determined. Thus clarification of the clinical and molecular profile of SCLC is required. Methods', '  We reviewed the clinical courses of 149 patients with SCLC who had undergone surgery at 16 institutes from January, 2003 through January, 2013. Eighty-nine paraffin-embedded tissue samples were subjected to immunohistochemistry using 8 antibodies, and to next-generation sequencing system (NGS) using MiSeq and TruSight Tumor Panel (Illumina) loading 26 genes (UMIN registration No. 000010116/10117). Results', '  Median relapse-free survival (RFS) and overall survival (OS) were 16.6 (95%CI=7.1-26.2), and 36.7 (17.3-56.2) months, respectively. Multivariate analysis revealed that OS was longer in patients without interstitial pneumonitis (IP) (HR=0.372, 95%CI=0.181-0.767, p=0.007), without history of malignancy (HR=0.446, 0.229-0.868, p=0.017), with preoperative diagnosis (HR=0.401, 0.210-0.767, p=0.006), with c-stage II and under (HR=0.204, 0.065-0.640, p=0.006), and with p-stage IA (HR=0.294, 0.142-0.605, p=0.001). Of the 89 patients whose samples were available, MED12 and TGF-RII were highly expressed in nucleus and cytoplasm, respectively in 92% and 61%. Multivariate analysis demonstrated that high expression of either c-Kit or HER2 in tumors is an independent factor for longer OS (HR=0.396, 95%CI=0.209-0.752, p=0.005). None of the tumors expressed ALK. There was no relationship between the expression of c-Met, EGFR, and VEGFRII and either of RFS or OS. Thirty-five samples were subjected to NGS so far. However, no druggable mutations of BRAF, EGFR, ERBB2, KRAS, KIT, PDGFRA, PIK3CA, FOXL2, GNAQ, GNAS, and FGFR2 were found. Conclusions', '  These results indicate that i) complication of IP and history of malignancy might be major decision factors of surgery, and', ' ii) patients with c-stage II should be considered for surgery in a prospective trial. Immunohistochemistry results assist us in gaining a better understanding of the biology of SCLC.']",
        "Doc_id":"ASCO_125324-144",
        "Doc_title":" Clinical and molecular profiling of surgically resected small-cell lung cancer",
        "_version_":1606189014759505920},
      {
        "Meeting_name":" Mechanisms of resistance to EGFR tyrosine kinase inhibitors involving HER-family ligands and receptors",
        "Background":"['Known mechanisms of acquired resistance to EGFR tyrosine kinase inhibitor (EGFR-TKI), including the second mutation of EGFR, T790M, MET amplification, and HGF overexpression, explain approximately 60% of cases, but the remaining mechanisms have not been clarified. To investigate novel mechanisms of acquired resistance to EGFR-TKI, we examined HER-family ligands and HER-family receptor status in non-small cell lung carcinoma (NSCLC) cell lines (n=13). Cell lines were divided into two groups with respect to EGFR-TKI sensitivity', ' highly sensitive (HCC827, PC-9, HCC2935, and HCC4006) and resistant (H1395, H1666, H596, H1437, A549, H226B, H1299, H460, H1792). We examined expression levels of eleven HER-family ligands_EGF, TGF, amphiregulin (AREG), betacellulin (BTC), HB-EGF, epigen (EPGN), epiregulin (EREG), and neuregulin (NRG) 1, NRG2, NRG3, and NRG4_in these cell lines. NRG2, NRG4, and EPGN were expressed at 39.5-, 31.4-, and 6.5-fold higher levels, respectively, in EGFR-TKI primary resistant NSCLC cell lines than in highly sensitive cell lines, whereas TGFA, EGF, and AREG were expressed at 0.22-, 0.3-, and 0.34-fold lower levels. Phosphorylation of EGFR was elevated in sensitive cell lines compared to resistant cell lines, but HER2-4 receptors did not evidence a difference in phsophorylation. These results suggest that the EGFR pathway is activated in sensitive cell lines, and HER2-4, which binds to EPGN, EREG, NRG2, and NRG4, might be activated in resistant cell lines. We prepared cell lines HCC827GR and HCC827ER, derived from HCC827, which acquired resistance to gefitinib or erlotinib, respectively. We analyzed HER-family ligands and receptors using these cell lines. Compared to parent cells, EPGN, EREG, HB-EGF, TGFA, NRG1, and AREG were up-regulated in HCC827GR. Phosphorylation status of EGFR, HER2, and HER3 was not altered, but that of HER4 was increased in HCC827GR. In HCC827ER, EGFR binding ligands AREG, BTC, and EGF were down-regulated, while phosphorylation of EGFR, HER2, and HRE3 was decreased. However, NRG2 was remarkably elevated and HER4 and its downstream STAT5 were phosphorylated. These results indicate that HER4 and its binding ligands may contribute to acquired resistance to EGFR-TKI. Considering these results, it is possible that the HER4-STAT5 pathway might be common to primary and acquired resistance to EGFR-TKI. We continue to investigate its significance.']",
        "Doc_id":"AACR_2012-1906",
        "Doc_title":" Mechanisms of resistance to EGFR tyrosine kinase inhibitors involving HER-family ligands and receptors",
        "_version_":1606189025913208832},
      {
        "Meeting_name":" Comparison of serum HER-2/neu between trastuzumab-based regimen and anthyracycline-based regimen during neoadjuvant chemotherapy in advanced primary breast cancer.",
        "Background":"['Background', ' Serum Her-2/neu has been known as molecular surrogating marker of predicting treatment response in Her-2 positive breast cancer. We compare the change of serum Her-2/neu during neoadjuvant chemotherapy between trastuzumab(H) and anthyracyline(A) based treatment. Methods', ' All breast cancers were tested by immunohistochemical stain and FISH for Her-2/neu before treatment. Serum Her-2/neu was twice measured by Chemiluminescence immunoassay(ADVIA centaurTMsystem) before neoadjuvant chemotherapy and before operation. The cutoff value was 10.2 mg/ml according to previous study. Pathologic complete response (pCR) was considered as no residual tumor or remnant ductal carcinoma in situ, partial response (PR) was less than 50% decrease in maximal diameter in pathologic tumor size. Results', ' Serum Her-2/neu of trastuzumab group was more decreased than of anthyracyline group (H; 12.9  14.5 ng/mL vs. A; 2.2  1.2 ng/mL, p=0.024). In trastuzumab group, pCR was relatively correlated with decrease of serum Her-2/neu (PR', ' 0.8  0.84 ng/ml vs. pCR', ' 21.1  13.2 ng/ml, p=0.08). Conclusions', ' A decrease in serum Her-2/neu levels during treatment was associated with pathologic response in patients receiving neoadjuvant chemotherapy, particularly, trastuzumab-based regimen. Serum Her-2/neu levels may serve to monitoring neoadjuvant therapy in Her-2/neu positive breast cancer.']",
        "Doc_id":"ASCO_33715-65",
        "Doc_title":" Comparison of serum HER-2/neu between trastuzumab-based regimen and anthyracycline-based regimen during neoadjuvant chemotherapy in advanced primary breast cancer.",
        "_version_":1606188990434639872},
      {
        "Meeting_name":" Routine tumor next-generation sequencing (NGS) to identify rare germline lung cancer risk mutations in EGFR and ERBB2.",
        "Background":"['Background', ' New insights into lung cancer genomics has required a new look at genetic determinants of inherited lung cancer risk. There are now four germline mutations in lung cancer oncogenes (EGFR T790M, V843I, R776H; and ERBB2 G660D) which have been reported in kindreds with a high prevalence of lung cancer in nonsmokers. We hypothesized that routine tumor NGS could be used to find rare kindreds with inherited lung cancer risk. Methods', ' An institute-wide database of tumor NGS results was queried for cases positive for one of the reported germline risk alleles in EGFR or ERBB2. At our center, tumor NGS is performed using a hybrid-capture platform spanning exons and key introns of ~400 cancer related genes, and is available for patients (pts) with consent to a research protocol. For living pts with a mutation detected at an allelic fraction (AF) > 25%, and excluding acquired T790M, genetic counseling and CLIA germline testing was provided. For pts with EGFR T790M, testing was performed on the INHERIT EGFR study (NCT01754025; ALCMI). Results', ' 51 cases were identified from a total of 13,488 cancers with NGS results', ' 45 with EGFR T790M (all lung cancer), 4 with EGFR R776H (NSCLC, endometrial cancer, and 2 glioma), 2 with ERBB2 G660D (NSCLC and glioblastoma). 34 pts with T790M detected after EGFR inhibitor were excluded, leaving 17 pts of interest. Germline testing was performed on 9 living pts with > 25% AF on NGS, and was positive in 8; 6 of these had germline EGFR T790M. Additionally, germline EGFR R776H was found in a never-smoker with metastatic endometrial cancer; she had a prior a history of NSCLC, and family history was notable for multiple members with lung, breast, and colon cancer. Germline ERBB2 G660D was found in a young never-smoker with metastatic NSCLC and a family history significant for lung cancer in multiple first-degree relatives. Conclusions', ' Rare germline lung cancer risk mutations in EGFR and ERBB2 can be identified on routine tumor NGS, and may indicate a risk of inherited lung cancer. Our study includes the second known report of a germline EGFR R776H or ERBB2 G660D mutations. Commercial germline NGS assays could be expanded to cover these rare but potentially high-penetrance variants.']",
        "Doc_id":"ASCO_186794-199",
        "Doc_title":" Routine tumor next-generation sequencing (NGS) to identify rare germline lung cancer risk mutations in EGFR and ERBB2.",
        "_version_":1606188991229460480},
      {
        "Meeting_name":" STING signaling in breast tumor microenvironment modulates immune checkpoint blockade efficacy in the neu-N mouse model of breast cancer.",
        "Background":"['Background', ' The presence of tumor infiltrating T cells (TILs) is associated with improved clinical outcomes in multiple tumor types and is also necessary for response to immune checkpoint blockade. While T cell responses to some tumors occur spontaneously, the majority of cancers are not naturally recognized by the immune system. The lack of response is attributed primarily to insufficient T cell infiltration into the tumor microenvironment (TME). Activating the STING pathway represents one strategy for increasing infiltration of T cells into the TME. This induces interferon- (IFN-) production, leading to dendritic cell (DC) activation and priming of tumor antigen specific CD8+ T cells that mediate tumor regression. The intratumoral injection (IT) of ML-RR-S2-CDA (ADU-S100), a synthetic cyclic dinucleotide STING agonist, has antitumor efficacy in several aggressive mouse tumor models, including B16 melanoma, CT26 colon carcinoma, Panc02 pancreatic carcinoma, and 4T1 triple negative breast cancer. However, the impact of antigen-specific tolerance on tumor regression associated with STING-activation remains poorly understood. Therefore, we evaluated the efficacy of IT ADU-S100 in both non-tolerant parental FVB/N and the immune tolerant neu/N transgenic mice bearing established HER-2+ breast tumors.']",
        "Doc_id":"AACR_2017-2993",
        "Doc_title":" STING signaling in breast tumor microenvironment modulates immune checkpoint blockade efficacy in the neu-N mouse model of breast cancer.",
        "_version_":1606188992216170496},
      {
        "Meeting_name":" Subgroup classification of receptor tyrosine kinase (RTK) pathway activation in KRAS-mutated metastatic carcinoma.",
        "Background":"['Background', '  Molecular stratification of metastatic carcinoma in body fluids has become critical to therapy selection, as these are often the only accessible disease sites. We performed multimodality RTK pathway analysis of metastatic carcinoma in pleural fluid to assess how functional RTK dysregulation correlates with initiating mutation.  Methods', '  Tumor samples from 45 patients with metastatic carcinoma diagnosed in pleural fluid were assessed (22 lung adenocarcinomas, 7 breast, 3 gastric, 4 ovarian, 9 others); with sequential analysis in 9 patients. Site of origin was determined by a combination of clinical history, cytomorphology, and CK7/20, CK5/6, napsin A, and TTF-1 immunostains. Mutation analysis of KRAS (codons 12, 13, and 61), BRAF, and PIK3CA (exons 1, 9, and 20) was performed with PCR-based pyrosequencing, with EGFR mutations in exons 18-21 assessed by Sanger sequencing. FISH analysis to assess copy number of the HER2, MET, ALK, and EGFR loci was performed using commercially available probes. Functional RTK pathway activation was assessed using semi-quantitative analysis using a panel of phospho(p)-antibodies including MET, EGFR, HER2 and AKT activation sites. Results', '  KRAS mutations were common in all tumors, including lung (11/22, 50%), breast (6/7, 86%), gastric (2/3, 67%), and ovarian (4/4, 100%) carcinomas. Cases without KRAS mutation showed EGFR mutations or BRAF mutations (lung), with PIK3CA mutations in 2 breast, 1 lung, and 1 endometrial tumor. The KRAS-mutated cases showed distinct subgroups characterized by other TK abnormalities, including genomic amplification of HER2 (17.2%), EGFR (3.4%), and MET (13.8%) and strong p-activation of MET (3.4%), EGFR (24.1%), and AKT (32.1%). Conclusions', ' Metastatic carcinoma in pleural fluid has high rates of KRAS mutation, regardless of site of origin Among KRAS-mutated tumors, there is a stable subgrouping/clustering of RTK activation patterns, indicative of distinct progression events. Given that KRAS mutation predicts lack of response to current RTK-targeted therapies, functional correlates of these observed genetic subgroups will be critical to designing novel treatments for this high-risk subgroup of carcinomas.']",
        "Doc_id":"ASCO_84941-102",
        "Doc_title":" Subgroup classification of receptor tyrosine kinase (RTK) pathway activation in KRAS-mutated metastatic carcinoma.",
        "_version_":1606188997101486080},
      {
        "Meeting_name":" Metastatic analysis of clonal epithelial and mesenchymal-like murine mammary tumor cells.",
        "Background":"['Tumor metastasis is the most common cause of cancer mortality, and yet it is among the most poorly understood processes in tumor progression. While carcinomas are composed primarily of epithelial cells, tumors contain a continuum of cells with epithelial and mesenchymal-like properties. This tumor cell heterogeneity is attributed to differentiation plasticity, which is characterized by epithelial to mesenchymal (EMT) or mesenchymal to epithelial transitions (MET). It has been proposed that tumor cells undergo EMT in order to disseminate from the primary tumor and MET in order to seed at secondary sites. The invasive mesenchymal carcinoma cell phenotype is thought to be a state required for tumor dissemination, but to date, pathologists have not found conclusive evidence of mesenchymal cells in human metastatic tumor samples. An alternative theory suggests that both mesenchymal and epithelial cells are required for metastasis to occur. According to this theory, detachment from the primary tumor and invasion by mesenchymal cells facilitates the movement of epithelial tumor cells that are able to seed at distant sites. We hypothesize that the presence of mesenchymal-like mammary tumor cells facilitate the metastasis of epithelial tumor cells and that only epithelial cells are able to seed at distant sites. To test this hypothesis, we cloned epithelial and mesenchymal-like primary cell lines from spontaneous mammary tumors produced in FVB MMTV/Neu mice. Epithelial cells have been stably transfected to express firefly luciferase and GFP, and we are in the process of cloning mesenchymal-like cells expressing Renilla luciferase and mCherry. We have preliminary data that shows that when clonal epithelial cells are administered into the mammary fat pad of FVB MMTV/Neu mice, tumors grow, but do not form metastatic lesions. In contrast, when stably transfected clonal epithelial cells are administered with non-transfected clonal mesenchymal-like tumor cells, luciferase+ metastatic lesions in the spleen, liver and lung are detected biophotonically, and GFP + cells are detected in the spleen and liver. These data indicate that epithelial cells are present (but does not rule out the presence of mesenchymal cells) at the metastatic site. Whether epithelial cells undergo EMT, and how metastasis is facilitated by the presence of mesenchymal cells remains to be determined.']",
        "Doc_id":"AACR_2013-1488",
        "Doc_title":" Metastatic analysis of clonal epithelial and mesenchymal-like murine mammary tumor cells.",
        "_version_":1606189032841150464},
      {
        "Meeting_name":" KL-ON113, a novel orally available dual EGFR kinase inhibitor targeting EGFR-activating and T790M mutants",
        "Background":"['Introduction', ' First generation reversible, ATP competitive inhibitors, gefitinib and erlotinib are effective treatments for a subset of non-small cell lung cancers, in particular specific EGFR-activating mutations. However their initial efficacy is limited by the development of drug resistance mutations, including the gatekeeper T790M mutation. Second-generation irreversible EGFR inhibitors that were designed to overcome the drug resistance by T790M mutation have thus far had limited success. Our goal was then to develop a dual kinase EGFR inhibitor effective against gefitinib sensitive and resistant (T790M) mutations. Herein, we describe the biological and pharmacokinetic properties of a representative molecule, KL-ON113 from a series of novel and small molecule EGFR inhibitors as a clinical development for non-small cell lung cancer (NSCLC).Experimental Procedures', ' Based on structure activity relationship (SAR) studies, we identified a novel dual kinase EGFR inhibitor, KL-ON113 effective against gefitinib sensitive and resistant (T790M) mutations. EGFR tyrosine kinase activity of KL-ON113 was determined using HTRF KinEASE assay kit (CisBio, Bedford, MA) with modifications. EGF induced cell proliferation assay (XTT) was conducted to determine the growth inhibitory effect of KL-ON113 in EGFR expressing WT and mutant cell lines. Inhibition of EGF induced EGFR phosphorylation (Y1173) in A431 cells was measured by PathScan Phospho-EGF Receptor (Tyr1173) Sandwich ELISA Kit (Cell Signaling Technology, Beverly, MA). Metabolic stability of the KL-ON113 was evaluated in microsomes obtained from mouse, rat, monkey, and human. Pharmacokinetic behavior of KL-ON113 in plasma after single dose oral administration or IV injection was determined in female Balb/c mice.Results', ' KL-ON113 demonstrated remarkable potency against the purified EGFR/HER2 including EGFR (wt), EGFR (L858R), EGFR (delE746_A750), EGFR (T790M), EGFR (L858R/T790M) and HER2 with IC50 of 12nM, 1.3nM, 0.9nM, 49nM, 325nM and 14nM, respectively with 100-fold more active against gefitinib/erlotinib resistant L858R/T790M EGFR mutant. Additionally, KL-ON113 caused a significant reduction in viability & EGFR phosphorylation (Y1173) in A431 cells, while no effect observed in normal WI-38 lung fibroblast cells confirming its selectivity. Pharmacokinetic studies in female Balb/c mice indicated good oral bioavailability of 80% for KL-ON113. Further, KL-ON113 was metabolically stable across the species studied.Conclusions', ' Our findings demonstrate that KL-ON113 as a potent dual kinase EGFR inhibitor effective against gefitinib sensitive and resistant (T790M) mutations with a favorable pharmacokinetic profile. KL-ON113 is also being tested for its in-vivo efficacy in NSCLC xenograft models harboring EGFR WT and EGFR L858R/T790M besides selectivity against other receptor tyrosine kinases.']",
        "Doc_id":"AACR_2014-1729",
        "Doc_title":" KL-ON113, a novel orally available dual EGFR kinase inhibitor targeting EGFR-activating and T790M mutants",
        "_version_":1606188997407670272},
      {
        "Meeting_name":" Novel role for MIG-6 in mediating TKI resistance in ALK-rearranged lung cancer",
        "Background":"['INTRODUCTION', ' Patients with ALK-rearranged non-small cell lung cancer (NSCLC) derive significant anti-tumor responses when treated with ALK tyrosine kinase inhibitors (TKIs), such as crizotinib, the first-in-class ALK TKI. However despite the high response rates to these agents, acquired resistance to ALK TKI therapy remains a significant barrier to overcome in order to maximize therapeutic responses in patients with ALK+ lung cancer. In crizotinib-resistant tumors, EGFR activation has been demonstrated to mediate acquired resistance in several independent studies. The tumor suppressor gene product MIG-6 (encoded by ERFFI1) acts as a natural inhibitor of signaling through EGFR (ErbB1) and other ErbB family members. However, a role for MIG-6 in ALK+ lung cancer has not yet been elucidated. Here, we investigated the regulation of human MIG-6 in ALK+ lung cancer cells.DESIGN', ' MIG-6 expression, protein interaction and phosphorylation status were evaluated in ALK+ lung cancer cell lines and human tumor samples. The impact of MIG-6 loss and gain of function on ErbB receptor activity and on cell proliferation/survival were determined in several models of TKI-sensitive and TKI-resistant ALK+ lung cancer.RESULTS', ' MIG-6 protein level is regulated by EML4-ALK fusion protein at both transcriptional and post-translational levels. Genetic or pharmacologic knock-down of ALK significantly reduced MIG-6 protein levels in ALK+/TKI sensitive cells. We established a novel interaction between MIG-6 and ALK fusion proteins (both EML4-ALK and other fusion partners), and this association was dependent on ALK kinase activity. MIG-6 can also be tyrosine-phosphorylated by EML4-ALK and be threonine-phosphorylated through EML4-ALK-dependent MAPK activation. The reduced MIG-6 protein level was accompanied by increased total and phosphorylated ErbB family members (EGFR, HER2, and HER3) in ALK+/TKI sensitive lung cancer cells. Consistent with this observation, MIG-6 protein level is also attenuated in ALK+/TKI resistant cells, following the decreased EML4-ALK activity, while EGFR signaling activity is remarkably up-regulated in these resistant cells. Crizotinib-resistant cells were re-sensitized upon exposure to EGFR/HER2 inhibitors in combination with crizotinib. In addition, MIG-6 reconstitution impeded the development of early adaptive resistance in crizotinib-sensitive cells and was also able to inhibit the proliferation of crizotinib-resistant cells.CONCLUSION', ' Our study presents an in-depth mechanistic understanding of how ErbB family members, such as EGFR, are up-regulated at the time of crizotinib resistance and provides insights into the early escape mechanisms tumor may have to evade ALK TKI therapy.']",
        "Doc_id":"AACR_2016-311",
        "Doc_title":" Novel role for MIG-6 in mediating TKI resistance in ALK-rearranged lung cancer",
        "_version_":1606188971015012352},
      {
        "Meeting_name":" Use of 18F-HX4 PET/CT to estimate tumor hypoxia enrolled subjects from ongoing Phase 2 trials using tarloxotinib bromide in advanced NSCLC and SCCHN.",
        "Background":"['Background', ' Tumor hypoxia is associated with resistance to chemotherapy and radiotherapy. Recurrent/metastatic squamous cell carcinomas of the head and neck & skin (SCCHN/SCCS) and non-small cell lung cancer (NSCLC) tumors can be hypoxic leading to EGFR-TKI resistance. Tarloxotinib bromide (TRLX) is a hypoxia-activated prodrug that releases an irreversible pan-ErbB TKI targeting WT EGFR, mutant EGFR and HER2. Hypoxic tumor targeting with TRLX may lead to greater TKI tumor exposure with less toxicity than current EGFR TKIs. 18F-flortanidazole (18F-HX4) is a new hypoxia PET imaging agent that has the potential to identify and quantify tumor hypoxia with better tumor hypoxia targeting than earlier PET hypoxia agents. However, cross-institutional comparison of PET results without a standardization program can be challenging leading to insufficient or inappropriate conclusions based on PET results. Methods', ' Two concurrent multicenter Phase 2 trials are investigating the safety and activity of single-agent TRLX in recurrent or recurrent/metastatic SCCHN and SCCS (NCT02449681) or NSCLC (NCT02454842). Subjects have a whole-body18F-HX4 PET/CT scan prior to treatment. PET scanners are prequalified using a phantom harmonization program to ensure consistent image quality and robust 18F-HX4 quantitation for cross-institutional comparison. 18F-HX4 uptake will be quantitated to help correlate tumor 18F-HX4 uptake with measurement-based tumor treatment responses. Results', ' Up to 4 sites have been qualified with anthropomorphic phantoms to standardize PET scans and avoid poor quantitation of 18F-HX4. Excellent image quality scans in 3 of 4 patients have shown 18F-HX4 tumor uptake with preliminary estimates of tumor hypoxia ranging from 0-21% for hypoxic fractions (% of tumor hypoxia relative to reference tissue) and volumes (volume of hypoxia relative to reference tissue) permitting feasibility of signal detection to be correlated with responses. Conclusions', ' Multicenter PET studies of 18F-HX4 uptake and tumor response to TRLX is ongoing. Our PET harmonization strategy has shown promising early results in tumor hypoxia visualization. Recruitment is ongoing. Clinical trial information', ' NCT02449681']",
        "Doc_id":"ASCO_171670-176",
        "Doc_title":" Use of 18F-HX4 PET/CT to estimate tumor hypoxia enrolled subjects from ongoing Phase 2 trials using tarloxotinib bromide in advanced NSCLC and SCCHN.",
        "_version_":1606189006430666752},
      {
        "Meeting_name":" Dynamics of HER-2 loss in mammary carcinoma of human HER-2 trangenic mice",
        "Background":"['Progression of HER-2+ breast cancer can result in the emergence of HER-2-negative tumor variants that activate alternative mitogenic pathways, either spontaneously or after therapy. We found that HER-2 loss occurs even in transgenic mouse models in which the oncogene is driven by viral promoters, thus mammary carcinoma of human HER-2 transgenic mice (huHER-2 mice) can be used to study not only the early phases of HER-2-driven mammary carcinogenesis, but also tumor progression beyond HER-2 addiction. Primary mammary carcinomas of huHER-2 mice express high levels of the oncogene, with a marked intratumoral heterogeneity. Cell lines grown from HER-2+ mammary carcinomas frequently undergo a progressive loss of expression. We have established a model system consisting of cell lines, clones and variants that exhibit one of three phenotypes', ' a) high and stable HER-2 expression in vitro and in vivo, b) high but labile HER-2 expression which is lost either during in vitro culture, after tumor growth in mice or after in vitro treatment with trastuzumab, and c) complete loss of HER-2 expression After HER-2 loss, most variants displayed a transition to an elongated, motile phenotype (epithelial to mesenchymal transition), an increased ability to generate mammospheres, a reduced expression of CD24 and an increased expression of CD44 (denoting mammary cancer stem cells). Tumorigenic and metastatic ability of HER-2-negative cells was increased in comparison to HER-2+ cells. As expected, HER-2 loss was accompanied by resistance to HER-2 targeted monoclonal antibodies and small molecule inhibitors. The study of therapeutic agents directed against downstream targets showed that HER-2-loss was accompanied by a loss of sensitvity to a Src inhibitor, whereas a PI3K inhibitor was highly effective regardless of HER-2 expression. Our results indicate that human HER-2 transgenic mice are a useful model to study the dynamics of HER-2 loss in advanced HER-2+ mammary carcinoma, and to analyze alternative therapeutic strategies.Supported by grants from the Italian Association for Cancer Research (AIRC).']",
        "Doc_id":"AACR_2014-1820",
        "Doc_title":" Dynamics of HER-2 loss in mammary carcinoma of human HER-2 trangenic mice",
        "_version_":1606188982049177600},
      {
        "Meeting_name":" Contribution of miR-205 in gefitinib-resistant lung cancer cell lines",
        "Background":"['Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), gefitinib is effective therapies for patients with advanced non-small cell lung cancer (NSCLC). Treatment with gefitinib frequently induces drug resistance in NSCLC. Two mechanisms of acquired resistance have been validated in patients. Secondly mutations in EGFR itself, EGFR T790M and amplification of the MET oncogene are observed in resistance case. However, it remains unclear how MET over expression contributes to TKI resistant NSCLC. Recently, micro RNA (miRNA) expression is noted and analyzed because the concern of these molecules in cancer pathogenesis and drug resistance has been elucidated. Circulating tumor cell (CTC) and miRNA are focused as sensitive and non-invasive biomarkers for cancer diagnosis. In this study, we aimed at the miRNA in the gefitinib-resistant cell lines, and evaluated the miRNAs being associated with resistance of gefitinib. We established gefitinib resistant cell lines, in which MET is amplified, PC-9/MET and PC-9/MET-1K by a stepwise escalation of gefitinib concentrations in vitro. Microarray and real time PCR analysis indicated that miR-205 is significantly elevated in both resistant cell lines, and ErbB3 was a significant target. We examine further to reveal that relation between miR-205 and EGFR family, such as ErbB2 and ErbB3. Our results suggest that miR-205 may function as a gefitinib resistance in NSCLC.']",
        "Doc_id":"AACR_2014-1840",
        "Doc_title":" Contribution of miR-205 in gefitinib-resistant lung cancer cell lines",
        "_version_":1606189003431739393},
      {
        "Meeting_name":" Next-generation sequencing in metastatic lung cancer patients",
        "Background":"['Background', '  Several patients with lung cancer (LC) maintain good performance status even after disease progression following all standard therapies. More recently, targeted therapies have been improving prognosis of patients with advanced LC. We aim at exploring the role of a next-generation sequencing (NGS) assay in identifying therapeutic targets for refractory LC. Methods', '  Patients diagnosed with metastatic LC with available paraffin-embedded tissue evaluated by the method of NGS (Foundation Medicine, USA) were included. Hybridization capture of 3,769 exons from 236 cancer-related genes and 47 introns of 19 genes commonly rearranged in cancer was applied to  50 ng of DNA extracted from 12 LC specimens and sequenced to high, uniform coverage. Genomic alterations (GA) were reported for each patient sample. Actionable GA were defined as those identifying anti-cancer targeted therapies available on the market or in registered clinical trials.  Results', '    Twenty-nine patients were included (86.2% adenocarcinoma, 6.9% squamous cell carcinoma). Median age was 59 years (range 30-80); 65.5% were male and 55.2% were smokers or previously smokers. A total of 40 GA were identified', ' 29 patients (72.4%) harbored    1 GA, and 16 patients harbored    1 actionable GA (55.2%). The most frequent actionable GA were detected in EGFR (24.1%), AKT2 (10.3%), STK11 (10.3%), MET (6.8%), HER2 (3.4%), ROS1 (3.4%), and FGFR1 (3.4%). Non-actionable GA were mostly detected in TP53 (48.3%), MCL1 (17.2%), and CDKN2A (13.8%). The use of trastuzumab in a patient with mutated HER-2 yielded a time to progression (TTP) of 8 months. Five patients previously identified as wild-type EGFR were found to actually have EGFR mutation, with a median TTP of 11 months (1-16m) with tyrosine kinase inhibitors. Conclusions', '  Comprehensive NGS may identify novel mutations in LC patients with potential clinical utility and serve as genetic biomarkers for personalized therapeutics.']",
        "Doc_id":"ASCO_152355-156",
        "Doc_title":" Next-generation sequencing in metastatic lung cancer patients",
        "_version_":1606188975860482048},
      {
        "Meeting_name":" Detection, frequency and actionability of recurrent copy number gains detected by non-invasive liquid biopsy of 3,942 lung and breast cancer samples.",
        "Background":"['Background', ' Circulating tumor DNA (ctDNA) testing must include detection of single nucleotide variants (SNVs), indels, fusions, and copy number amplifications (CNAs) to identify all NCCN-recommended genomic targets. We examined CNA landscape in a large clinical cohort of breast and lung cancer ctDNA samples analyzed with Guardant360 (G360) test, classifying recurrent gene-level copy number changes across distinct oncogenic pathways and disease subtypes. Methods', ' We developed an improved CNA detection pipeline and evaluated its analytical and clinical performance on a set of cell-line spike-ins with known amplifications and 72 clinical plasma samples from patients with stage IV breast cancer with known ERBB2 amplification/overexpression. We then examined 1,935 lung adenocarcinoma and 2,007 breast carcinoma clinical cases', ' CNA patterns in samples with and without known driver mutations were compared using Fishers exact test to identify candidate driver amplification events. Results', ' Analytical sensitivity, specificity, and precision of the new CNA pipeline improved significantly - average coefficient of variation (CV) of copy number estimates across 18 genes on the panel was 1.2% for spike-in replicates, all spike-ins and copy number neutral samples were detected correctly, and signal-to-noise ratio increased 4.3-fold. We observed high concordance between tissue-verified amplification events in breast carcinoma subset when the mutant allele fraction of the driver mutation exceeded 0.5%. In the lung adenocarcinoma cohort, CNA-driver mutations were identified in ~7% of 1,935 samples, excluding cases known functional driver events. Focal amplification events in MET, CCND1, and ERBB2 were enriched in samples lacking other driver oncogene mutations (p-value < 0.001). Conclusions', ' Copy number variation is an important mechanism of oncogene activation in lung and breast cancers. Highly accurate quantification of copy number state in ctDNA allows for clinically meaningful identification of amplified therapeutic targets with otherwise wildtype DNA sequence.']",
        "Doc_id":"ASCO_171421-176",
        "Doc_title":" Detection, frequency and actionability of recurrent copy number gains detected by non-invasive liquid biopsy of 3,942 lung and breast cancer samples.",
        "_version_":1606188980808712192},
      {
        "Meeting_name":" Efficacy of EGFR/HER2 duel-kinase inhibitors in PDX models harboring known and novel HER2-mutations",
        "Background":"['Background', ' Neratinib and afatinib are small molecule therapies that irreversibly bind to the kinase domain of the epidermal growth factor receptors 1 (HER1/EGFR) and 2 (HER2/ERBB2). Afatinib is currently approved for non-small-cell lung cancers harboring acquired EGFR mutations; however both agents have recently reported clinical activity in HER2-mutated breast cancer. HER2 mutations have also been reported in melanoma and colorectal cancer and at least two mutations (S310F/V777L) have been shown to affect EGFR/HER2 signaling. Whether other reported or novel mutations are important in EGFR/HER2 signaling in colorectal and other cancer types is unclear. To better understand effects of HER2 mutations we characterized a panel of patient-derived xenograft tumor models representing colorectal, ovary, pancreas and endometrial cancers using RNA- and DNA-based sequencing. EGFR and HER2 expression was also quantitated using immunohistochemistry (IHC). Models identified positive for HER2 mutation by sequencing were evaluated in vivo, testing antitumor activity of neratinib, afatinib and other targeted therapies.Methods', ' START-PDX models were established from tissue or fluid samples as previously described. DNA or RNA were extracted and subjected to NGS and HER2 and other cancer-related mutations reported; growth factor receptor densities were interrogated using standard IHC. Drug studies were performed evaluating sensitivity of models to single agent neratinib, afatinib, lapatinib, trastuzumab and T-DM1 administered on standard treatment regimens. Study endpoints included tumor volume and time from treatment initiation with T/C values and tumor regression reported at study completion.Results', ' DNA and RNA sequence analysis of 300 models identified eleven HER2 mutations including six previously reported in COSMIC (S310F, A386D, H473R, D582N, V777L, R678Q) and five novel variants (R330Q, G366R, Q398K, I628T, A1216D) in thirteen total models. High EGFR staining was reported in two colorectal models', ' ST427 (HER2V777L) and ST428 (HER2A1216D) while high EGFR and HER2 staining was reported in a lung model designated ST1243 (HER2S310F). In vivo treatment with neratinib or afatinib resulted in tumor growth inhibition in some tested models including ST022 (HER2G366R/R678Q) ovary and ST204 (HER2A386D) pancreas and tumor regressions were reported with either agent in the ST427 (HER2V777L) colorectal line. Neratinib or afatinib were also found active in one each of four tested endometrial models. Lapatinib, trastuzumab and T-DM1 were inactive in all tested HER2-mutant models.Conclusion', ' We have sequenced a panel of PDX models and identified six previously reported and five novel HER-2 mutations in thirteen models which we screened in vivo for sensitivity to EGFR/HER2 duel kinase inhibitors and HER2-targeting therapies with the colorectal model ST427 (HER2V777L) identified as most sensitive to neratinib and afatinib.']",
        "Doc_id":"AACR_2016-4760",
        "Doc_title":" Efficacy of EGFR/HER2 duel-kinase inhibitors in PDX models harboring known and novel HER2-mutations",
        "_version_":1606188972582633472},
      {
        "Meeting_name":" Inhibition of adenosine A2A receptor (A2AR) by CPI-444 enhances CD8+ T cell killing of a HER-2/neu expressing murine tumor",
        "Background":"['Immunotherapies such as checkpoint inhibitors that block immune suppressive mechanisms are transforming the way some cancers are treated. The identification of additional mechanisms that suppress immune cell function is stimulating the search for other immune modulating agents that are additive or synergistic with current immune checkpoint inhibitors or are capable of overcoming mechanisms of resistance and tolerance. Extracellular adenosine and its signaling through A2AR increases the activity of regulatory T cells (Tregs), and attenuates tumor-specific CD4+/CD8+ T cells. In this study we evaluated the role of a small-molecule inhibitor of A2AR in enhancing antitumor immunity against murine Her-2/neu (neu)-expressing breast cancer. We examined whether an A2AR inhibitor would enhance the activity of cancer specific CD8+ T cells when given with a T cell inducing vaccine. To test this, neu-expressing mammary tumor bearing HER-2/neu transgenic (Neu-N) mice were treated with low dose cyclophosphamide (Cy) to deplete Tregs followed one day later with a granulocyte-macrophage colony-stimulating factor (GM-CSF) and neu-expressing whole cell vaccine (GVAX). Mice were treated with the A2AR inhibitor, CPI-444, by oral gavage daily for twelve days. Mice also received adoptively transferred high-avidity nave neu-specific CD8+ T cells intravenously one day after vaccination. Mice were monitored for tumor progression, and tumor-infiltrating lymphocytes (TIL) were harvested from additional mice at multiple time points and analyzed for T cell activation by flow cytometry. Inflammatory changes in the tumor microenvironment were assessed by immunohistochemistry. We found that T cells adoptively transferred to mice together with Cy, a neu-targeted vaccine and CPI-444 are more effective at reducing established tumors and delaying tumor progression when compared with mice treated with Cy, vaccine, adoptively transferred T cells and vehicle control. Of particular note, mice receiving the same treatment but with CPI-444 in lieu of vehicle had a significant mean difference in tumor area of 6.446mm2 (P<0.05) when compared to the vaccine and vehicle control cohort. When compared to the tumor alone cohort, mice receiving the full therapeutic regimen had a significant mean difference in tumor area of 13.59mm2 (P<0.001). Mechanistic studies are underway to assess the activity of the adoptively transferred T cells in the TIL. These studies may provide the rationale to test an A2AR inhibitor in combination with adoptively transferred T cells and/or vaccines in patients with cancer.']",
        "Doc_id":"AACR_2016-320",
        "Doc_title":" Inhibition of adenosine A2A receptor (A2AR) by CPI-444 enhances CD8+ T cell killing of a HER-2/neu expressing murine tumor",
        "_version_":1606188978536448000},
      {
        "Meeting_name":" In vivo and in vitro generation and characterisation of EGFR-TKI resistance in patient-derived xenograft (PDX) and cell line-derived xenograft (CDX) models of NSCLC with activating EGFR mutations",
        "Background":"['Background', ' Non-small cell lung cancer (NSCLC) patients that have activating mutations in the epidermal growth factor receptor (EGFR) gene are treated with EGFR tyrosine kinase inhibitors (TKIs) e.g. Erlotinib (Tarceva) and Gefitinib (Iressa). Most NSCLC patients with activating EGFR mutations will respond to EGFR-TKIs; however, in about 50% of these cases a secondary mutation in EGFR (T790M) subsequently occurs which results in resistance to treatment. Other mechanisms of clinical resistance can also occur such as amplification of c-MET kinase, Her-2 and EMT conversion; however, additional routes of resistance are poorly defined. Using a novel NSCLC patient-derived xenograft (PDX) model, driven by the L858R EGFR mutation, we set out to recapitulate the reported clinical routes of resistance to EGFR inhibitors and to evaluate if additional mechanism could also be identified.Methods', ' LU6422 is a Caucasian NSCLC adenocarcinoma PDX model with an activating EGFR mutation (L858R) which is maintained subcutaneously in vivo admixed with a human stromal cell component. HCC827 is NSCLC adenocarcinoma cell line with an activating EGFR mutation (exon 19 del E746-A750).Resistant models of LU6422 and HCC827 were generated in vivo and in vitro (respectively) through repeated dosing or exposure to EGFR-TKIs. Resistant tumour material was characterised for further mutations in the EGFR gene by direct sequencing and for c-MET, Axl and Her2 over-expression and genomic amplification by quantitative PCR. Combination efficacy treatment (in vitro and in vivo) was carried out to verify documented resistance mechanisms.Results', ' Nave LU6422 and HCC827 tissue exhibited exquisite sensitivity to EGFR-TKIs (100% reduction in pre-treatment tumour volume, p<0.0001). Following successive cycles of EGFR-TKI treatment several resistant subtypes were generated, cloned and characterized. Combination treatment of resistant HCC827 variants restored efficacy to nave treatment levels.Conclusions', ' EGFR-TKI resistant subtypes were generated in vivo and in vitro from a proprietary patient-derived xenograft model (LU6422) and the HCC827 cell line and were characterised for their resistance mechanisms.Pre-clinical modes of acquired resistance will be invaluable in assessing novel agents targeting the EGFR pathway and the development of new combination strategies which seek to prevent or overcome resistance to EGFR-TKIs.']",
        "Doc_id":"AACR_2014-4875",
        "Doc_title":" In vivo and in vitro generation and characterisation of EGFR-TKI resistance in patient-derived xenograft (PDX) and cell line-derived xenograft (CDX) models of NSCLC with activating EGFR mutations",
        "_version_":1606189006496727041},
      {
        "Meeting_name":" PD-L1 assessment in FNA (EBUS) dervied samples.",
        "Background":"['Background', ' Pembrolizumab therapy for non-small cell lung cancer requires PD-L1 immunohistochemistry (IHC). FDA approval was based on staining of resections or core biopsies. Little is known about PD-L1 expression in fine needle aspiration (FNA) specimens including EBUS of mediastinal lymph nodes. Methods', ' IHC was performed using the PD-L1 IHC 22C3 pharmDx test on formalin fixed paraffin embedded FNA cell blocks of 8 squamous cell carcinomas and 15 adenocarcinomas (ACA) (age', ' 42-84, mean', ' 63, median', ' 63; 11 female and 12 male). Mutation data (50 gene NGS panel, and ALK, ROS1, RET and MET FISH) was available for 14 ACA. Membranous PD-L1 staining of any intensity and extent was recorded in at least 100 tumor cells (tumor proportion score). The tumors were grouped as', ' no staining (<1%), low expression (1-49%) and high expression (50% or more). Results', ' Six (26%) tumors showed no staining, 6 (26%) low expression and 11 (48%) high expression (table 1). High PD-L1 expression was seen in 1 ALK, 1 braf, 1 EGFR, 1 Her2 exon20, 2 kras mutated tumors and 2 tumors with no or unknown mutation status, low PD-L1 expression in 1 braf and 1 EGFR mutated case and 1 tumor without mutation. No expression was seen in 1 ROS1, 1 kras mutated tumor and 1 tumor without mutation. One EBUS biopsy also had PD-L1 assessed on a transbronchial biopsy of the primary tumor showing similar staining (30% versus 20%). Conclusions', ' PD-L1 immunohistochemistry appears to be feasible using cell blocks of fine needle aspirates containing adeqaute number of viable tumor cells. The majority of ACA were also adequate for NGS mutation and FISH analysis. High PD-L1 expression was seen in approximately half the tumors, which is greater than has been observed in resections/core biopsies, this finding merits further study. High expression of PD-L1 was seen in both squamous cell carcinoma and adenocarcinoma, and tumors with and without common driver mutations. PD-L1 Expression according to histologic type.Histologic typeNo expressionLow expressionHigh expressionAdenocarcinoma (n15)4 (27%)3 (20%)8 (53%)Squamous cell carcinoma (n8)2 (25%)3 (37.5%)3 (37.5%)Total (n23)6 (26%)6 (26%)11 (48%)']",
        "Doc_id":"ASCO_193604-199",
        "Doc_title":" PD-L1 assessment in FNA (EBUS) dervied samples.",
        "_version_":1606189026168012800},
      {
        "Meeting_name":" Association between caring for a high proportion of older patients and adhering to standard care for younger patients.",
        "Background":"['Background', ' Multiple comorbidities and physiologic decline often prevent older patients from receiving the same standard care provided to younger patients. Therefore, providers who mainly treat older patients may become accustomed to not adhering to standards and thus might be less likely to provide standard care to younger patients. In this study, we compared the care provided to younger patients between facilities that care for a large number of elderly patients and those that treat relatively few older patients. Methods', ' We used a nationwide registry-linked claims database of 297 hospitals. Among the quality indicators (QIs) we formerly developed, we selected 2 and 3 QIs for lung cancer and gastric cancer, respectively, based on the variation in adherence across facilities. Facilities were divided into 2 groups based on the proportion of older patients (75) with each cancer type. We then compared the QI adherence in treating patients younger than 60 years old between the groups. The difference in adherence to standards of care (quality scores) between the 2 groups of facilities was assessed by using a logistic regression model adjusting for patient age and sex. Results', ' We analyzed data for 6,708 patients with lung cancer and 26,470 patients with gastric cancer. Respective quality scores for facilities with more older patients versus facilities with fewer older patients were 63.4% versus 66.1% (p=0.439) for the EGFR mutation test before the first chemotherapy among stage IV lung adenocarcinoma patients; 63.2% versus 52.5% (p=0.238) for concurrent chemoradiotherapy (CCRT) for localized small cell lung carcinoma patients; 51.6% versus 46.9% (p=0.229) for HER2 test before the first chemotherapy among patients with unresectable gastric cancer; 81.8% versus 79.7% (p=0.354) for Helicobacter pylori test on patients with gastric cancer who had ESD/EMR; and 60.9% versus 60.7% (p=0.948) for adjuvant chemotherapy within 6 weeks among pathological stage II/III gastric cancer patients. Conclusions', ' Caring for a high proportion of older patients is not associated with diminished provision of standard care to younger patients.']",
        "Doc_id":"ASCO_180036-198",
        "Doc_title":" Association between caring for a high proportion of older patients and adhering to standard care for younger patients.",
        "_version_":1606188993493336064},
      {
        "Meeting_name":" The RRas2/TC21 GTPase is essential for breast tumorigenesis and lung metastasis",
        "Background":"['Rras2/TC21 is a Ras superfamily GTPase with still unknown functions in vivo. Several observations suggest that this protein may be involved in tumorigenic processes. Thus, it has been shown that the expression of constitutively active RRas2 mutants leads to high levels of cell transformation in vitro. Moreover, this GTPase has been found overexpressed in a number of tumors, including lymphomas, oral and esophageal carcinoma, and breast cancer. To address the role of this protein in epithelial tumors, we have carried out an extensive characterization of this GTPase using RRas2 knockout mice and shRNA knockdown tumor cells. These studies revealed that RRas2 is not important for the development and/or malignant progression of skin and oral squamous cell carcinoma. Instead, we have observed that the RRas2 deficiency severily impairs breast cancer tumorigenesis and the tropism of metastatic cancer cells to the lung. The characterization of the role of RRas2 in primary tumorigenesis indicates that this GTPase is important for the proliferation and angiogenesis of tumors. In the case of metastasis, RRas2 is important for the survival and proliferation of cancer cells in the lung parenchyma. By contrast, this GTPase is not required for the lymph node infiltration, intravasation, or extravasation of cancer cells. Interestingly, the requirement of RRas2 is still maintained in breast cancer cells that express active mutants of K-Ras, indicating that RRas2 plays essential roles downstream of both Her2 and K-Ras. Signaling experiments indicate that RRas2 contributes to those processes by modulating the activation of phosphatidylinositol 3-kinase  and downstream targets such as Akt, FoxO1/FoxO3 and S6 ribosomal protein.']",
        "Doc_id":"AACR_2012-2147",
        "Doc_title":" The RRas2/TC21 GTPase is essential for breast tumorigenesis and lung metastasis",
        "_version_":1606189004618727424},
      {
        "Meeting_name":" Knockdown of EGFR to investigate its therapeutic potential for treatment of non-small cell lung cancers",
        "Background":"['Background', ' Epidermal growth factor receptor (EGFR) is a transmembrane protein consisting of an extracellular ligand-binding domain, and its activation leads to a multitude of effects including cell proliferation, cell differentiation, angiogenesis, metastasis, and antiapoptosis. EGFR can be a partner of heterodimer of other EGFR family such as HER2 and HER3. EGFR is often overexpressed in non-small cell lung cancer (NSCLC). Anti-EGFR agents including EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have considered to be effective for NSCLC when drug sensitive EGFR mutation is present. However, inherent and acquired resistances are major problems of EGFR targeting therapies. In this study, we knock-downed EGFR using small interfering RNAs (siRNAs) in NSCLC cell lines to examine the significance of targeting EGFR for NSCLC therapy. Materials and methods', ' We treated 14 NSCLC cell lines including nine EGFR mutant and five EGFR wild-type cell lines by geftinib or siRNAs for EGFR knock-down (siR-EGFR). Three cell line, PC-9-GR-N1, RPC-9, and HCC827-Met, were experimentally established as acquired resistant cells to gefitinib. The anti-tumor effect was determined by MTS or colony formation assay. The protein expression was evaluated using Western blotting. Results', ' All cell lines showed the expression of EGFR protein and siR-EGFR treatment down-regulated EGFR protein in all 14 cell lines. siR-EGFR suppressed cell viability in 7 of 9 EGFR mutant cells ranged from 8.0% to 73%. PC-9-GR-N1 and RPC-9 also showed inhibition. NCI-H1670 and HCC827-Met harboured EGFR mutation but were not inhibited. Of note, PTEN was deleted in NCI-H1670 and c-MET was amplified in HCC827-Met. Cell viability of all EGFR wild-type cells was not inhibited except NCI-H411. Conclusion', ' Our results indicated that EGFR can be the therapeutic target of NSCLC with EGFR activation. By contrast, targeting EGFR is not appropriate strategy for tumor of which EGFR is not activated even though EGFR is expressed.']",
        "Doc_id":"AACR_2012-7",
        "Doc_title":" Knockdown of EGFR to investigate its therapeutic potential for treatment of non-small cell lung cancers",
        "_version_":1606189004761333760},
      {
        "Meeting_name":" Breast cancer anti-estrogen resistance 4 (BCAR4) is a novel oncogene in lung cancer.",
        "Background":"['BCAR4 was identified as tamoxifen resistance related gene in breast cancer due to its function to activate estrogen-independent cell growth. Instead of estrogen receptor, ERBB2 and ERBB3 genes were activated by BCAR4 in tamoxifen resistant cells. Recently, the function of BCAR4 as a long non-coding RNA (lncRNA) was reported to regulate a non-canonical Hedgehog/GLI2 pathway in breast cancer. However, the association of BCAR4 and lung cancer has not been identified. Here, we describe the oncogenic effect of BCAR4 in human lung cancer. Expression pattern of BCAR4 was examined in lung cancer cell lines, primary tumor tissues, and adjacent normal tissues. BCAR4 was highly expressed in 71% of lung cancer cell lines and especially in 43% of cancer tissues of lung adenocarcinoma patients who did not harbor the activational mutations of EGFR nor KRAS. Exogenous expression of BCAR4 protein promoted cell growth of non-tumorigenic bronchial epithelial cell line, BEAS-2B, and lung cancer cell line, NCI-H1299. We also confirmed the oncogenic feature of BCAR4 by colony forming assay using stably expressing cells. These effects were notably reduced after knockdown of BCAR4 by small interfering RNA. BCAR4 encoded a functional protein and its overexpression resulted in the enhanced migration than controls cells. This result proposed a similar role of BCAR4 in lung cancer considering its previously reported role in breast cancer metastasis. We also detected a fusion gene of BCAR4 in a lung cancer tissue by analyzing RNA-sequencing data. BCAR4 protein as well as its fusion form showed the improved tumorigenic feature in the mouse xenograft model with lung cancer cells. We compared the gene expression pattern in BCAR4 overexpressed cells to identify the possible mechanism of the oncogenic effect of BCAR4. Cyclin D1, Cyclin E, and MMP1 mRNA and protein levels were significantly increased after BCAR4 overexpression. However, downstream genes of GLI2 signaling were not altered by protein expression of BCAR4 arguing an alternative role for lncRNA BCAR4. Our results suggest a novel oncogenic role of BCAR4 protein in lung cancer.']",
        "Doc_id":"AACR_2017-3137",
        "Doc_title":" Breast cancer anti-estrogen resistance 4 (BCAR4) is a novel oncogene in lung cancer.",
        "_version_":1606188972251283456},
      {
        "Meeting_name":" Strategic inhibition of adenosine A2A receptor (A2AR) by CPI-444 improves CD8+",
        "Background":"['It has been demonstrated that a higher CD8+ to CD4+FoxP3+ T regulatory cells (Tregs) ratio coincides with improved therapeutic outcomes for patients receiving immunotherapies in the clinic. The last several years of research have drawn attention to many such therapeutics and strategies. Adenosine is an abundant extracellular signaling molecule in the tumor microenvironment (TME) of many cancers. Signal transduction through the GPCR A2AR enhances the immunosuppressive activity of Tregs while simultaneously attenuating tumor-specific CD4+/CD8+ T cells. We have evaluated the appropriate coordination and dosing for a small-molecule inhibitor of A2AR in a Her-2/neu expressing murine model of breast cancer. We have demonstrated its capacity to augment existing therapeutic strategies in this tolerant model. To test our hypotheses on the ability of the small molecule to work in concert with existing therapeutics, we tested the role of CPI-444 when given with a T cell-inducing vaccine. Neu-expressing mammary tumor bearing HER-2/neu transgenic (Neu-N) mice were administered combinations of low-dose cyclophosphamide (Cy) to deplete Tregs, followed one day later with a granulocyte-macrophage colony-stimulating factor (GM-CSF) and neu-expressing whole cell vaccine (GVAX). The day following administration of GVAX, mice received adoptively transferred high-avidity nave neu-specific CD8+ T cells intravenously one day after vaccination. Administration of specific components in this strategy (i.e. Cy, GVAX, adoptive transfer) were altered to gain insight into the mechanistic effects of CPI-444 in vivo through analysis of tumor progression, tumor clearance, and flow cytometric analysis of the TIL. Mice treated with the A2AR inhibitor or the vehicle control were administered each by oral gavage daily for 14 days (survival) or until 4 days post-adoptive transfer (TIL) at the peak infiltrate time. Of the strategies tested, Cy, followed by concomitant administration of GVAX with 100mg/kg of CPI-444 for 14 days, and a single adoptive therapy treatment provided a 55% overall survival (OS) compared with 0%-20% OS in vehicle controls (P<0.005). Further, we have observed both broad and specific changes in the T cell compartment of the tumor-infiltrating leukocyte (TIL) population. Broadly we have observed a refinement in the T cell portion of the TIL with decreased numbers of T cells overall, but an increase in specific prognostic ratios, namely a relative increase in favorability of the CD8+', 'Treg ratio when compared to controls (P<0.05). We hypothesize that strategic combination therapy of CPI-444 with existing therapeutics can refine the local immune profile to enhance favorable outcomes in vivo. CPI-444 is currently involved in numerous clinical trials; this work may provide rationale for the expansion of these trials into new cancer types.']",
        "Doc_id":"AACR_2017-5579",
        "Doc_title":" Strategic inhibition of adenosine A2A receptor (A2AR) by CPI-444 improves CD8+",
        "_version_":1606189015321542656},
      {
        "Meeting_name":" My Cancer Genome",
        "Background":"['Background', '  Lung cancer has traditionally been treated according to histologic subtype with a plateau in the efficacy of combination chemotherapy.  Recent advances have identified oncogenic driver mutations in lung cancer that predict response to targeted therapies. However, knowledge resources are limited regarding the clinical relevance of such mutations.   Methods', '  We performed a literature review regarding the prevalence and clinical significance of various treatments for ~40 mutations in 10 genes (EGFR, KRAS, BRAF, NRAS, PIK3CA, MEK1, AKT1, HER2, PTEN, and ALK) for non-small cell lung cancer (NSCLC). Data from prospective and retrospective trials as well as preclinical studies was collected.   Results', '  ~100 articles/abstracts were synthesized into the publicly available My Cancer Genome website (mycancergenome.org) which launched in Jan 2011. Content includes information about the oncogene pathway (e.g. What is EGFR-), the clinical significance of the gene for a specific type of cancer (e.g. EGFR in NSCLC), and a summary of clinically relevant data related to a particular gene mutation (e.g. EGFR Exon 19 deletion in NSCLC).  Information regarding mutation directed clinical trials open for accrual both at Vanderbilt Ingram Cancer Center and worldwide is provided using a direct query of clinicaltrials.gov. This decision support tool is integrated into Vanderbilts electronic medical record to provide actionable decision support for mutation directed treatment prioritization and clinical trial availability. Clinicians, patients, and researchers with access to the internet can also access the website freely and directly.   Conclusions', '  My Cancer Genome is an international resource to assist clinicians in prioritizing genome directed cancer therapies.  The first implementation includes content for NSCLC.  We are now expanding the content to include melanoma, breast cancer, colon cancer and other malignancies. New data will be incorporated on an ongoing basis.  We welcome public/private partnerships to expand content and make this a truly global resource.']",
        "Doc_id":"ASCO_82277-102",
        "Doc_title":" My Cancer Genome",
        "_version_":1606188981206122496},
      {
        "Meeting_name":" An integrated analysis of EMT across diverse cancer types identifies new potential therapeutic targets",
        "Background":"['Background', ' Epithelial-to-mesenchymal transition (EMT) is a marker of resistance to specific targeted drugs in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSC), and other epithelial cancer and may be associated with poor patient outcomes. Here we performed an integrated molecular analysis in 1934 tumors representing 11 different cancer types in the Cancer Genome Atlas (TCGA) and 1264 representative cell lines to investigate new potential therapeutic targets (PTTs) in mesenchymal tumors.Methods', ' For each tumor, we correlated the EMT score (based on expression of an EMT gene signature) with mutation status, copy number alterations (CNA), mRNA, miRNA, and protein expression. PTTs expressed in mesenchymal tumors were investigated in vitro using publically available drug sensitivity datasets (DSDs) by correlating IC50s with EMT score.Results', ' Most cancer types exhibited a range of EMT scores that included both epithelial and mesenchymal tumors, with the exception of kidney clear cell carcinoma (KIRC) (all mesenchymal) and ovarian serous cystadenocarcinoma (OV) (primarily epithelial). Patients with mesenchymal OV and HNSC experienced shorter overall survival (p=0.029 and 0.076, respectively). BAP1 and PP2R1A mutations were more frequent in mesenchymal tumors, independent of primary site (adjusted p value <0.05). Conversely, NSD1 and KEAP1 mutations were more frequent in tumors with low EMT scores (epithelial) (p<0.05). Overall mutation burden and CNAs were not associated with mesenchymal status. A striking association between miR expression and EMT score was observed across most tumor types, including low miR 200 family and high miR 199a and 214 expression in mesenchymal cancers (r>0.3). PTTs commonly expressed in mesenchymal tumors included AXL, PDGFRA/B, MMP2 and DDR2 (r>0.6). Of these, investigation of the DSDs supported in vitro sensitivity of mesenchymal cell lines overall to PDGFR and GSK3 inhibitors, but resistance to drugs targeting ErbB family members, including the dual VEGF/EGFR inhibitor vandetanib (p<0.001) and drugs targeting Her2 and/or EGFR (p<0.001). In contrast, other EMT-associated drug resistance was tissue specific, such as resistance of mesenchymal breast cancer lines to mTOR inhibition (p 0.03).Conclusions', ' Application of the EMT signature to diverse tumor types identifies highly conserved patterns of gene and miRs expression, including high miR-199a expression in mesenchymal cancers. While mutational landscape and CNAs were most often driven by tumor type, protein expression and drug sensitivity were influenced by a combination of tumor type and EMT status. New associations between drug response and EMT were identified, such as the sensitivity of mesenchymal cancers to PDGFR and GSK3 inhibitors, that warrant further investigation.']",
        "Doc_id":"AACR_2014-1040",
        "Doc_title":" An integrated analysis of EMT across diverse cancer types identifies new potential therapeutic targets",
        "_version_":1606189004807471104},
      {
        "Meeting_name":" Identification of a novel genetic abnormality, the amplification of rictor (rapamycin-insensitive companion of mTOR), in a patient with non-small cell lung cancer.",
        "Background":"[\"Despite recent advances, clinically-relevant oncogenic drivers have not been identified in about half of lung adenocarcinormas. Here, we report rictor (rapamycin-insensitive companion of mTOR) amplification as a novel genetic abnormality in a young patient with non-small cell lung cancer. This male patient was a never smoker and was diagnosed with lung adenocarcinorma at the age of 18. He initially presented with refractory cough and persistent left lung lesions. Pathology was consistent with lung adenocarcinorma, poorly differentiated. Extensive molecular testing was negative for common genetic alterations in K-RAS, EGFR, ALK, HER2, RET, AKT, PIK3CA, BRAF and ROS1. His tumor was subsequently subjected to next generation DNA sequencing (FoundationOne, Foundation Medicine, Cambridge, MA) targeting a cohort of more than 180 cancer-related genes. This analysis identified rictor amplification of at least 6 copies as the sole DNA abnormality. Immunohistochemistry further documented rictor overexpression in the patient's lung tumor. The neoplastic lung tissue exhibited diffuse and strong cytoplasmic staining for rictor, compared to surrounding non-neoplastic tissues. Furthermore, the tumor tissue showed diffuse overexpression of phospho-S473 Akt, an essential downstream target of rictor.Rictor is a key component of mTORC2 complex, where it modifies actin cytoskeleton organization, cell proliferation and survival. Activation of rictor signaling has been suggested to play critical roles in regulating cancer cell migration, invasion and metastasis in breast, ovarian, and colorectal cancers and gliomas. To our knowledge, this is the first report of rictor amplification in lung cancer. Moreover, we found that blockade of the rictor-mTORC2 pathway by siRNA-mediated rictor knockdown or with pharmacological inhibitors led to decreased phosphorylation of S473-AKT and growth inhibition in lung cancer cell lines. Thus, rictor amplification may represent a potential novel target in lung cancer. We will perform further studies to determine whether rictor amplification is a unique molecular subtype of lung cancer. Further, we hope to identify which targeted drugs are active against tumors with rictor amplification and overexpression.\"]",
        "Doc_id":"AACR_2013-2033",
        "Doc_title":" Identification of a novel genetic abnormality, the amplification of rictor (rapamycin-insensitive companion of mTOR), in a patient with non-small cell lung cancer.",
        "_version_":1606189003242995712},
      {
        "Meeting_name":" Human HER2-overexpressing mouse breast cancer cell lines derived from MMTV.f.HuHER2 mice",
        "Background":"['Preclinical evaluation of therapeutic agents against metastatic breast cancer require cell lines and animal models that recapitulate clinical metastatic breast cancer as much as possible. We have previously used cell lines derived from the neu-N transgenic model to investigate anti-neu targeting of metastatic breast cancer using an alpha-emitter labeled antibody reactive with the rat variant of HER2/neu expressed by the neu-N model. To investigate alpha-emitter targeting of metastatic breast cancer using clinically relevant, commercially available anti-HER2/neu antibodies, we have developed cell lines derived from HuHER2 mice (MMTV.f.HuHER2 obtained from Genetech). HuHER2 mice develop breast cancer spontaneously and with a higher frequency than normal mice.We extracted primary mammary gland tumors, purified the epithelial breast cancer cells, and established 7 different HuHER2 cell lines. We also established 2 different cell lines from spontaneous lung metastases (HuHER2-L1 and -L2). We evaluated HuHER2 protein expression in the cell lines by western blot analysis. Cell surface receptor expression was evaluated by immunofluorescence (IF) staining. We performed qRT-PCR to assess phenotypic measures of aggressiveness and metastatic propensity. The following were evaluated', ' ER, PR, Twist1, Vimentin and E-Cadherin. Sensitivity to trastuzumab antibody, in vitro, was also assessed by evaluating changes in cellular metabolism via the MTT assay.HuHER2 protein was overexpressed in all of the isolated cell lines. One of the cell lines (denoted HuHER2-6) had approximately 1.5-8 times more protein expression compared to the other 6 cell lines developed. The two cell lines derived from spontaneous lung metastases showed approximately 1.5-fold greater HER2 protein expression than HuHER2-6. HuHER2-6 cell surface HER2 receptor staining by IF was similar to that of BT-474, a high HuHER2 expressing cell line. The 2 lung cell lines also showed comparable cell-surface staining. ER mRNA levels assessed by qRT-PCR were 20% and 0.05% of the level measured in normal mammary gland for the HuHER2-6 and HuHer2-L2 lines, respectively. The PR levels were also substantially lower (<0.01%) relative to normal mammary gland (MG) tissue. The HuHER2-6 line expressed 1.4 times more HuHER2/neu mRNA than BT-474. The mRNA for E-Cadherin in HuHER2-L1 and -L2 was 20% of MG tissue. The mRNA for TWIST1 and Vimentin were similarly elevated 3-fold and 1.5-fold, respectively, relative to MG. At trastuzumab concentrations ranging from 10 to 500 ug/ml, cell metabolism was decreased to 50%.These lines show all the hallmarks of highly aggressive, metastatic breast cancer and are being used to establish a left cardiac ventricle injection model of widespread HER2/neu positive metastatic breast cancer to evaluate combination therapy with alpha-particle emitter labeled HER2/neu reactive antibodies.']",
        "Doc_id":"AACR_2016-4279",
        "Doc_title":" Human HER2-overexpressing mouse breast cancer cell lines derived from MMTV.f.HuHER2 mice",
        "_version_":1606189027378069504},
      {
        "Meeting_name":" Involvement of receptors tyrosine kinase in the modulation of store-operated calcium entry",
        "Background":"['A multitude of studies show that alterations in Ca2+ signalling initiate or support the development of hallmarks of cancer. In particular, the role of store-operated Ca2+ entry (SOCE) in tumorigenesis and tumour progression has been subject to intense investigation. SOCE is the main mechanism by which external Ca2+ enters into the cell. It is initiated by depletion of ER Ca2+ stores and mediated by several proteins such as STIM1, an ER transmembrane protein sensing Ca2+ within the ER and ORAI1, a plasma membrane Ca2+ channel. We recently showed that SOC inhibition interfered with EGFR-dependent signalling in non-small cell lung carcinoma cells.In this study, we observed that STIM1 depletion reduced neuregulin-dependent proliferation of breast cancer cells. Since neuregulin binds to ErbB3 and/or ErbB4 and therefore activates ErbB2, this result prompted us to investigate whether ErbB proteins might modulate SOCE. We observed that lapatinib, a dual inhibitor of EGFR and ErbB2, dramatically inhibited SOCE. As expected, lapatinib also inhibited phosphorylation of EGFR, ErbB2 and downstream pathways of both receptors. Specific inhibition of EGFR by erlotinib or gefitinib had no effect on SOCE. In contrast, specific inhibition of ErbB2 by CP724714 mimicked the effects of lapatinib. We also investigated the role of downstream pathways of ErbB2 in the modulation of SOCE. Inhibition of the MAPK and the JAK-STAT pathways does not modify the amplitude of SOCE. Contrariwise, LY294002 and MK2206, two inhibitors of the PI3K pathway, dramatically reduced SOCE. Interestingly, in silico analysis showed that STIM1 might be phosphorylated by Akt.All these results suggest that SOCE is important in the proper function of ErbB2-dependent signalling. This raises the possibility to target molecular mediators of SOCE in order to interfere with the proliferation of cancer cells.']",
        "Doc_id":"AACR_2016-4594",
        "Doc_title":" Involvement of receptors tyrosine kinase in the modulation of store-operated calcium entry",
        "_version_":1606189042197594112},
      {
        "Meeting_name":" An online tool for the validation of survival-predicting biomarkers in non small-cell lung cancer using microarray data of 1,329 patients.",
        "Background":"['To decipher the molecular basis of lung cancer and to improve treatment strategies we have to identify genes correlated to therapy response and to survival. Here, we present the development of a new, freely available online tool suitable for the real-time meta-analysis of published lung cancer microarray datasets to validate expression based survival related biomarker candidates.First we have searched the caBIG, GEO and TCGA repositories to identify datasets with published gene expression data and survival information. In this, three GEO platforms (GPL96, GPL570 and GPL3921) were considered as these possess 22,277 common probes, which were used for constructing the database. All together 1,329 NSCLC samples in 9 independent datasets were identified, 85% have overall survival and 45% progression free survival info, one-third adenocarcinomas and one-third squamous cell carcinomas, 57% male and the average overall survival is 45 months. Kaplan-Meier survival plot, and the hazard ratio with 95% confidence intervals and logrank P value are calculated and plotted in R using Bioconductor packages. To assess the prognostic value of a gene, each percentile (of expression) between the lower and upper quartiles are computed and the best performing threshold is used as the final cutoff in a Cox regression analysis. The complete meta-analysis tool can be accessed online at', ' www.kmplot.com/lung.We demonstrate the application of this integrative analysis pipeline by validating 22 previously published survival associated biomarkers including VEGF, ADAM28, ANXA3, CADM1, CD24, CD82, CDK1, CEA, cyclin E, ERCC1, EZH2, HER2, IFNAR2, MMP9, OPN, P16, p53R2, RAD51, S100A4, survivin, XAF1 and XIAP. Of these, high significances (p<1E-16) were achieved by ANXA3 (HR=0.63), CADM1 (HR=1.7), IFNAR2 (HR=0.54), RAD51 (HR=1.9) and XAF1 (HR=0.58). Five additional genes were significant', ' S100A4 (HR=1.46, p=3.6E-4), CD82 (HR=1.34, p=0.018), OPN (HR=1.33, p=0.02), HER2 (HR=1.3, p=0.02) and CD24 (HR=0.75, p=0.3). The remaining genes did not achieved statistical significance.In summary, we developed an online available meta-analysis tool for the validation of genes associated with survival in NSCLC.']",
        "Doc_id":"AACR_2013-2368",
        "Doc_title":" An online tool for the validation of survival-predicting biomarkers in non small-cell lung cancer using microarray data of 1,329 patients.",
        "_version_":1606188989844291584},
      {
        "Meeting_name":" Frequency and clinical characterization of NSCLC patients harboring PIK3CA mutations identified within a regional screening network.",
        "Background":"['Background', ' PIK3CA mutations are a rare oncogenic event of potential therapeutic relevance in NSCLC. Here we report frequency and characteristics of patients with PIK3CA mutated lung tumors. Methods', ' Patients with NSCLC and PIK3CA mutations were identified within our regional Network for Molecular Screening in Lung Cancer. We further analyzed the presence of BRAF, KRAS, EGFR mutations as well as ALK translocation, ERBB2 and FGFR1 amplifications in PIK3CA mutated samples. Clinical data on age, sex, TNM classification and tumor stage, histological type, grading, overall survival, smoking status, comorbidity, BMI and secondary malignancies were retrieved from clinical charts in accordance with the local ethics committee. Results', ' PIK3CA mutations were detected with a frequency of 3.7% (24% exon 20,76% exon 9) in 1000 patients. Histologically 32% were defined as squamous cell carcinoma, 48% as adenocarcinoma and 18% other histological subtypes or NSCLC-NOS. Exon 9 mutations were present in the acinar and lepidic subtype, whereas exon 20 mutations were seen in the papillary and solid subtype. Cooccuring genetic lesions were observed in 16%  (mutations in KRAS=2, EGFR=1, BRAF=1; FGFR1 amplification=2). 14 were female, 23 male with a mean age of 69 years.  21 of these patients were further clinically annotated. 11 patients presented with stage IIIb/IV eligible for palliative treatment and 10 stage I  IIIa eligible for surgical therapy +/- adjuvant therapy. All but 1 patient were smokers with an average BMI of  26,2kg/m2 with a typical high load of comorbidity mainly of cardiovascular diseases, 8 of 21 patients showed prior malignancies in their medical history. The median overall survival within this population has not been reached yet. Conclusions', ' Screening for PIK3CA mutations is feasible. A high proportion (38%) of patients with PIK3CA mutated lung cancer have prior malignancies and show a high load of comorbidity. Furthermore PIK3CA mutations are not exclusive to KRAS, EGFR or BRAF mutations or FGFR1 amplifications. Successful identification of patients with oncogenic lesions in lung cancer in a screening network might allow future personalized treatment of these patients.']",
        "Doc_id":"ASCO_96154-114",
        "Doc_title":" Frequency and clinical characterization of NSCLC patients harboring PIK3CA mutations identified within a regional screening network.",
        "_version_":1606189037508362240},
      {
        "Meeting_name":" A comprehensive noninvasive approach for the stratification of lung cancer patients for targeted therapies.",
        "Background":"['Background', '  Cancer is a disease caused by the accumulation of genetic alterations which initiate and promote the uncontrolled growth and metastasis of cancer cells. These genetic alterations are the targets of multiple approved therapies, preferentially inhibiting cancer cells while limiting damage to normal cells. Given the advances in the efficacy of targeted therapies, current guidelines recommend molecular testing of specific genes to match patients with targeted therapies for which there is clinical benefit. However, approximately one-third of non-small cell lung cancer (NSCLC) patients lack tissue samples for analysis and are not eligible for targeted therapies. Circulating tumor DNA (ctDNA), shed into the blood from tumor tissue, contain alterations specific to the genetic profile of the malignancy in tissue and can stratify patients for targeted therapies through a liquid biopsy.  Methods', '  We have developed LungSelect, a ctDNA approach to interrogate clinically actionable genetic alterations in NSCLC that are recommended by clinical guidelines or targeted in late stage clinical trials. LungSelect uses digital next-generation sequencing approaches to comprehensively examine single-base mutations, insertions and deletions in BRAF, EGFR, ERBB2, KRAS and NRAS while assessing translocations in ALK, EGFR, NTRK1,RET and ROS1with a high degree of precision and accuracy.  Results', '  To evaluate the analytical sensitivity of LungSelect, we examined well characterized somatic mutations through a combination of tumor derived DNA and wild-type derived DNA at various levels of tumor contribution, achieving a lower limit of detection of > 0.01% with a specificity of > 99.9%. In addition, we examined the utility of LungSelect to detect these genetic alterations in late-stage lung cancer patients through comparison of plasma and matched tissue biopsy specimens. These analyses revealed a high concordance between the genetic alterations identified in plasma and matched tissue biopsies.  Conclusions', ' LungSelect comprehensively detects genetic alterations non-invasively, allowing for a greater proportion of patients to obtain the survival benefit associated with targeted therapies in NSCLC.']",
        "Doc_id":"ASCO_149700-156",
        "Doc_title":" A comprehensive noninvasive approach for the stratification of lung cancer patients for targeted therapies.",
        "_version_":1606189029706956800},
      {
        "Meeting_name":" Molecular and clinicopathologic characteristics of HER2-mutant lung adenocarcinoma (ADC).",
        "Background":"['Background', '    Activating mutations within the tyrosine kinase domain of HER2 have been reported in a small subset of lung ADCs.  HER2 mutations are mutually exclusive with EGFR and KRAS mutations and are associated with increased sensitivity to specific kinase inhibitors in preclinical models. To date, the frequency, molecular, and clinicopathologic characteristics of HER2 mutant lung ADC in the US have not been well defined.   Methods', '    Consecutive clinical cases of lung ADC (n=419) known to be negative for mutations in EGFR (exons 19-21) and KRAS (codons 12-13) were selected based on DNA availability.  HER2 mutation analysis was done by fragment analysis for small indels in exon 20 and a Sequenom assay panel for the most common point mutations.  A subset of tumors (n=245) was tested for ALK fusions by FISH.  Results', '  HER2 mutations were present in 4.8% (20/419) of lung ADCs.  Nineteen (95%) were exon 20 insertions and 1 (5%) was a point mutation (L755S).  None of the 16 HER2-mutants tested by FISH harbored an ALK fusion. The incidence of HER2 mutations in the triple negative (EGFR/KRAS/ALK) group was 6.5% (16/245).  Morphologically, 75% (15/20) were moderately (9) or poorly differentiated (6) ADCs of mixed phenotype.  Two (10%) were well differentiated and 3 could not be graded due to small sampling.  Eight tumors had a bronchoalveolar component and 2 had a mucinous component.   The patients (65% female) had a median age of 56 at diagnosis (range 43-87); 8 patients presented with advanced disease; 12 patients were never smokers.  The prevalence of HER2 mutations was significantly higher (p=0.0005) in never smokers (13.5%) than in current/former smokers (2.6%) but there was no significant difference between females (5.8%) and males (4.9%).   Conclusions', '  HER2 mutations in lung ADCs are mutually exclusive with EGFR and KRAS mutations and ALK fusions. The clinical and pathologic features of HER2 mutant patients show similarities to EGFR mutant cases. While the overall prevalence of these mutations is low, estimated at 2.2% of all lung ADCs, testing of triple negative patients identifies HER2 mutations in 6.5%, thereby more efficiently screening for this subset of patients who could potentially benefit from alternate targeted therapies.']",
        "Doc_id":"ASCO_84257-102",
        "Doc_title":" Molecular and clinicopathologic characteristics of HER2-mutant lung adenocarcinoma (ADC).",
        "_version_":1606189036072861696},
      {
        "Meeting_name":" Detection of soluble protein biomarkers in NSCLC serum samples by meso scale discovery electrochemiluminescence platform",
        "Background":"['Identification of soluble biomarkers has become a critical non-invasive approach for disease diagnosis and monitoring in the treatment of solid tumors. Non-Small Cell Lung Cancer (NSCLC) is the most common form of lung cancer, accounting for approximately 85% of all lung cancers worldwide. The EGFR family of genes is known to be highly expressed in NSCLC tumors and play a critical role in the progression of the disease. Although patients initially respond well to EGFR TKI therapy, acquired resistance occurs through several mechanisms, including compensatory cMET pathway activation (Robinson et al. 2013). Previous reports have demonstrated that soluble forms of EGFR, Her2 and cMET are generated through either alternate splicing of mRNA or proteolytic cleavage of the full length receptors (Wilken et al. 2013). Serum concentrations of these receptors can be correlated with prognosis as well as treatment response (Gregorc, 2004, Kasahara, 2010 Heinmoller, 2003). Soluble receptor ligands, including Hepatocyte growth factor (HGF), have also been evaluated in NSCLC and a strong correlation has also been observed between the levels of serum HGF and disease outcome in patients treated with EGFR-TKIs (Kasahara et al. 2010).In this study, we evaluated concentrations of sEGFR, sMET, sHER2,, and HGF in NSCLC versus healthy normal serum samples via meso scale discovery (MSD) platform. Inventoried and custom MSD assays were optimized to measure these proteins in a training set consisting of 19 NSCLC and 16 normal healthy serum samples. Significantly lower concentrations of sEGFR and sHER2 were observed in the NSCLC serum samples compared to normal (p value = 0.0092 for both receptors), whereas, in contrast, the levels of HGF were significantly higher in the NSCLC patient samples (p value <0.0001). No significant difference in sMET concentration was observed between NSCLC and normal serum. Based on this data, it was determined that a ratio of protein concentration of each soluble receptor (EGFR, Her2 and cMET) to HGF yielded a greater differentiation between NSCLC and normal samples (p value <0.0001, = 0.0041,and 0.0327 respectively). Cut-off values to define NSCLC versus normal patients were established for each ratio and validated in a blinded independent cohort, consisting of 50 NSCLC and 12 healthy normal serum samples. PPV and NPV were then calculated to determine sensitivity and specificity for each protein ratio. Results from the validation study show an almost complete separation between healthy and NSCLC patient samples (p value <0.0001, AUC = 1)for all three ratios tested (sEGFR/HGF, sHER2/HGF and sMET/HGF), with a PPV = 100%, 98%, 100% and NPV = 100%, 100%, 85.7%, respectively. Overall, these findings indicate potential clinical applications for these protein pairs as non-invasive biomarkers of NSCLC diagnosis, prognosis and treatment monitoring to support emerging TKI therapies']",
        "Doc_id":"AACR_2016-5027",
        "Doc_title":" Detection of soluble protein biomarkers in NSCLC serum samples by meso scale discovery electrochemiluminescence platform",
        "_version_":1606188994218950657},
      {
        "Meeting_name":" Secondary nonbreast malignancies (SNBM) after primary breast cancer (BC).",
        "Background":"['Background', '  BC survivors are at higher risk of developing SNBM due to treatment effects and shared behavioral and genetic factors. Associations between histologic subtypes of primary BC and secondary endometrial or ovarian cancer have been reported. Less is known about subtype-specific associations with other secondary solid tumors. We aimed to determine the prevalence of SNBM across US Oncology practices and what subtype-specific associations, if any, exist between primary BC and SNBM.   Methods', '  We conducted a retrospective database analysis identifying BC patients (pts) diagnosed between 01/2007 and 05/2013. SNBM were ascertained from codified fields in pts electronic records. Age at BC diagnosis, BC stage, estrogen receptor (ER), progesterone receptor (PR), HER2 status, BMI and smoking history were collected. Chi-square tests were used to compare categorical variables. Logistic regression was used to predict likelihood of secondary malignancies in separate multivariate models.  Results', '  105,795 pts with stage 0-IV BC were identified. 2,237 (2.1%) were diagnosed with  1 SNBM. Mean age at diagnosis and follow-up were 59.5 and 2.6 years respectively. Pts with SNBM were more likely to have', ' older age,  stage I, HER-2 negative disease, BMI 25 and past/current smoking history. SNBM were most commonly', ' Non-small cell lung cancer (NSCLC) (n=346), colorectal (CRC) (n=250), uterine (n=192), ovarian (n=130), thyroid (n=106) and kidney cancer (n=73). No associations were found between BC subtypes and ovarian, uterine, thyroid or NSCLC. Significant positive and negative associations between triple-negative breast cancer (TNBC) and secondary CRC and kidney cancer, respectively, were noted. In multivariate analysis, TNBC was predictive of secondary kidney cancer (OR 2.00, p=0.019). TNBC (OR 0.47, p=0.009), age 55 (OR 0.27, p<0.0001) and BMI 30 (OR 0.64 for BMI 25-30, p=0.019) were negative predictors of secondary CRC.  Conclusions', '  Our study is the first to report direct and inverse associations between primary TNBC and secondary kidney and CRC, respectively. The short follow-up precludes treatment-related effects. Results may potentially be attributed to genetic, environmental or lifestyle factors and warrant further research.']",
        "Doc_id":"ASCO_136942-151",
        "Doc_title":" Secondary nonbreast malignancies (SNBM) after primary breast cancer (BC).",
        "_version_":1606189024270090240},
      {
        "Meeting_name":" Molecular profiling of 502 patient cohort with NSCLC using a 27 somatic gene panel.",
        "Background":"['Background', ' Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and a tumor with broad spectrum of targeted therapies already available or in clinical trials. Thus, molecular characterization of the tumor using the Next Generation Sequencing (NGS) technology, has become a key tool for NSCLC patients treatment decision and clinical management. Methods', ' The performance of a custom 23 gene multiplex amplification hot spot panel, based on Ion AmpliSeq Technology, was evaluated for the analysis of tumor DNA extracted from FFPE (Formalin Fixed Parraffin Embedded) tissue. Furthermore the Ion AmpliSeq RNA Fusion Lung Cancer Research Panel was used for fusion RNA transcript analysis. Tumors mutation spectrum was determined in a cohort of 502 patients with NSCLC using the aforementioned targeted gene panels. Results', ' The panel used for tumor DNA analysis in this study exhibit high rates (100%) of sensitivity, specificity and reproducibility at a mutation frequency of 3%. At least one DNA mutation was detected in 374 patients (74.5%) and an RNA fusion was identified in 16 patients, (3.2%). In total, alterations in a cancer driver gene were identified (including point mutations, gene rearrangements and MET amplifications) in 77.6% of the tumors tested. Among the NSCLC patients, 13.5% (68/502) presented a mutation in a gene with approved targeted therapy (EGFR, ALK ROS1) and 9.4% had an alteration in a gene related to emerging targeted therapies according the NCCN guidelines. These alterations include ERBB2, BRAF and MET mutations, MET amplification and RET rearrangements. The remaining 51.6% of the patients had a mutation in a gene that could be related to an off label therapy or give them access to a clinical trial. Conclusions', ' Thus the NGS panel validated is a reliable approach of clinical applicability for tumor molecular profile detection in NSCLC patients.']",
        "Doc_id":"ASCO_189381-199",
        "Doc_title":" Molecular profiling of 502 patient cohort with NSCLC using a 27 somatic gene panel.",
        "_version_":1606188989988995072},
      {
        "Meeting_name":" Outcomes with chemotherapies and molecular characteristics of HER2-mutant lung cancers.",
        "Background":"['Background', '   Human epidermal growth factor receptor 2 (HER2, ERBB2) mutations occur in 3% of lung adenocarcinomas and are increasingly being identified with the growing adoption of multiplex next-generation genotyping. HER2-mutant lung cancers impart a distinct natural history with a median overall survival from stage IV diagnosis of 1.6 years (Kris JAMA 2014). While case reports and series have shown activity of HER2-targeted agents in these patients, little is known about outcomes of systemic treatments.  Methods', '   Patients with stage IV HER2-mutant lung cancers at Memorial Sloan Kettering were reviewed. Patient demographics, types of HER2 mutations, survival, and duration of systemic treatments were documented.   Results', '    37 patients with HER2-mutant lung cancers were identified', ' median age 62; majority were women (n = 24), never smokers (n = 21), and had adenocarcinomas (n = 36, 1 adenosquamous). A 12bp in-frame insertion in exon 20 (p.A775_G776insYVMA c.2324_2325ins12) was present in 23 (62%, 95% CI 45-78%) patients. In addition, there were four 9bp insertions, one 6bp insertion, and five 3bp insertions in exon 20, and four single base pair substitutions (3 exon 20, 1 exon 8). The median overall survival from date of diagnosis of stage IV disease was 2.3 years (95% CI 1.2-2.7). The median duration of all chemotherapy was 8 months (range 0.8-43 months). Median duration of treatment was 6 months for pemetrexed platinum/bevacizumab, 3 months for taxane platinum/bevacizumab, 4 months for gemcitabine, 4 months for vinorelbine, 5 months for mitomycin vinblastine. The median duration of targeted therapy was 3 months for trastuzumab, 4 months for small molecule HER2 tyrosine kinase inhibitors, 3 months for erlotinib. No objective responses were noted with trastuzumab (n = 2) or lapatinib (n = 4) alone.  Conclusions', '   Most HER2-mutant lung tumors demonstrate an identical 12bp in-frame insertion (YVMA) in exon 20. In our cohort, the median duration of treatment with chemotherapy was double that of HER2-targeted therapies. Pemetrexed-containing regimens had the longest duration of treatment. As we search for better targeted therapies for patients with HER2-mutant lung cancers, chemotherapy remains an important component of care.']",
        "Doc_id":"ASCO_151022-156",
        "Doc_title":" Outcomes with chemotherapies and molecular characteristics of HER2-mutant lung cancers.",
        "_version_":1606189006808154113},
      {
        "Meeting_name":" Correlation of expressions of ER/PR/HER-2 receptor status with clinicopathological parameters in Mauritian breast cancer patients.",
        "Background":"['Background', '    Breast cancer is by far the commonest site of cancer registered in Mauritius with an ASR of 56.0/105 in females. This study intends to correlate the expressions of HER-2, estrogen receptor (ER) and progesterone receptor (PR) with clinicopathological parameters in breast carcinoma. It is in fact the ever first study of its kind to be carried out in the Mauritian context. Methods', '    A prospective study was conducted during a period of two years (2013-2014) at the Central Health Laboratory, Victoria Hospital; whereby 78 paraffin blocks of consecutive breast cancer cases diagnosed were subjected to ER/ PR testing by immunohistochemistry (IHC). As regards to HER-2 testing, they were sent to Lancet laboratories, South Africa for IHC. Chi-Square test was used to evaluate IHC results with prognostic parameters for breast cancer. Results', '    In the present study, 77 were females and 1 was male; the mean age of patients was 52.7 years ranging from 26 to 80 years, 33 patients (42.3%) were below 50 years of age. 52 cases had defined menopausal status, 67.3% were post-menopausal and 32.7% were pre-menopausal. Infiltrating ductal carcinoma (NOS) was the commonest 48/78 (61.5%) and the other variants 30/78 (38.5%). The overall immunoexpression of ER/PR/HER-2 were 73.6%, 61.8%, 35.9% respectively; HER-2 was overexpressed (3+) in 23.3% of cases and triple negative cases accounted for 17.9%. In terms of laterality, we found that right breast was slightly more involved (53.9%) than left breast (46.2%). ER/PR positivity was associated with Lymph node involvement with marginal significance (p = 0.074). No significant association was found between ER/PR/HER2 as well as with age, tumor size and grade. Conclusions', '    There are high rates of positive expressions of ER/PR/HER-2/neu among the Mauritian population with breast carcinoma. This year the Central Health Laboratory is planning to set up a comprehensive IHC service with on-site testing for HER-2; hence further studies are to be anticipated on the topic.']",
        "Doc_id":"ASCO_147625-156",
        "Doc_title":" Correlation of expressions of ER/PR/HER-2 receptor status with clinicopathological parameters in Mauritian breast cancer patients.",
        "_version_":1606189027460907008},
      {
        "Meeting_name":" Expression profiling of cofilin-1 in breast cancer cell lines and biopsies.",
        "Background":"['Introduction. Despite oestrogen and human epidermal growth factor receptor (HER2) targeted therapies improving patient survival, breast cancer continues to be a significant cause of premature death since many tumors do not respond to treatment or acquire resistance. Hence there remains the need to identify novel targets for therapy and biomarkers for prediction of response to treatment. A quantitative proteomics study of matched normal and tumor biopsies identified 63 proteins to be significantly increased or decreased in stage-specific tumors. Some have previously been associated with breast cancer, while others such as cofilin-1 represent new targets for investigation. Cofilin-1 was subject to a range of analyses to determine its association with breast cancer.Materials and Methods. Western blotting (WB) was performed on protein extracts from breast cancer cell lines and matched normal and tumor biopsies from Cypriot patients with different stages of the disease. Immunohistochemistry (IHC) was carried out on core biopsies from the Leeds Breast Tissue Bank. Multiple reaction monitoring (MRM) mass spectrometry was performed on trypsin-digested protein extracts from biopsies. Data from protein (Human Protein Atlas) and genomics (BioGPS, TiGER, UniGene) databases were assimilated with the experimental results.Results. WB indicated that cofilin-1 was ubiquitously expressed in tumor cell lines, representative of Luminal A, Luminal B, basal-like, claudin-low and HER2 phenotypes, at higher levels than normal breast cell lines. WB also indicated increased expression of cofilin-1 in invasive carcinoma tissues, compared to matched normal. Patients with ductal carcinoma in situ or fibroadenoma exhibited less clear results, either increasing slightly or remaining unchanged. MRM analysis of three cofilin-1 peptides in tissue extracts of invasive carcinoma patients indicated expression only in tumor. IHC of core biopsies exhibited strong staining for cofilin-1 in ductal invasive carcinoma tissues with no staining in normal breast cells. Genomics and proteomics databases indicate that cofilin-1 is expressed in a diverse range of normal tissues including major organs, gastro-intestinal tract, skin and tonsils. However, mRNA and protein levels are observed to be increased in skin, lung, liver, pancreatic and breast tumors.Discussion. The original quantitative proteomics data indicated only relatively small changes in expression (less than 2-fold) due to dynamic range limitations of the technique. Additional analytical approaches substantiated that cofilin-1 is significantly up-regulated in advanced breast cancer patients. Further patient sets are required to confirm the importance of cofilin-1 levels in early stages of breast cancer compared to benign tissues. Bioinformatics provided further confidence in our findings, highlighting the value of utilising databases for evidence of disease-specific proteins.']",
        "Doc_id":"AACR_2013-2505",
        "Doc_title":" Expression profiling of cofilin-1 in breast cancer cell lines and biopsies.",
        "_version_":1606188992210927616},
      {
        "Meeting_name":" Further molecular profiling of tumors harboring therapeutic targets within non-small cell lung cancer.",
        "Background":"['Background', '    Treatment of NSCLC has been revolutionized in recent years with the introduction of several targeted therapies for selected genetically altered subtypes of NSCLC. A better understanding of molecular characteristics of NSCLC, which features common drug targets, may identify new therapeutic options.  Methods', '    Over 6,700 non-small cell lung cancer cases referred to Caris Life Sciences between 2009 and 2014. Diagnoses and history were collected from referring physicians.  Specific testing was performed per physician request and included a combination of sequencing (Sanger, NGS or pyrosequencing), protein expression (IHC), gene amplification/rearrangement (CISH or FISH), and/or RNA fragment analysis.  Results', '    Tumors profiles from patients with hormone receptor positive disease (HER2, ER, PR, or AR positive by IHC) (n=629), HER2 mutations (n=8) ALK rearrangements (n=55), ROS1 rearrangement (n=17), cMET amplification or mutation (n=126), and cKIT mutation (n=11) were included in this analysis and compared to the whole cohort. Tumors with ALK rearrangement overexpressed AR in 18% of cases, and 7% presented with concomitant KRAS mutation. Lower rates of PTEN loss, as assessed by IHC, were observed in ALK positive (20%), ROS1 positive (9%) and cKIT mutated tumors (25%) compared to the overall NSCLC population (58%). cMET was overexpressed in 66% of ROS1 translocated and 57% of HER2 mutated tumors. cKIT mutations were found co-existing with APC (20%) and EGFR (20%) mutations. Pathway analysis revealed that hormone receptor positive disease carried more mutations in the ERK pathway (32%) compared to 9% in the mTOR pathway. 25% of patients with HER2 mutations harbored a co-existing mutation in the mTOR pathway.  Conclusions', '    Pathway profiling reveals that NSCLC tumors present more often than reported with several concomitant alterations affecting the ERK or AKT pathway. Additionally, they are also characterized by the expression of potential biological modifiers of the cell cycle like hormonal receptors, representing a rationale for dual inhibition strategies in selected patients. Further refining of the understanding of NSCLC biomarker profile will optimize research for new treatment strategies.']",
        "Doc_id":"ASCO_134054-144",
        "Doc_title":" Further molecular profiling of tumors harboring therapeutic targets within non-small cell lung cancer.",
        "_version_":1606188988404596737},
      {
        "Meeting_name":" Screening for EGFR, KRAS, and PIK3CA mutations in well-characterized, immunohistochemically confirmed squamous cell carcinoma of lung.",
        "Background":"['Background', ' The occurrence of EGFR and KRAS mutations in squamous cell carcinoma (SQCC) of lung is controversial due in part to very limited pathology data in many published studies, and the prevalence of other mutations is not established. We hypothesized that full pathologic and immunohistochemical (IHC) characterization of genotyped SQCC cases could help resolve these uncertainties.  Methods', ' Fifty resected SQCC with IHC confirmation (TTF1-/p63+) were screened for hot-spot point mutations in EGFR, KRAS, PIK3CA, AKT1, BRAF, ERBB2, and MAP2K1 by Sequenom and EGFR exon 19 deletions by standard methods. In addition, 15 SQCC found to harbor EGFR (n=9) or KRAS (n=6) mutations on routine clinical testing underwent a detailed clinicopathologic and IHC reassessment.  Results', ' No EGFR or KRAS mutations were found in 50 pure resected SQCC (0% observed incidence; 95% CI 0-7%), whereas PIK3CA and AKT1 mutations were identified in 6% (95% CI 1-17%) and 2% (95% CI 0-11%) of cases, respectively. Reassessment of 15 SQCC with EGFR/KRAS mutations revealed that none could be confirmed to represent pure SQCC. Seven of 15 (47%) cases were small biopsy/cytology specimens showing SQCC but specimens from other sites (metastatic or primary) revealed adenocarcinoma (ADC) or adenosquamous carcinoma (AD-SQC) harboring mutations identical to those in SQCC (when other-site mutation data was available). One case (7%) was a small biopsy showing SQCC but subsequent same-site resection revealed AD-SQC. Six cases (40%) were re-classified as solid ADC after IHC.  Conclusions', ' EGFR/KRAS mutations do not occur in pure SQCC, and when detected in specimens reported as SQCC they may represent a component of AD-SQC or solid ADC. These findings highlight the importance of IHC for the accurate diagnosis of SQCC, which is essential for interpreting molecular data. For pure SQCC in resection specimens, routine EGFR mutation testing is not indicated. Because small specimens may not distinguish SQCC from AD-SQC, testing should be guided by clinical parameters as further addressed by Paik et al (abstract submitted, ASCO 2011). Low-frequency PIK3CA/AKT1 mutations in SQCC are of interest as potential therapeutic targets.']",
        "Doc_id":"ASCO_84202-102",
        "Doc_title":" Screening for EGFR, KRAS, and PIK3CA mutations in well-characterized, immunohistochemically confirmed squamous cell carcinoma of lung.",
        "_version_":1606189004420546560},
      {
        "Meeting_name":" Radiogenomics in 332 metastatic non-small cell lung cancer (NSCLC) patients.",
        "Background":"['Background', ' Radiogenomics is focused on defining the relationship between image and molecular phenotypes. Therefore, we assess the association between metastatic sites at baseline CT and molecular abnormalities (MA) in NSCLC patients (pts). Methods', ' One senior radiologist reviewed retrospective basal CT scans of metastatic NSCLC pts from Gustave Roussy included in the MSN cohort. Tissue biopsy samples of these pts were collected for detecting the molecular profile by NGS platform (Ion-torrent) and/or Sanger sequencing molecular test as daily clinical practice. Radiological characteristics regarding metastatic sites were correlated with the molecular profile. Results', ' From 06/2009 to 06/2015, 332 metastatic NSCLC pts treated with first-line platinum-based chemotherapy were included (median age 59 years, 63% males, 14% never smokers, 76% adenocarcinoma, 11% with squamous cell carcinoma). Number of metastatic sites by patient was', ' one for 49%, 2 for 28%, 3 for 14%, > 4 for 9%. After 32.4 months of median follow-up, the median overall survival was of 15.3 months (95%CI', ' 12.9-17.8). Overall, 60% of NSCLC pts had a MA', ' 28% KRAS mutation, 14% EGFR mutation, 6% ALK rearrangement, 5% MET amplification or mutation, and 7% other mutations (BRAF and PI3K mutation, and HER2 mutation or amplification). Among pts with KRAS (n = 93), EGFR (n = 47), ALK (n = 21) and MET(n = 16) abnormalities, the respective percentages of brain, adrenal, metastatic pleural effusion, bone and lung metastases were', ' 39%/28%/18%/40%/33%; 45%/6%/36%/47%/49%; 52%14%/19%/43%/48%; and 44%/25%/0%/44%/25%. Among the 12 pts with peritoneal carcinomatosis, 5 had a mutation (3 with KRAS, 1 NRAS and 1 BRAF). Conclusions', ' Bone is the most common site of metastases in NSCLC pts. Baseline metastatic sites in molecular selected NSCLC pts are different according to the molecular abnormality. Among KRAS mutant tumours there are a higher percentage of adrenal metastases and a trend toward association with peritoneal carcinomatosis, whereas among ALK tumors exists higher percentage of brain metastases than pleural effusion. MET tumors have a tropism for the brain similar to the other molecular abnormalities, whereas lung metastases are especially frequent in EGFR and ALK tumours.']",
        "Doc_id":"ASCO_169610-176",
        "Doc_title":" Radiogenomics in 332 metastatic non-small cell lung cancer (NSCLC) patients.",
        "_version_":1606189022723440640},
      {
        "Meeting_name":" Tgfbr1 haploinsufficiency is a potent modifier of breast cancer risk.",
        "Background":"['Background', ' We previously identified a hypomorphic TGF- type 1 receptor variant (TGFBR1*6A) that is associated with cancer risk and has impaired TGF- signaling capability. Two recent large meta-analyses of case control studies have found a significant association between TGFBR1*6A and risk of several types of cancer, including breast cancer (ORs 1.16,1.01-1.34; 1.15,1.01-1.31). To investigate the effects of constitutively decreased TGFBR1 signaling on cancer development, we developed a novel mouse model of Tgfbr1 haploinsufficiency to mimic the decreased TGFBR1 signaling observed in individuals with higher risk of cancer. Using this model, we demonstrated that Apcmin;Tgfbr1+/- mice develop more than twice as many intestinal tumors as Apcmin controls. The aim of the current study was to assess the effects of Tgfbr1 haploinsufficiency on breast carcinogenesis by crossing Tgfbr1+/- mice with the MMTV-c-Neu mouse model.Methods', ' Fully congenic (100%) FVB/N-Tgfbr1+/- mice were crossed with FVB/N-Neu mice, and female virgin progeny were kept for analysis. Mammary glands were collected from 10, 12, and 40 week-old Neu and Neu;Tgfbr1+/- mice. Mice assessed for tumor development were sacrificed 80 days after the initial tumor palpation or at the earliest sign of morbidity. Whole lungs, tumor tissue, and primary tumor cells were collected for additional analysis. Long-term evaluation of 2-year-old Tgfbr1+/+ and Tgfbr1+/- mice was also conducted to directly assess the impact of Tgfbr1 haploinsufficiency on mammary gland and lung development.Results', ' Mammary gland whole mounts revealed that Neu;Tgfbr1+/- mice have more ductal branching at all time points compared to Neu mice. In the assessment of breast tumor development, Neu;Tgfbr1+/- mice were observed to have a significantly shorter tumor latency period (171 days) compared to Neu mice (220 days) (p=0.004). Seventy percent of Neu;Tgfbr1+/- mice (14/20) developed surface lung metastases, while 36.4% were observed in Neu mice (8/22), a borderline significant difference (p=0.061). The TGF--mediated growth inhibition of Neu;Tgfbr1+/- primary tumor cells was 32.2% lower than that of Neu tumor cells (p=0.007). Neu;Tgfbr1+/- tumor cells and tissue had significantly reduced Smad2/3 phosphorylation and total Cdkn1b (p27Kip1) expression compared to Neu mice. Long-term evaluation of Tgfbr1+/- and wild-type mice revealed no signs of mammary gland hyperplasia or differences in lung fibrosis in either group.Conclusion', ' This study is the first in vivo evidence that Tgfbr1 haploinsufficiency promotes breast carcinogenesis by increasing breast cancer proliferation. The relevance of this data to human breast cancer warrants additional investigations into the effects of decreased TGFBR1 signaling on tumor development and progression and identifies potential targets for prevention and treatment.Citation Format', ' Michael J. Pennison, Diana S. Rosman-Balzer, Lakisha Moore-Smith, Jacquelyn W. Zimmerman, Trenton R. Schoeb, Andra R. Frost, Ming Zhang, Peter M. Siegel, Boris C. Pasche. Tgfbr1 haploinsufficiency is a potent modifier of breast cancer risk. [abstract]. In', ' Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA)', ' AACR; Cancer Res 2013;73(8 Suppl)', 'Abstract nr 1406. doi', '10.1158/1538-7445.AM2013-1406']",
        "Doc_id":"AACR_2013-1406",
        "Doc_title":" Tgfbr1 haploinsufficiency is a potent modifier of breast cancer risk.",
        "_version_":1606189014150283264},
      {
        "Meeting_name":" Comprehensive analysis of potential immunotherapy genomic biomarkers by profiling paired tumor/normal exome of 1,000 Chinese cancer patients.",
        "Background":"['Background', ' With the broadening landscape of immunotherapy use, it is important to identify patients who are likely to benefit from the therapy. We reported the comprehensive analyses of potential predictive biomarkers for PD1/PD-L1 inhibitors based on Chinese patients exome profiling data. Methods', ' Over 1,000 cancer patients from 70 hospitals across 20 provinces in China were recruited and the whole exome of tumor/normal samples of each patient were sequenced. Four potential genomic biomarkers', ' tumor mutation burden (TMB), mismatch repair deficiency (MMR), microsatellite instability (MSI), and PD-L1 (CD274) amplification (PD-L1 AMP) were analyzed in this Chinese cohort and compared with the mainly Caucasian cohort in TCGA database. Results', ' At least one of the four preselected genomic biomarkers was identified in 40.8% of this Chinese cancer patient cohort by clinical whole exome sequencing (CWES) analysis. Similar to TCGA cohort, the top 3 high TMB tumor types are lung, esophagus and colorectal cancer. Chinese hepatocellular carcinoma (HCC) patients showed higher TMB than the TCGA cohort (Median', ' 106 vs. 65 non-synonymous mutations per tumor NMT), which might be due to different etiologies. Five late stage cancer patients (3 lung, 1 melanoma and 1 gallbladder) using PD1/PD-L1 blockade with high TMB showed durable clinical benefit (SD6months/PR/CR). Comparing with TCGA data, Chinese colorectal cancer cohort (252 patients) had relative lower MSI-high or MMR related mutations (8.33% vs. 12.5%, and 3.97% vs. 10.0% respectively). PD-L1 AMP most frequently occurred in lung squamous (14.3% VS 9.8% TCGA), HER2-positive breast cancer (8.8% VS 6.8% TCGA with unknown HER2 status) and sarcoma (6.0% VS 9.4%TCGA). One Chinese renal cell carcinoma patient with PD-L1 AMP received anti-PD-1 treatment and on-going PFS is 7 months by far. Conclusions', ' Our CWES analysis and limited clinical follow-up observations suggested that about 40% Chinese cancer patients had at least one of the 4 potential immunotherapy predictive biomarker mutations. Long-term follow-up is needed to verify the validity of those markers.']",
        "Doc_id":"ASCO_188568-199",
        "Doc_title":" Comprehensive analysis of potential immunotherapy genomic biomarkers by profiling paired tumor/normal exome of 1,000 Chinese cancer patients.",
        "_version_":1606189031886946304},
      {
        "Meeting_name":" Clinical significances of ErbB family receptors, Myc, and mitogen-activated protein kinase (MAPK) in patients with early-stage non-small cell lung cancer.",
        "Background":"['Background', '  EGFR deregulation has been extensively studied in non small-cell lung cancer (NSCLC), but less is known about the expression and role of other ErbB receptors and their downstream signal transductions. Myc and MAPK are key downstream components of the EGFR pathway and have significant roles in cell survival, proliferation, and growth. The purpose of this study is to determine the prognostic value of  EGFR,  ErbB2,  ErbB3, ErbB4, Myc and MAPK  by immunohistochemistry (IHC) in early stage NSCLC. Methods', '  109 NSCLC were evaluated', ' median age was 67 years (range 4084); Male/Female', '93/16; squamous (SCC)/adenocarcinoma (ADC)/BAC/other', ' 52/36/3/18; smoker/never smoker', '100/9, and stage I/II/III', '67/17/25.  The tumors with 10% positive cells were classified positive, further confirmed by Receiver Operating Characteristic (ROC) analysis. Kaplan-Meier estimates of survival and time to recurrence were calculated for clinical and biologic variables using Cox model for multivariate analysis  Results', '  EGFR and EbrB3 were associated with SCC (p<0.0001 and p=0.004, respectively) whereas ErbB2 and Myc with ADC (p=0.004 and p<0.0001, respectively) . EGFR and ErbB3 were significantly associated (p=0.003), as well as MAPK and ErbB4 (p=0.02). At  a median follow-up of 75 months the contemporary overexpression of EGFR, ErbB2 and MAPK was associated with shorter disease free survival (DFS) (HR=5.4, p=0.002)  and overall survival (OS) (HR=8.9, p<0.0001). At multivariate analysis adjusting for stage, the co-expression of EGFR, ErbB2 and MAPK was an independent predictor for worse DFS and OS (HR=5.7, p=0.004; HR=8.67, p<0.001, respectively).  Conclusions', '  Our results suggest that in early stage NSCLC, the co-expression of EGFR, ErbB2 and MAPK  predicted a worse prognosis. ErbB3, ErbB4 and Myc were not prognostic factors. Such features may have important implications for future targeted therapies. We thank  Italian Association for Cancer Research (AIRC) for supporting the study.']",
        "Doc_id":"ASCO_100326-114",
        "Doc_title":" Clinical significances of ErbB family receptors, Myc, and mitogen-activated protein kinase (MAPK) in patients with early-stage non-small cell lung cancer.",
        "_version_":1606188984143183872},
      {
        "Meeting_name":" Activation of HER Family signaling as a mechanism of acquired resistance to ALK Inhibitors in EML4-ALK-positive Non-Small Cell Lung Cancer.",
        "Background":"['Purpose', ' Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) such as crizotinib show marked efficacy in patients with non-small cell lung cancer positive for the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein. However, acquired resistance to these agents has already been described in treated patients, and the mechanisms of such resistance remain largely unknown.Experimental Design', ' We established lines of EML4-ALK-positive H3122 lung cancer cells that are resistant to the ALK inhibitor TAE684 (H3122/TR cells) and investigated their resistance mechanism with the use of immunoblot analysis, ELISA, reverse transcription and real-time PCR analysis, and an annexin V binding assay. We isolated EML4-ALK-positive lung cancer cells (K-3) from a patient who developed resistance to crizotinib and investigated their characteristic.Results', ' The expression of EML4-ALK was reduced at the transcriptional level, whereas phosphorylation of the epidermal growth factor receptor (EGFR), HER2, and HER3 was up-regulated, in H3122/TR cells compared with those in H3122 cells. This activation of HER family proteins was accompanied by increased secretion of EGF. Treatment with an EGFR-TKI induced apoptosis in H3122/TR cells, but not in H3122 cells. The TAE684-induced inhibition of extracellular signal-regulated kinase (ERK) and STAT3 phosphorylation observed in parental cells was prevented by exposure of these cells to exogenous EGF, resulting in a reduced sensitivity of cell growth to TAE684. K-3 cells also manifested HER family activation accompanied by increased EGF secretion.Conclusions', ' EGF-mediated activation of HER family signaling is associated with ALK-TKI resistance in lung cancer positive for EML4-ALK.']",
        "Doc_id":"AACR_2013-4446",
        "Doc_title":" Activation of HER Family signaling as a mechanism of acquired resistance to ALK Inhibitors in EML4-ALK-positive Non-Small Cell Lung Cancer.",
        "_version_":1606188981883502592},
      {
        "Meeting_name":" Identification of new therapeutic targets and molecular predictors of response in oesophageal cancer",
        "Background":"['Purpose of the studyOesophageal cancer is the seventh most common cause of cancer related death worldwide. Disease relapse is frequent and treatment options are limited. With the exception of HER-2 and EGFR amplification, there are currently no validated biomarkers to predict response to biological therapies in this disease. The purpose of this study was to identify new biomarker defined therapeutic approaches for patients with oesophageal cancer.Experimental approachWe have undertaken a functional screening approach focused on the druggable kinome to generate a first map of the genetic dependencies found in oesophageal cancer. A panel of 19 oesophageal and 130 non-oesophageal cancer cell lines were screened with siRNA targeting 720 kinases to generate functional profiles. By integrating this dataset with exome sequencing and copy number data, we identified key genetic dependencies (KGDs) associated with oesophageal histology (adenocarcinoma or squamous cell carcinoma) or key driver genotypes including amplifications in c-MYC, CCND1, EGFR and ERBB2, as well as loss of functional mutations in SMAD4 and ARID1A.ResultsInterrogation of the oesophageal functional genomics dataset established oncogene addiction effects including c-MYC, which is amplified in 30% of oesophageal carcinomas. We confirmed that a novel isoform of Bruton agammaglobulinaemia tyrosine kinase gene (BTK-C) was expressed in oesophageal cancer models and that silencing of BTK resulted in selective lethality in c-MYC amplified oesophageal cell lines. To further assess the impact of BTK inhibition in oesophageal cancer, we treated a panel of oesophageal cell lines with increasing doses of ibrutinib, a small molecule tyrosine kinase inhibitor of BTK. Analysis of ibrutinib SF50 revealed that there was preferential sensitivity to ibrutinib in c-MYC amplified oesophageal cell lines. Furthermore, we observed a significant association between mutation of the chromatin remodelling factor gene SMARCA4 and dependency upon the bromodomain protein BRD4. We also identified SMAD4 kinase genetic dependencies including AKT1 and a number of its substrates (FGR, MAP3K3, CHEK1 and WEE1). We noted a densely connected group of kinases that regulate the mitotic cell cycle in the SMAD4 dependency network, and found that SMAD4 mutant cell lines exhibited an increased sensitivity to drugs, including paclitaxel, that target the mitotic checkpoint.ConclusionsOur results support the potential of BTK small molecule inhibition as a novel therapeutic strategy in c-MYC amplified oesophageal carcinoma. Loss of function SMAD4 mutations represents a candidate biomarker of response to drugs that target the mitotic checkpoint in oesophageal cancer.']",
        "Doc_id":"AACR_2016-69",
        "Doc_title":" Identification of new therapeutic targets and molecular predictors of response in oesophageal cancer",
        "_version_":1606188989097705472},
      {
        "Meeting_name":" NGS-based measurement of gene expression of 2560 oncology-related biomarkers in formalin-fixed, paraffin-embedded (FFPE) tissues",
        "Background":"['Background', ' HTG Molecular (HTG) developed a targeted Next Generation Sequencing (NGS)-based gene expression assay that measures mRNA levels of 2,560 genes (2,532 oncology-related biomarker genes). The HTG EdgeSeq Oncology Biomarker Panel Assay (OBP) is based on a novel derivative of our quantitative nuclease protection chemistry (qNPA) that enables extraction-free quantitation (detection) of mRNA from variety of sample types including formalin-fixed, paraffin embedded (FFPE) tissue.Purpose', ' To determine (1) linearity across a range of sample inputs, (2) recommended sample input amounts for FFPE, cells, and extracted RNA, and (3) reproducibility of the HTG EdgeSeq Oncology Biomarker Panel Assay in measuring the mRNA expression of 2,560 genes.Methods', ' Lysates of 5 micron sections of FFPE tissues (lung, breast, prostate, and colon carcinoma; melanoma; 25 mm2 to 0.78 mm2 per reaction), THP-1 and HCC78 cell lines (7500 cells to 234 cells per reaction), and Universal RNA (URNA; 25 ng to 1.56 ng per reaction) were used for the linearity and sample input studies. URNA (25 ng per reaction) was used to demonstrate reproducibility of the assay across multiple days and processors (one processor across three days and three processors on one day). Sequencing libraries were generated from the qNPA reactions and run on an Illumina MiSeq sequencing platform. The HTG EdgeSeq Parser was used for post-sequencing data processing. Linear regression (R2) and Pearson correlation coefficients (r) were used to assess linearity and reproducibility of the assay.Results', ' The R2 for linearity across four concentration points for lung FFPE tissue (6.25-0.78 mm2), cell lines (1875-234 cells), and URNA (12.5-1.56 ng) were >0.97, 0.99, and 0.99, respectively. The (r) between low (1.56 mm2) and high (12.5 mm2) sample inputs for each FFPE tissue type was > 0.98. The (r) for intra-run, inter-day, and inter-run reproducibility were > 0.95, > 0.98, and > 0.98 respectively. In addition, differential expression of tissue-specific genes was identified in the respective FFPE tissues, including NKX2 and MUC1 in lung, ERBB2 in breast, NKX3, KLK2, and KLK3 in prostate, and SPP1 and PRAME in melanoma.Conclusions', ' The HTG EdgeSeq Oncology Biomarker Panel Assay for a 2,560-gene panel of oncology-related biomarkers is linear over a wide range of sample inputs, can comprehensively analyze very small, clinically relevant tissues, and is highly reproducible. The demonstrated performance of the assay in breast, lung, colon, and prostate cancer and melanoma FFPE samples enables multiplex oncology biomarker profiling of these and other malignant neoplasms.']",
        "Doc_id":"AACR_2016-1383",
        "Doc_title":" NGS-based measurement of gene expression of 2560 oncology-related biomarkers in formalin-fixed, paraffin-embedded (FFPE) tissues",
        "_version_":1606188979040813057},
      {
        "Meeting_name":" LungMATCH",
        "Background":"['Background', ' For metastatic non-small cell lung cancer (NSCLC), guidelines include molecular testing for actionable biomarkers and recommend broad profile testing. Yet previous studies indicate that not all patients with NSCLC receive testing, even for actionable mutations in EGFR, ALK, and ROS. We hypothesized low testing rates for patients calling a community HelpLine and that we could increase rates with one-on-one caller education and free precision medicine services. Methods', ' Caller statistics were collected on the toll-free Lung Cancer Alliance (LCA) HelpLine from Sept 1, 2016  Jan 31, 2017. Recruitment to the LungMATCH molecular testing program began Nov 10, 2017. Patients are recruited through conversations on the LCA HelpLine, then consented into Perthera Cancer Analysis (PCA) through an IRB-approved registry protocol. PCA includes tissue acquisition, multi-omic molecular profiling, and medical review of testing results and clinical and treatment history. PCA reports are returned to both treating physicians and patients. Data is being collected longitudinally on treatment decisions, patient outcomes including progression-free and overall survival, and patient experience. Results', ' Data from the LCA Helpline identified a gap in molecular testing. 50% (57/115) of patients asked if they received any kind of molecular testing replied \"No\". Of 32 patients who were tested and knew the results, patients indicated potentially actionable changes in EGFR(15), ALK(8), PD-L1(3), RET, MET, BRAF, and HER2, along with KRAS (4). Since LungMATCH launch, 23 interested patients were referred for PCA. Six patients consented and are undergoing PCA with seven more in the consent process. Reasons for non-consent include', ' doctor refusal, initiation of testing at the treating institution, concern about financial implications, and one death. Updated results will be presented. Conclusions', ' Our data indicate that patients with lung cancer are not receiving molecular testing in accordance to guidelines. To address this, we created a program through nonprofit-corporate partnership that navigates patients and their physicians through comprehensive precision therapy. This type of program is feasible and there is patient interest.']",
        "Doc_id":"ASCO_186095-199",
        "Doc_title":" LungMATCH",
        "_version_":1606188991565004801},
      {
        "Meeting_name":" Preserved histological and molecular phenotypes following serial in vivo propagation of patient-derived xenografts of small cell lung cancer",
        "Background":"['Background', ' Limited availability of tissue samples is a major impediment to small cell lung cancer (SCLC) research but patient-derived xenograft (PDX) offers a potential alternative. The high genomic instability of SCLC necessitates the need to establish whether the molecular characteristics of PDXs are preserved across serial propagation in mice.Method', ' PDX were raised using biopsy samples from patients with relapsed SCLC under an IRB-approved protocol. Image guided or bronchoscopic biopsies were directly implanted subcutaneously into SCID mice within 60 minutes of collection and without in vitro culture. Tumor growth was monitored and animals were sacrificed while overall tumor size remained <2g. Harvested tumors were immediately re-implanted into a new set of 5 mice for up to 5 generations while freezing remnant tumor samples in liquid nitrogen for future use. Tumor histology was assessed by standard H&E and immunohistochemistry for neuroendocrine markers (NSE, chromogranin and Synaptophysin). Harvested DNA from tumor samples from all generations of PDX using QiAmp DNA Mini Kit was employed for targeted sequencing at greater than 2,000x coverage on the Illumina MiSeq instrument. A 17-gene panel including frequently encountered genetic aberrations in lung cancer (EGFR, KRAS, TP53, STK11, PTEN, NRAS, ERBB2, MET, NF1 and PIK3CA) was used to characterize molecular phenotype of PDX samples. Molecular homogeneity was assessed by comparing the genetic profile of each PDX across all generations. All identified mutations were compared to the COSMIC database.Results', ' We have successfully raised PDX from 5 of 9 patient biopsies with a lag time from initial implantation to adequate tumor growth ranging between 1.5 and 11 months. Propagation of PDX across generations has been performed for 5 generations (1PDX), 3 generations (2PDXs), 2 generations (2PDXs) and 1 generation (1PDX). There was good preservation of tumor histology assessed by H&E and IHC across generations. Mutations in TP53 gene (c.422G>A[p.Cys141Tyr]; c.913A>T[p.Lys305Ter], c.488A>G[p.Tyr163Cys], c.892G> [p.Glu298Ter]) detected in tumor samples from the first generation mice were preserved across all subsequent generations tested. Additionally, there were no new aberrations detected in this panel of 17 genes when comparing early to later generations of PDX. Conclusions', ' Despite the high degree of genomic instability expected in SCLC, serially propagated PDX of SCLC maintained histologic and molecular characteristics across many generations. Our finding that original tumor characteristics remain well preserved in PDX supports future use of this resource as reliable platform for translational research in SCLC.Supported through the Georgia Cancer Coalition Distinguished Scholar Award and NIH/NCI 5K23CA164015 grant to TK Owonikoko']",
        "Doc_id":"AACR_2014-1227",
        "Doc_title":" Preserved histological and molecular phenotypes following serial in vivo propagation of patient-derived xenografts of small cell lung cancer",
        "_version_":1606188989350412288},
      {
        "Meeting_name":" Observational study to evaluate the pattern of trastuzumab (T) use and survival outcomes in HER2-positive (HER2+) early breast cancer (EBC)",
        "Background":"['Background', '     HER-2 have shown to be over-expressed in 20-25 % of primary breast cancer, and is associated with poor prognosis. Several large, randomized studies have reported a significant reduction in the risk of recurrence when trastuzumab is administered with chemotherapy in EBC HER2+ cancer. The aim of this study is to identify the pattern of use of  T and survival outcomes in HER2+ EBC in Sicily.  Methods', '     This observational, multicenter, retrospective study was conducted in 11 oncology centers in Sicily during 2006-2010. Inclusion criteria', ' age 18 years, surgery for early breast cancer, diagnosis of invasive disease, HER2-positivity as defined by current guidelines, and treatment with T.  Results', '     569 patients (pts) were included. Surgical outcomes', ' quadrantectomy 58.1%, mastectomy 33.7% and tumorectomy 8.2%. Tumor stage', ' T1 50.6%, T2 37.9% and T3 11.5%. Histology', ' invasive ductal carcinoma 94.7%,. Histological Grade', ' G3 55.6%. Node status', ' N0 52.6%, N1 27.3%, N2 12.5%, N3 6.7% and Nx 0.9%. Hormonal status', ' estrogen receptor positive 60.1% and progesterone receptor positive 47.3%. Proliferation', ' Ki67 10% in 82.4%. Neoadjuvant and adjuvant T was administered in 11.9% and 93.4% pts, respectively. Sequential administration of T after adjuvant chemotherapy was the most common schedule. Cytotoxic agents used', ' anthracyclines 76.04%, taxanes 33.02% and both agents in combination 26.8%. Relapses were observed in 5.6% pts. The main metastatic sites were', ' liver 18.75%, bone 12.5%, lung 12.75%, brain 12.75%, locoregional and contralateral 12.5% and lymph nodes 9.4%. N positivity and hormone receptor negativity are significantly associated to relapse. Cardiac toxicity (LVEF reduction >10%) was observed in 3.5% pts. DFS at  25 months of FU was similar to that of HERA DFS at 23.5 months of FU.  Conclusions', '    Our study confirms the efficacy and safety of T in early HER2+ breast cancer, although includes a better prognostic population. These data indicate a satisfactory level of adherence to the international guidelines in the management in HER-2 positive EBC, showing a significant improvement in DFS when T was added to adjuvant chemotherapy.']",
        "Doc_id":"ASCO_83932-102",
        "Doc_title":" Observational study to evaluate the pattern of trastuzumab (T) use and survival outcomes in HER2-positive (HER2+) early breast cancer (EBC)",
        "_version_":1606189029149114369},
      {
        "Meeting_name":" Identification of the Her-2 expression-regulating miRNAs by microdissection and RT-PCR in breast cancer tissue",
        "Background":"['Her-2/neu oncogene is overexpressed in human breast cancer and is correlated with the tumor cell proliferation, metastasis, and resistance against chemo- and hormonotherapy. The expression levels of both Her-2/neu gene and HER-2 protein are recommended for evaluation of treatment efficacy as well as for selection of treatments. However, clinical studies have shown that the Her-2/neu gene and the HER-2 protein are differently expreesed in 10-15% of human breast cancers and we hypothesized that the expression difference might be related to the post-transcriptional regulation of the Her-2/neu gene by microRNAs (miRNAs). To identify the specific miRNAs, we first analyzed 120 human breast cancer samples for the Her-2/neu gene amplification and protein expression with fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). Fourty-four cancer samples (36.7%, 44/120) showed overexpression of HER-2 protein with IHC (IHC+) and 26 samples (26.5%, 26/98) exhibited Her-2/neu gene amplification with FISH (FISH+). Interestingly, five samples exhibited amplification of the Her-2/neu gene, but absence of the HER-2 protein expression (FISH+/IHC-). We then dissected the FISH+/IHC- tumor cells using laser capture microdissection from the five samples. Tumor cells with FISH+/IHC+ from another set of five samples were also dissected and analyzed as the control. Based on TargetScanHuman and literature search, five candidate miRNAs including miR-125b, -1224-3p, -1296, -193a-5, and -331-3p were screened with quantitative real-time RT-PCR and their expression levels in the FISH+/IHC- cells were 3.1-, 2.7-, 1.7-, 1.7-, and 1.3-fold higher than in the FISH+/IHC+ cells, respectively, with a significant difference for miR-1224-3p and miR-1296 (both P < 0.01). These results indicate that miR-1224-3p and miR-1296 may be responsible for the different expressions of Her-2/neu gene and its protein by regulating the Her-2/neu gene posttranscription, thus down-regulating the HER-2 protein expression in FISH+/IHC- breast cancer cells.']",
        "Doc_id":"AACR_2012-5030",
        "Doc_title":" Identification of the Her-2 expression-regulating miRNAs by microdissection and RT-PCR in breast cancer tissue",
        "_version_":1606188972382355456},
      {
        "Meeting_name":" Expression of cancer type amino acid transporter LAT1 is a prognosis prediction factor in breast carcinoma",
        "Background":"['Purpose', ' Amino acid transporters play important roles in cell survival and proliferation. L-Type amino acid transporter 1 (LAT1) is one of the major Na+-independent neutral amino acid transporters. LAT1 has an aspect of oncofetal protein. Recently, high levels of LAT1 expression have been reported in various tumors, such as prostate cancer, pancreas cancer, bile duct cancer, lung cancer and stomach cancer.We revealed LAT1 expression is an independent prognosis marker in stomach cancer, prostate cancer and pancreas cancer. The purpose of the present study was to investigate the LAT1 expression in breast carcinoma and relationship between LAT1 expression and prognosis.Materials & Methods', ' We enrolled 290 patients with invasive breast carcinoma surgically resected between 2006 and 2010 at Kitasato University Hospital and Toho University Omori Medical Center, Japan. We investigated LAT1 expression in the enrolled breast carcinoma cases by immunohistochemical staining. All cases were divided into two groups, 78 cases of triple negative carcinoma (TNBC) and 212 cases of non-triple negative carcinoma (NTNBC), with immunohistochemistry of estrogen and progesterone receptors and Her2. After LAT1 expression was compared between TNBC and NTNBC, correlations among LAT1 expression, Ki-67 labeling index (LI), CD98 expression, and clinicopathological findings was assessed.Results', ' TNBC showed significantly higher LAT1 expression than NTNBC. TNBC also showed significantly higher CD98 expression rather than NTNBC. LAT1 expression of extraductal invasive cancer cells was significantly higher than those of intraductal carcinoma cells. A significantly positive correlation was observed between LAT1 expression and CD98 expression. Further, a positive correlation between LAT1 expression and Ki-67 LI was found. Log-rank test in overall breast cancers revealed that high LAT1 expression group showed significantly poor prognosis, compared to low LAT1 group. In NTNBC, high LAT1expression cases possessed poorer prognosis than low LAT1 expression cases.Conclusion', ' In invasive ductal carcinoma of breast, LAT1 expression has a potential for a prognosis prediction factor. LAT1 offers a potential target for anti-cancer therapy by its inhibitor JPH203 which has been developed by us.']",
        "Doc_id":"AACR_2015-5286",
        "Doc_title":" Expression of cancer type amino acid transporter LAT1 is a prognosis prediction factor in breast carcinoma",
        "_version_":1606189014034939905},
      {
        "Meeting_name":" Biomarker testing methods in breast, gastric, and lung cancers",
        "Background":"['Background', '  Biomarkers are an integral part of cancer care.  A variety of testing methods exist, allowing institutional selection of which technologies to use and in what order to run them. This descriptive study provides a benchmark on methods used in practice for biomarker testing in breast (BC), gastric/esophageal (GC), and non-small cell lung cancers (NSCLC).  Methods', '  We conducted an IRB-approved web survey of the 58 NCI designated cancer centers (pathologists and oncologists) providing adult care in BC, GC, and NSCLC. We developed a survey instrument with 14 BC, 5 GC, and 10 NSCLC items asking about methods used, order of testing, turn around time (TAT) and if tests are internally developed (ID).  Results', '  For BC, 32% (18/57) of sites run concurrent rather than reflex HER2 FISH and IHC testing, citing quality assurance reasons. Average TAT for concurrent vs reflex testing is 6.5 and 9.5 days. Rates of ID tests are 14% (8/57) for PgR, 12% (7/57) for ER and 7% (4/57) for HER2. For GC, 39% (21/54) of sites run concurrent HER2 FISH and IHC tests, citing reasons of quality assurance and evolving guidelines. TAT for concurrent vs reflex testing is 6.3 and 9.5 days. 19% (10/54) of sites use ID HER2 tests. All reporting sites use EGFR and ALK testing in NSCLC and 96% use KRAS. 24% (13/55) of sites run them concurrently with an average TAT of 7.6 days, while the average TAT for sites with sequential testing is 22.8 days. CAP recommends a 10 day TAT for NSCLC tests, and 92% (12/13) of sites with concurrent testing meet this guideline vs only 11% (4/38) of sites with sequential testing (p<.0001). Rates of ID tests are 57% (30/53) for KRAS, 47% (26/55) for EGFR and 35% (19/55) for ALK, for which a kit is listed on the FDA drug label. There is a difference in the use of ID tests between BC and NSCLC, p<.0148.  Conclusions', '  Concurrent testing for BC and GC HER2, and for NSCLC markers is a common practice at NCI cancer centers; and it improves TAT. Concurrent NSCLC testing allows meeting CAP TAT guideline, but sequential testing does not. New markers (GC HER2, EGFR, KRAS and ALK) are commonly adopted, with a higher rate of internally developed tests than for BC HER2.']",
        "Doc_id":"ASCO_115787-132",
        "Doc_title":" Biomarker testing methods in breast, gastric, and lung cancers",
        "_version_":1606188978701074432},
      {
        "Meeting_name":" Targeting FACT complex suppresses mammary tumorigenesis in Her2/neu transgenic mice",
        "Background":"['We have recently found that expression of Facilitates Chromatin Transcription (FACT) complex consisting of SSRP1 and SPT16 protein subunits is elevated in many types of cancer comparing with normal tissues. Moreover, survival of tumor cell, but not normal cells is significantly compromised upon genetic knockdown of any of the FACT subunits. In our recent studies we have shown that FACT is essential for the transcriptional activity of NF-B and Heat Shock Factor 1 and identified small molecules that inhibit activity of both transcription factors by causing functional inactivation of FACT. Since both NF-kB and HSF1 are activated in the process of transformation, we proposed that FACT may be involved in tumor transformation and that inhibition of FACT activity may prevent or reduce tumorigenesis. Objectives of our study were', ' (i) to check if FACT level is changed in the process of oncogene-induced transformation in vitro and in vivo; and (ii) to test safety and efficacy of anti-FACT therapy with Curaxin-137 in prevention of tumor formation in mice prone to cancer due to oncogene overexpression. We used in vitro (Ha-ras12V) and in vivo (MMTV-neu transgenic mouse model) models of transformation to monitor changes in FACT subunits. We treated the MMTV-neu transgenic mice, in which mammary carcinomas are spontaneously developed due to estrogen receptor-regulated expression of the Her2 proto-oncogene, with Curaxin-137 to determine whether the drug has any toxic effect on normal tissues and/or impact on mammary carcinogenesis. Expression of FACT was elevated in the process of transformation in all models tested. Chronic administration of Curaxin-137 to MMTV-neu mice at doses not having any toxic effect, inhibited tumor onset, delayed tumor progression, and prolonged survival of mice in a dose-dependent manner. Curaxin-137 induced much stronger changes in FACT in tumors than in normal organs, expressing FACT (spleen). Thus, Curaxin-137 may be considered as a potential preventive and/or early stage therapeutic agent for breast cancer.']",
        "Doc_id":"AACR_2012-3843",
        "Doc_title":" Targeting FACT complex suppresses mammary tumorigenesis in Her2/neu transgenic mice",
        "_version_":1606188984890818560},
      {
        "Meeting_name":" Characteristics and behavior of HER-2/neu positive tumors in patients under 35 years of age with breast cancer.",
        "Background":"['Background', ' Breast cancer (BC) rarely occurs in young women. Presentation, behavior and prognosis of BC in such patients (pts), when compared with older women, are unclear. It is believed that tumor is more aggressive in biologic nature in this group of pts. Objective', ' to describe Her2/neu status, tumor behavior and prognosis in women aged 35 and under with BC. Methods', ' We reviewed the records of 45 women aged 35 years or less, with diagnosis of BC between 1999 and 2007. The original Her2 status was analyzed by immunohistochemistry (IHC) with a polyclonal antibody. The results were interpreted using score 0 to 3+. Fluorescence in situ hybridization (FISH) was performed in all samples. Results', ' Her2/neu overexpression showed up in 8 tumors (17.7%) and all of them were confirmed by FISH. In this group of pts (FISH positive) hormone receptors were positive in 50%. Stage at diagnosis was I 2 pts and II 6 pts. 5 out of the 8 pts with Her2/neu tumors had axillary node involvement (11.1% out of the total of population), and tumor size was more than 2cm at diagnosis. All of them were invasive ductal carcinoma. Postoperative radiotherapy was given to 6pts while all pts with Her2/neu positive tumors received chemotherapy with anthracyclines, taxanes and trastuzumab. Disease free survival of 24 month was achieved in 5pts, 1pt died with bone, lung and liver metastases. 2pts had progressive disease (bone and lung metastases one of them, and local recurrence the other one). Conclusions', ' In our population of pts, 17.7% were Her 2/neu positive. In this small group of pts lymph node involvement was frequent and tumor size was more than 2cm. Progressive disease with distant metastases in bone, lung and liver was observed. Despite of these negative characteristics 5 out of 8 pts (62.5%) had DFS of 2 years.']",
        "Doc_id":"ASCO_34487-65",
        "Doc_title":" Characteristics and behavior of HER-2/neu positive tumors in patients under 35 years of age with breast cancer.",
        "_version_":1606188987831025664}]
  }}
